	Case3:13-cv-03567-EMC Document10	4 Filed09/19/14 Page1 of 141
1	Jonathan Gardner	
2	Mark S. Goldman Carol C. Villegas	
3	LABATON SUCHAROW LLP 140 Broadway	
4	New York, NY 10005 Telephone: (212) 907-0700 Fax: (212) 818-0477	
5	jgardner@labaton.com mgoldman@labaton.com	
6	cvillegas@labaton.com	
7	Lead Counsel for Plaintiffs and the Class	
8	Shawn A. Williams ROBBINS GELLER RUDMAN	
9	& DOWD LLP One Montgomery Street	
10	Suite 1800 San Francisco, CA 94104	
11	Telephone: (415) 288-4545 Fax: (415) 288-4534	
12	shawnw@rgrdlaw.com	
13	Local Counsel	
14	UNITED STAT	ES DISTRICT COURT
15	NORTHERN DIST	RICT OF CALIFORNIA
16)
17 18	IN RE VOCERA COMMUNICATIONS, INC., SECURITIES LITIGATION) MASTER FILE NO. 3:13-cv-03567 EMC
19	This Document Relates to:) CONSOLIDATED CLASS ACTION) COMPLAINT FOR VIOLATIONS OF
20	All Actions.) THE FEDERAL SECURITIES LAWS
21) JURY TRIAL DEMANDED
22		
23		
24	REDACTED VERSION OF DOC	UMENT SOUGHT TO BE SEALED
25		
26		
27		
28		
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLA MASTER FILE NO. 3:13-CV-03567 EMC	ATIONS OF THE FEDERAL SECURITIES LAWS

	Case	e3:13-c	cv-03567-EMC Document104 Filed09/19/14 Page2 of 141	
1			TABLE OF CONTENTS	
2	NATU	JRE OF	THE ACTION	1
3	NATU	IRE OF	THE CLAIMS	7
4	PART	ONE:	THE FRAUD CLAIMS UNDER THE EXCHANGE ACT	7
5	I.	JURIS	SDICTION AND VENUE	7
6	II.	PART	TES	8
7		A.	Lead Plaintiffs	8
8		B.	Defendants	9
9	III.	SUBS	TANTIVE ALLEGATIONS	11
10		A.	Vocera Business Overview	11
11		B.	Hospital Revenues Drive Vocera's Business	13
12		C.	The Importance of Bookings and Backlog to Revenue Visibility	14
13		D.	The Company and Market Focus on Revenue and EBITDA	15
14		E.	Relevant Legislation Affecting the Hospital Industry	17
15			1. The Affordable Care Act	17
16			2. Budget Control Act	18
17		F.	Vocera's Growth Strategy	18
18			1. The IPO	18
19			2. Vocera's Purported Class Period Success	20
20			3. Vocera's Secondary Offering	22
21		G.	The Negative Effects of the ACA and BCA on Vocera's Business Persist Throughout the Class Period and Are Known By Defendants But Hidden	
22			From Investors	24
23			1. The Internal Audit Report	25
24			2. The ACA Was Negatively Affecting Vocera's Growth at the Time of the IPO and Throughout the Class Period	26
25			 The Effects of Sequestration Are Felt in 2012 	20
26			But Not Publicly Reported Until 2013	28
27 28			4. Throughout the Class Period, the Company Cannibalized its Backlog in Order to Keep Its Growth Story Alive In the Minds of Investors	29
			CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS D. 3:13-CV-03567 EMC	

		5.	Unable to Further Tap Into Backlog, The Company Violated Its Internal Revenue Recognition Policies In Order to Make It's 4Q12 and 1Q13 Numbers
		6.	Negative Information on Growth Is Known or Recklessly Disregarded By Defendants
	H.	Defen	e Reassuring the Market that Vocera's "Growth Story" Is Intact, idants Unloaded Millions of Dollars Worth of Company Stock and From the Executive Bonus Plan
		1.	Defendant Zollars' and Lang's Stock Sales
		2.	The Individual Defendants Benefit From Inflating Revenue and EBITDA
	I.	Busin	idants Eventually Admitted that Sequestration Was Affecting the ess But Continue to Mislead the Market About the Effects of the on its Primary Business
	J.	Vocer Busin	a Finally Admitted that the ACA Was Negatively Affecting its ess and Reduced Annual Guidance Dramatically
IV.	PER	IOD STA	TS' MATERIALLY FALSE AND MISLEADING CLASS ATEMENTS AND OMISSIONS AND ANALYST AND MARKET THERETO
	A.	March	n 28, 2012 IPO
	B.	Class	Period Financials
	C.	Class	Period Guidance
	D.	May 9	9, 2012 - Form 8-K and Press Release
	E.	May 9	9, 2012 - 1Q12 Earnings Conference Call
	F.	May 1	14, 2012 - Form 10-Q
	G.	July 1	1, 2012 – J.P. Morgan Analyst Report
	H.	Augu	st 2, 2012 - Form 8-K and Press Release
	I.	Augu	st 2, 2012 - 2Q12 Earnings Conference Call
	J.	Augu	st 14, 2012 - Form 10-Q
	K.	Septer	mber 6, 2012 - Secondary Offering
	L.	Nover	mber 5, 2012 - Form 8-K and Press Release
	M.	Nover	mber 5, 2012 - 3Q12 Earnings Conference Call
	N.	Nove	mber 13, 2012 - Form 10-Q
	О.	Nove	mber 28, 2012 – Piper Jaffray Report

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page4 of 141

	P.	November 30, 2012 – J.P. Morgan Analyst Report	
	Q.	January 7, 2013 – J.P. Morgan Healthcare Conference	
	R.	February 27, 2013 – Form 8-K and Press Release	
	S.	PARTIAL DISCLOSURE – February 27, 2013 Earnings Conference Call	
	Τ.	March 12, 2013 – Form 10-K	
	U.	March 2013 – Statements to Analysts	
	V.	FINAL CORRECTIVE DISCLOSURE – May 2, 2013 - Form 8-K and Earnings Conference Call	
V.	LOSS	CAUSATION	
VI.		ICABILITY OF PRESUMPTION OF RELIANCE: D ON THE MARKET DOCTRINE	. 1
VII.	NO SA	AFE HARBOR	. 1
	A.	Many of Defendants' False and Misleading Statements Were Not Forward-Looking	. 1
	B.	Several False and Misleading Statements are Not Properly Identified as "Forward-Looking"	. 1
	C.	Defendants' False and Misleading Statements Were Not Accompanied by Meaningful Cautionary Language	. 1
	D.	Defendants Knew that the Risks they Warned of Had Already Come to Pass	. 1
FIRST	Violat	M FOR RELIEF ion of § 10(b) of the Exchange Act and Rule 10b-5 Ilgated Thereunder Against All Defendants	. 1
SECO	Violat	AIM FOR RELIEF ion of § 20(a) of the Exchange Act st the Individual Defendants	. 1
PART		THE STRICT LIABILITY AND IGENCE CLAIMS UNDER THE SECURITIES ACT	. 1
VIII.	JURIS	DICTION AND VENUE	. 1
IX.	PART	IES RELATING TO THE SECURITIES ACT CLAIMS	. 1
	A.	The Securities Act Plaintiff	. 1
	B.	The Securities Act Defendants	. 1
		1. The Officer Defendants	. 1
		2. The Director Defendants	. 1
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS D. 3:13-CV-03567 EMC	

		3. The Underwriter Defendants	
Χ.		FUAL ALLEGATIONS RELATING TO THE SECURITIES ACT	
	A.	Vocera Business Overview	
	B.	Hospital Revenues Drive Vocera's Business	
	C.	Relevant Legislation Affecting the Hospital Industry - The Affordable Care Act	
	D.	The Importance of Bookings and Backlog to Revenue Visibility	
	E.	Vocera's Growth Strategy	
	F.	The IPO	
	G.	Vocera's Secondary Offering	
	H.	The Negative Effects of the ACA Affect Vocera's Business at the Time of the IPO and Secondary Offering	
KI.	FAC	OFFERING MATERIALS CONTAINED UNTRUE STATEMENTS OF Γ AND OMITTED MATERIAL FACTS NECESSARY TO MAKE THE ERING MATERIALS NOT MISLEADING	
	A.	The IPO	•••
	B.	The Secondary Offering	
THIR	Viola	IM FOR RELIEF tions Of Section 11 Of The Securities Act Against Vocera, rs, Zerella, the Director Defendants, and the Underwriter Defendants	••••
FOUR	For V	LAIM FOR RELIEF iolations Of Section 12(a)(2) Of The Securities Act ast Vocera And The Underwriter Defendants	
FIFTH	For V	IM FOR RELIEF Violations Of Section 15 Of The Securities Act ist the Officer Defendants and The Director Defendants	
XII.	CLAS	SS ACTION ALLEGATIONS – APPLICABLE TO ALL CLAIMS	
XIII.	PRAY	YER FOR RELIEF	•••
KIV.	JURY	Z DEMAND	

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page6 of 141

Court appointed Lead Plaintiffs Arkansas Teacher Retirement System and Baltimore
 County Employees' Retirement System ("Plaintiffs") individually and on behalf of a class of
 similarly situated persons and entities as specified below, allege the following against Vocera
 Communications, Inc. ("Vocera" or the "Company") and the defendants named herein,¹ upon
 personal knowledge as to themselves and their own acts, and upon information and belief as to
 all other matters.

7 Plaintiffs' information and belief as to allegations concerning matters, other than 8 themselves and their own acts, is based upon, among other things, a review and analysis of (i) 9 press releases, news articles, transcripts, and other public statements issued by or concerning 10 Vocera and the Defendants; (ii) research reports issued by financial analysts concerning Vocera's 11 business; (iii) reports filed publicly by Vocera with the Securities and Exchange Commission 12 (the "SEC"); (iv) an investigation conducted by and through Plaintiffs' attorneys, which included 13 interviews of former employees of Vocera; (v) internal Vocera documents; (vi) news articles, 14 media reports and other publications concerning the mobile communications industry and 15 markets; and (vii) other publicly available information and data concerning Vocera, its securities, 16 and the markets therefor. Plaintiffs believe that substantial additional evidentiary support for the 17 allegations herein exists and will continue to be revealed after Plaintiffs have a reasonable 18 opportunity for discovery.

19

NATURE OF THE ACTION

Plaintiffs bring this federal securities class action on behalf of themselves and all
 similarly situated persons and entities who (1) purchased or otherwise acquired the securities of
 Vocera between March 28, 2012 and May 2, 2013, inclusive, and were damaged thereby,
 seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act"),
 and/or (2) purchased or otherwise acquired the common stock of Vocera pursuant or traceable to
 the IPO and/or the Secondary Offering, defined herein, and were damaged thereby, seeking to
 pursue remedies under the Securities Act of 1933 (the "Securities Act").

27

28

¹ Defendants are defined in Sections II.B and IX.B.

2. Vocera is a provider of mobile communications solutions, primarily for hospitals
 and other healthcare centers in the United States whose main products are a wearable voice
 communication badge and software platform that allow users to connect instantly with other
 hospital staff members. The Company also provides consulting, training, and technical support
 services for its customers.

Sales to private, non-government run hospitals make up over 80% of the
Company's revenues, with government hospitals such as those run by the Department of Defense
and Veterans Affairs accounting for about 10% of its revenue. The remaining 10% of sales are
to clients such as hotels or casinos.

4. Vocera's mobile communication solutions require a hospital to employ voice
 grade wireless or a Wi-Fi network throughout the hospital to function properly. Installing these
 systems requires a substantial upfront capital investment by hospitals. It can take anywhere from
 nine to twelve months to install and launch a Vocera communication system in a hospital.

5. Vocera started as a small private company in 2000, but in the years leading up to
its IPO in March 2012, the Company grew exponentially. Between 2009 and 2011, the
Company's revenues doubled from approximately \$40 million per year to approximately \$80
million per year. In its IPO materials, the Company described an almost limitless potential for
growth and expansion into what it called a \$6 billion niche market that had barely been
penetrated by Vocera, and for which there was little or no competition.

Kocera promoted itself as a solution to the communication challenges that
 hospitals faced, allowing a hospital to increase revenue while reducing expenses through a more
 efficient use of its resources. In its IPO materials, Vocera told the market that its post-IPO
 growth would be buoyed by the recently enacted healthcare reform legislation, which Vocera
 claimed incorporated incentives for hospitals to purchase products like Vocera's mobile
 communications system that would improve both the quality of care hospitals could provide and
 patient satisfaction.

- 27
- 28

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page8 of 141

- 7. Vocera raised over \$70 million in net proceeds in the IPO. Investors embraced
 Vocera's growth story and on March 29, 2012, the day after the IPO, the Company's stock price
 soared to \$24.91, an increase of over 55% from the offering price of \$16.00.
- 4

5

6

7

8

9

8. Vocera *seemed to be* off to a strong start as a public company. In its first reporting period after the IPO, the Company posted a significant increase in revenue for the first quarter of 2012, improving 26% over the revenue reported in the first quarter of 2011. Vocera also issued full year revenue guidance of \$100-\$102 million, which was a year over year increase of 26% to 28%. These results signaled the market that Vocera's pre-IPO success and growth had continued, and that the Company was set up for increasing future growth.

10 9. During the first earnings call with analysts after Vocera became a public 11 company, Robert Zollars, Vocera's CEO, assured the market that newly enacted healthcare 12 reform was not having a negative effect on Vocera's business, and that the growth story 13 presented in the IPO materials remained in place. Zollars also made the point that management 14 had "high visibility" into Vocera's expected revenue and earnings, which allowed Defendants to 15 provide the market with reliable revenue and earnings guidance. The market understood this 16 "high visibility" to come from Vocera's business model, which placed new sales or bookings 17 into backlog, with revenue recognized periodically and predictably over the nine to twelve month 18 installation period for a new mobile communication system.

19 10. During the Class Period, Vocera continued to present investors with its story of 20 continued growth, emphasizing both how its business was not being affected negatively by 21 healthcare reform, and its "high visibility" into upcoming revenue and earnings. Quarter after 22 quarter, Vocera met or beat the earnings and revenue guidance provided to investors, and 23 Defendants continued to reiterate Vocera's strength and their "high visibility" into the 24 Company's business. By consistently meeting the rising guidance Defendants provided to 25 investors, the price of Vocera's common stock increased from the IPO price of \$16.00 per share 26 to a Class Period high of \$32.97 per share on September 25, 2012.

27 11. Taking advantage of Vocera's rising stock price, the Company conducted a
28 secondary stock offering ("Secondary Offering") at \$28.75 per share on or about September 7,


Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page9 of 141

2012. Vocera raised over \$36 million in proceeds from the Secondary Offering. Pursuant to a
 partial release of the lock up adopted in the IPO that would otherwise have prevented them from
 selling shares, Zollars and Brent Lang, Vocera's COO, together sold a total of over \$7 million
 worth of stock in the Secondary Offering.

5 12. Behind the scenes, Defendants knew that Vocera's ability to grow at pre-IPO
6 rates, which it guided the market to expect, was not feasible.

7

8 Defendants also knew that healthcare reform, and Vocera's customers' 9 uncertainty about the impact of healthcare reform, were in fact impacting hospitals' willingness 10 to commit to the high capital expense necessary to purchase a mobile communication system 11 from Vocera. Former high-level employees of Vocera, whose accounts are corroborated and 12 supported by internal Company documents, confirm that at the same time Defendants were 13 touting annual growth levels nearing 30% and denying that healthcare reform was negatively 14 affecting its business. Vocera was unable to keep pace with at least in part 15 because of the effects of healthcare reform.



1

2

15.

To avoid this,

3 Defendants reached into its backlog of orders that were not scheduled for shipment and
4 installation and pushed customers to accept deliveries earlier than scheduled. Doing so allowed
5 Vocera to recognize the resulting revenue earlier than planned and to meet guidance.

6 16. By pulling from future revenue to make their numbers in the current quarter, i.e.,
7 by "smoothing" the Company's quarterly numbers, Defendants were able to manipulate Vocera's
8 reported revenues upward to meet its revenue shortfalls. During the Class Period, Defendants
9 failed to disclose that the only way Vocera was able to meet guidance, given the reduced level of
10 new bookings, was through this "smoothing" process. Defendants also failed to disclose the
11 adverse impact this "smoothing" process was having on the Company's backlog levels, or the
12 impact it had on their "visibility" into future revenue and earnings.

17. The premature, quarter-end pulling of orders and bookings out of backlog created
a vicious cycle, forcing Defendants to repeat that exercise in each succeeding quarter. As the
Class Period progressed, there were fewer and fewer orders remaining in backlog that could be
moved up for shipment. It was a cycle that could not go on indefinitely. Backlog continued to
be depleted and was not replenished by a sufficient number of new sales bookings. Nonetheless,
Defendants continued to project growth in revenue and earnings, and continued to tell the market
that Vocera was meeting guidance as a result of the Company's "strong" performance.

20 18. Defendants not only misled investors about the rate of the Company's growth and 21 the known, negative impact of healthcare reform and sequestration, they took advantage of the 22 artificially increased stock price. Zollars and Lang collectively sold over \$11 million in stock 23 during the Class Period—sales that were completely out of line with their post Class Period 24 trading. All the Individual Defendants, defined below, also benefitted handsomely in the form of 25 bonuses for hitting adjusted EBITDA and revenue targets, which were achieved as a result of 26 their fraudulent scheme to smooth revenue and earnings and to misrepresent the known, adverse 27 impact of healthcare reform.

19 At the end of 4Q12, Vocera was "falling off a cliff." Desperate to meet guidance 1 2 and continue the perception that Vocera was "one of the strongest growth companies," the 3 Individual Defendants, on at least two occasions, caused Vocera to ship product to hospitals 4 earlier than the agreed upon scheduled date, this time without customer approval, in violation of 5 Vocera's revenue recognition practices.

20. On February 27, 2013, in a partial revelation of the truth, Defendants announced 6 7 for the first time that the government had slowed its healthcare funding due to budget 8 sequestration, resulting in several government deals "slipping" to future quarters. The Company 9 issued weak 1Q13 guidance and admitted that its bookings were down and its backlog had decreased year over year. However, Defendants continued to mislead the market by telling 10 11 investors that its private hospital customers, Vocera's primary revenue drivers, were "healthy and 12 performing well." Defendants issued 2013 annual revenue guidance in a range from \$120 to 13 \$130 million, an increase of 20% to 30% over 2012, signaling that Vocera's growth story was 14 still alive and well. Indeed, Defendants told that market they were confident they would hit their 15 2013 annual targets due to the "highly recurring [] nature" of the Company's revenue model. 16 Despite Defendants' attempts to blunt the effects of this news, Vocera's stock dropped from \$29.07 to \$26.37, or over 9%, on heavy volume. 17

18 21. In the months that followed, Defendants continued to tout the strength of the 19 government hospital pipeline (despite internally known continuing effects of sequestration) and 20 "momentum [] in the core U.S. healthcare business," reaffirming guidance as late as March 23, 21 2013. Just five weeks later, however, on May 2, 2013, investors were shocked when, for the first 22 time as a public company, Vocera missed its already lowered 1Q13 guidance and lowered 23 guidance for the year to a range of \$100 to \$110 million.

On an earnings call held that day, Defendants finally admitted that healthcare 24 22 25 reform was having a significantly negative effect on growth in its core private hospital business, 26 as "lower utilization and reduced reimbursement rates" resulting from healthcare reform were 27 causing these hospitals to "put in place large expense reduction initiatives," and that the effects

of sequestration, which was affecting government hospitals, would continue to be felt in the
 future. Defendants also admitted that their visibility into future revenues was compromised.

As a result of these revelations, Vocera's stock plunged over 37% – closing at an
all-time low of \$12.15 per share on May 3, 2013, more than 24% below the IPO price, 57%
below the price of the Secondary Offering, and over 63% below the Class Period high of \$32.97.
Analysts were "clearly surprised" by the "magnitude of the shortfall" in revenue and the lowered
guidance going forward, as well as by the "lack of clarity around recurring revenues" and the
"[un]predictability" of the "recurring revenue stream," wondering why management failed to
indicate the "drastic reduction in guidance" despite several earlier opportunities to do so.

10

NATURE OF THE CLAIMS

11 24. In this Complaint, Plaintiffs assert two different sets of claims. Counts One and 12 Two assert fraud claims under Section 10(b) and Section 20(a) of the Exchange Act of 1934 13 against Vocera, Robert Zollars, William Zerella, and Brent D. Lang. Counts Three, Four, and 14 Five assert strict-liability and negligence claims under the Securities Act against those 15 defendants who are statutorily responsible under Sections 11 and 12(a)(2) for materially untrue 16 statements and misleading omissions made in connection with Vocera's IPO and Secondary 17 Offering and control person claims related to these Offerings under Section 15 of the Securities 18 Act, defined specifically herein in "Part Two: The Negligence Claims Under the Securities Act." 19 Plaintiffs specifically disclaim any allegations of fraud in these non-fraud claims brought under 20 the Securities Act.

21

22

I.

PART ONE: THE FRAUD CLAIMS UNDER THE EXCHANGE ACT JURISDICTION AND VENUE

23 25. The claims asserted herein arise under Sections 10(b) and 20(a) of the Exchange
24 Act, 15 U.S.C. §§ 78j(b) and 78t(a), and Rule 10b-5 promulgated thereunder by the SEC, 17
25 C.F.R. § 240.10b-5.

26 26. This Court has jurisdiction over the subject matter of this action pursuant to
27 Section 27 of the Exchange Act, 15 U.S.C. § 78aa, and 28 U.S.C. §§ 1331 and 1337(a).

2 Z7. Venue is proper in this judicial district pursuant to Section 27 of the Exchange
 Act and 28 U.S.C. § 1391(b).

3 28. Many of the acts and omissions charged herein, including the dissemination of
4 materially false and misleading information to the investing public, occurred in this district.
5 Vocera has operations in this district and division, including its principal place of business at 525
6 Race Street, San Jose, CA 95126.

7 29. In connection with the acts alleged in this Complaint, defendants (defined below),
8 directly or indirectly, used the means and instrumentalities of interstate commerce, including, but
9 not limited to, the mails, interstate telephone communications, and the facilities of the New York
10 Stock Exchange ("NYSE"), the world's largest stock exchange by market capitalization.

11 **II. PARTIES**

12

A. Lead Plaintiffs

30. Lead Plaintiff Arkansas Teacher Retirement System ("ATRS") is a public pension
fund organized in 1937 for the benefit of the current and retired public school teachers of the
State of Arkansas. ATRS is headquartered in Little Rock, Arkansas and has over \$14 billion
dollars in assets under management. As set forth in Docket No. 42-1, ATRS purchased shares of
common stock of Vocera during the Class Period, and suffered damages as a result of the
violations of the federal securities laws alleged herein.

19 31. Lead Plaintiff Baltimore County Employees' Retirement System ("Baltimore 20 County") is a defined benefit pension plan headquartered in Towson, Maryland. Baltimore 21 County was established in January 1945 and provides retirement benefits to employees of 22 Baltimore County, and employees of the Baltimore County Revenue Authority, the Baltimore 23 County Board of Education, the Baltimore County Board of Library Trustees, and the 24 Community College of Baltimore County who are not eligible to participate in the Maryland 25 State Retirement and Pension Systems. As of June 30, 2013, Baltimore County held 26 approximately \$2.3 billion dollars in assets for the benefit of its 17,000 participants. As set forth 27 in Docket No. 42-1, Baltimore County purchased shares of common stock of Vocera during the 28 Class Period, and suffered damages as a result of the violations of the federal securities laws.

B. Defendants

1

32. Defendant Vocera is a Delaware corporation with its principal executive offices
located at 525 Race Street, San Jose, California 95126. Vocera describes itself as a provider of
mobile communication solutions focused on addressing critical communications challenges
facing hospitals. Throughout the Class Period, Vocera common stock traded actively on the
NYSE under the ticker symbol "VCRA."

33. Defendant Robert J. Zollars ("Zollars") was appointed Chief Executive Officer
and Chairman of the Board in June 2007, and served in these positions until June 1, 2013. From
May 2006 to May 2007, he served as chief executive officer of Wound Care Solutions, Inc., an
operator of outsourced chronic wound care centers. During the Class Period, as more fully
alleged herein, Zollars made materially false and misleading statements or omissions in Vocera's
quarterly conference calls, SEC filings, industry events, and events for analysts, investors, and
the media.

34. Defendant Brent D. Lang ("Lang") was appointed President and Chief Operating
Officer in October 2007. From January 2007 to June 2007, he served as Acting Chief Executive
Officer, and from June 2001 through January 2007, he served as Vice President of Marketing
and Business Development. In June 2013, after the Class Period ended, he assumed the role of
President and CEO. During the Class Period, as more fully alleged herein, Lang made materially
false and misleading statements or omissions in Vocera's quarterly conference calls, SEC filings,
industry events, and events for analysts, investors, and the media.

35. Defendant William R. Zerella ("Zerella") was appointed Chief Financial Officer
("CFO") in October 2011. From July 2006 to September 2011, he served as chief financial
officer for Force10 Networks Inc., a networking company that was acquired by Dell Inc. in
August 2011. During the Class Period, as more fully alleged herein, Zerella made materially
false and misleading statements or omissions in Vocera's quarterly conference calls, SEC filings,
industry events, and events for analysts, investors, and the media.

- 27
- 28

36. The Defendants enumerated in Paragraphs 33 to35 are collectively referred to
 herein as the "Individual Defendants." In "Part One: The Fraud Claims Under the Exchange
 Act," (¶¶25-300) the Individual Defendants together with Vocera are the "Defendants."

37. Each of the Individual Defendants, by virtue of his high-level position with 4 5 Vocera, directly participated in the management of the Company, was directly involved in the 6 day-to-day operations of the Company at the highest levels, and was privy to confidential 7 proprietary information concerning the Company and its business, operations, growth, financial 8 statements, and financial condition during his tenure with the Company, as alleged herein. As 9 set forth below, the materially misstated information conveyed to the public was the result of the 10 collective actions of these individuals. Each of these individuals, during his tenure with the 11 Company, was involved in drafting, producing, reviewing, and/or disseminating the statements at 12 issue in this case, approved or ratified these statements, or was aware or recklessly disregarded that these statements were being issued regarding the Company. 13

14 38. As senior executive officers and/or directors of a publicly held company whose 15 common stock was, and is, registered with the SEC pursuant to the Exchange Act, and whose 16 common stock was, and is, traded on the NYSE, and governed by the federal securities laws, the 17 Individual Defendants each had a duty to disseminate prompt, accurate, and truthful information with respect to the Company's business, operations, financial statements, and internal controls, 18 19 and to correct any previously issued statements that had become materially misleading or untrue, 20 so that the market prices of the Company's publicly traded securities would be based on accurate 21 information. The Individual Defendants each violated these requirements and obligations during 22 the Class Period.

39. The Individual Defendants, because of their positions of control and authority as
senior executive officers and/or directors of Vocera, were able to and did control the content of
the SEC filings, press releases, and other public statements issued by Vocera during the Class
Period. Each of these individuals was provided with copies of the statements at issue in this
action before they were issued to the public and had the ability to prevent their issuance or cause

them to be corrected. Accordingly, each of these individuals is responsible for the accuracy of
 the public statements detailed herein.

40. 3 The Individual Defendants, because of their positions of control and authority as 4 senior executive officers and/or directors of Vocera, had access to the adverse undisclosed 5 information about Vocera's business, operations, and financial statements through access to 6 internal corporate documents, conversations with other corporate officers and employees, 7 attendance at Vocera management and Board of Directors meetings and committees thereof, and 8 via reports and other information provided to them in connection therewith, and knew or 9 recklessly disregarded that these adverse undisclosed facts rendered the positive representations 10 made by or about Vocera materially false and misleading.

41. The Individual Defendants are primarily liable as participants in a fraudulent
scheme and course of conduct that operated as a fraud or deceit on purchasers of Vocera
securities by disseminating materially false and misleading statements and/or concealing material
adverse facts. The scheme: (i) deceived the investing public regarding Vocera's products,
business, operations, and management, and the intrinsic value of Vocera securities; and (ii)
caused Plaintiffs and members of the Class to purchase Vocera securities at artificially inflated
prices.

18

III. SUBSTANTIVE ALLEGATIONS

19

A. Vocera Business Overview

42. Vocera is a provider of mobile communications solutions. The Company claims
to help its customers, primarily hospitals, improve patient safety and satisfaction, and increase
hospital efficiency and productivity through the use of its patented communications system and
software.

43. Hospital communications are typically conducted through disparate components,
including overhead paging, pagers and mobile phones, often relying on written records of who is
serving in specific roles during a particular shift. According to Vocera, these legacy
communication methods are inefficient, often unreliable, noisy and do not provide "closed loop"
communication (in which a caller knows if a message has reached its intended recipient).

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page17 of 141

Moreover, these communication deficiencies can negatively impact patient safety, delay patient
 care and result in operational inefficiencies, including increased costs.

44. Vocera's communication platform, which is meant to address all the problems
inherent in legacy hospital communications methods, consists of "Voice Communications,"
"Secure Messaging," and "Care Transition" solutions. Vocera obtains substantially all of its
revenue from the sale of its Voice Communications solution.

The Voice Communications solution includes a wearable voice communication
badge and a software platform that enables users to connect instantly with other hospital staff
members. The software platform contains sophisticated voice recognition software and call
management functionality. It enables two-way voice communications without the need to
remember a phone number, or even know the name of the person on call in a particular
department. The badge is worn by hospital employees, clipped to his/her shirt or lanyard.

46. The Secure Messaging solution securely delivers text messages, alerts and other
information directly to and from smartphones, and is designed to replace paging and unsecured
short messaging service, or SMS systems.

47. The Care Transition solution consists of a hosted voice and text based software
that captures, manages and monitors patient information when a patient is transferred from one
caregiver to another. The solution enables caregivers to capture and transfer important
information about patients in either written or voice recorded form from any phone or PC.

48. Vocera also offers services to complement its products. The additional services
include consulting services under the name "ExperiaHealth," professional services, which help
the customer deploy, manage and update their Vocera systems, and 24 hour a day technical
support.

24 25

26

49. During the Class Period, Vocera's product sales accounted for approximately two-thirds of its revenue.

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page18 of 141

	(in thousands, except per share data)	2012	Percentage of Revenue	2013	Percentage of Revenue
2	Consolidated statements of operations data:				
	Revenue				
3	Product	\$ 65,028	64.4%	\$ 62,393	60.9%
	Service	\$ 35,929	35.6%	\$ 40,105	39.1%
4	Total revenue	<u>\$100,957</u>	<u>100%</u>	<u>\$102,498</u>	<u>100%</u>

5
50. Revenue from product sales consists of hardware revenue and software revenue.
Hardware revenue refers to the actual device, batteries, chargers, lanyards, clips and other badge
accessories. Software revenue consists of a perpetual license to the Voice Communication
solution. Additional software revenue is derived from the sale of term licenses, which are
renewed on a subscription basis. Product revenue is generally recognized upon shipment of
hardware, while software revenue is recognized ratably over the applicable term.

Service revenue consists of sales of software maintenance, extended warranties
 and professional services. Software maintenance is typically invoiced annually in advance,
 recorded as deferred revenue, and recognized as revenue ratably over the service period.
 Professional services revenue is recognized as the services are provided. Extended warranties
 are invoiced in advance, recorded as deferred revenue, and recognized ratably over the extended
 warranty period.

17

18

19

52. According to Vocera, the Company does not have any direct competitors as it is the only Company to offer instant, hands-free communication through voice-activated, role based and activity based calling.

20

B. Hospital Revenues Drive Vocera's Business

S3. As of December 2011, the Company's products were used in 875 hospitals and
healthcare facilities and Vocera's customer base ranged from large hospital systems to small
local hospitals, as well as other healthcare facilities. Substantially all of Vocera's revenue is
derived from sales of the Voice Communication solution to the healthcare market and, in
particular, hospitals. Sales of the Voice Communication solution to the healthcare market
accounted for 91%, 92%, and 91% of the Company's revenue for the three months ended March
31, 2013 and the years ended 2012 and 2011, respectively.

54. Private hospitals make up the bulk of the Company's hospital clients, with
 government hospitals, such as those run by the Department of Veteran Affairs (the "VA"), or the
 Department of Defense (the "DOD") accounting for approximately 10% of revenue.
 Historically, bookings have tended to peak in the back half of each year as hospitals seek to
 spend budgets before fiscal year end, and are lowest in the first quarter.

55. Vocera's products require that a hospital have in place voice grade wireless or a
Wi-Fi network installed throughout the hospital, including in access points in stairwells, and also
require that a hospital install system servers to operate the hardware and software. Installing
these systems requires a substantial, upfront capital investment by the hospital. The sales cycle
for a Vocera installation and roll out typically requires nine to twelve months.

56. Vocera's hospital customers initially deploy Vocera solutions in specific
departments before expanding into other departments. The cost of the initial deployment
depends on the number of users and departments involved, the size and age of the hospital and
the condition of the existing wireless infrastructure, if any, within the hospital. During 2011, the
initial purchase order for new hospital deployments of a Voice Communication solution ranged
from approximately \$50,000 to \$2.7 million, with an average initial deployment cost of
\$360,000.

18

C. The Importance of Bookings and Backlog to Revenue Visibility

19 57. "Bookings" are orders that are placed for Vocera's products and services. 20 Because Vocera requires that a hospital have certain infrastructure in place in order to operate 21 the Vocera communication system, there is often a delay in rolling out Vocera's product. Even 22 after the infrastructure is in place, and Vocera ships badges and software, Vocera must also train 23 its customers to use the badge. During the Class Period, approximately 85% of Vocera's 24 bookings came from existing customers looking to upgrade their network or expand use of 25 Vocera's communication system into new departments. Only 15% of bookings came from new 26 customers. Bookings convert to revenue when implementations can be scheduled and when 27 Vocera ships new badges.

1	58.	Bookings from new customers, and at least a portion of the bookings of repeat				
2	business, will	typically go into backlog. "Backlog" refers to products or services that have been				
3	ordered but the	at have not yet been delivered or provided. The backlog typically contains orders				
4	that have spec	ific future delivery dates for different aspects of Vocera's product (<i>i.e.</i> , training,				
5	installation, so	oftware, badges). Since a Vocera roll out can take nine to twelve months, a				
6	healthy, or hig	h, backlog signals robust future revenues, and visibility into growth.				
7	59.	The Company did not report its backlog to investors during the Class Period until				
8	the first correc	ctive disclosure on February 27, 2013, but Vocera repeatedly told the market that				
9	the large num	ber of repeat customers (85% of its revenue) provided a predictable and reliable				
10	revenue stream	n and for "visibility" into future revenues. Analysts understood the importance of				
11	the Company'	s backlog and its implications on revenue visibility and growth. For example, on				
12	May 7, 2012,	a William Blair analyst commented:				
13		The visibility of Vocera's revenue model is further explained by				
14		<i>its growing backlog and deferred revenue balance.</i> The company's backlog has more than doubled from \$9.4 million in				
15		2009 to an estimated \$22.5 million at the end of 2011, in part because of increased new client deployments and expansions at				
16		existing customers pushing related revenue into the next period as well as growth in the professional services segment. Backlog				
17		consists primarily of orders for software and devices deployments that have yet to take place, as well as scheduled professional				
18	D	service engagements.				
19	D.	The Company and Market Focus on Revenue and EBITDA				
20	60.	Vocera provided various metrics to investors to show the financial health of the				
21	Company. Ar	nong these metrics were revenue and adjusted EBITDA, a non-GAAP				
22	measurement	the Company used to evaluate its financial performance and profitability.				
	EBITDA is an	acronym for Earnings Before Interest, Taxes, Depreciation and Amortization. As				
23 24	set forth in the	e IPO Offering Materials, defined herein, Vocera provided investors with adjusted				
24	EBITDA that reflected net income or loss, adjusted to exclude interest income and expense,					
25 26	taxes, deprecia	ation and amortization, stock-based compensation, acquisition related costs, and				
26 27	the change in	fair value of warrant and option liabilities. Adjusted EBITDA was of particular				
27 28	importance to	the Individual Defendants because the Company based its executive bonuses on				
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 15 0. 3:13-CV-03567 EMC				

both adjusted EBITDA and revenue.² Analysts also considered adjusted EBITDA to be an 1 2 important financial measure of Vocera's performance. In its analyst reports, William Blair 3 regularly described adjusted EBITDA as "the key profit metric to monitor." In an analyst report 4 issued on May 9, 2012, J.P. Morgan commented that a higher EBITDA "indicat[ed] the business 5 is overall on solid footing to deliver at or above our expectations."

6 61. The Individual Defendants were also intensely focused and intimately involved in 7 tracking and understanding the recognition of revenue and the timing thereof. A former Senior Manager of Order Administration at Vocera ("CW1")³ provided details regarding the Individual 8 9 Defendants' active participation in Vocera's revenue meetings. CW1 stated that Vocera's 10 management held monthly meetings. In the last month of the quarter there were weekly 11 meetings and as the quarter drew to a close, daily revenue meetings. According to CW1, these 12 meetings were held in the executive conference room and were attended by Vocera's executives, 13 including but not limited to, Zerella, Lang, Jay Spitzen, the General Counsel, O'Hagen, the Chief 14 Accounting Officer, Michael Hutchinson, the VP of Finance, and sometimes Zollars. CW1 15 attended these meetings as well. According to CW1, Zollars attended the meetings roughly 50% 16 of the time, Zerella and his two vice presidents, Mike Hutchinson and Mark O'Hagan were 17 always there, and Lang was at the meetings about 90% of the time. CW1 elaborated: "Zerella 18 and every high-ranking executive was at these meetings...as I was. I never saw a group that was 19 so intent to know every number and involved in all of those decisions."

- 20
- 21 ² Vocera's Executive Compensation Plan is described more fully herein in Section III.H.2. 22 ³ The former Senior Manager of Order Administration at Vocera is described as CW1. CW1 was employed by Vocera from 2008 until August 2013. In 2011, CW1 began reporting to the 23 former CFO, Martin Silver. After Silver's departure, CW1 reported to Mike Hutchinson as interim CFO and then to Zerella. At one point, CW1 reported to Mark O'Hagan, Chief Accounting Officer. CW1's team was responsible for backlog and the administration of orders. 24 CW1 ensured that all of the requisite paperwork was in order and the contracts were signed 25 before orders were sent to customers. Every order that was booked whether it was "booked and shipped" or remained on backlog was managed by his team. CW1 added that an example of an 26 order on backlog were supply orders or services that had not been deployed yet. CW1 reiterated that it was his role to "oversee" every single order at Vocera. CW1's group was divided by 27 regions, western US and eastern US. CW1 also participated in revenue meetings (where Individual Defendants were present), where backlog was discussed. All CWs are referred to in 28 the masculine form to protect their identities.

62. CW1 indicated that Vocera utilized a number of software systems to track
 Company metrics, including Excel spreadsheets to track orders and backlog. CW1 noted that the
 sales organization developed forecast reports from input received by the sales staff using
 Salesforce.com software. CW1 stated that the Company used an older Microsoft ERP system up
 to and including 1Q13, called the Great Plains ERP. Tensoft was another software system used
 to track booking changes and commissions.

63. CW1 stated that after the IPO, under the Zerella regime, the reports handed out at
the revenue meetings became more and more robust. These reports included a detailed list of
orders (both potential and achieved), as well as the likelihood, as a percentage, that the order
would close by quarter end. According to CW1, the attendees at the revenue meetings would go
through every order in detail.

12

E.

13

Relevant Legislation Affecting the Hospital Industry

1. The Affordable Care Act

64. On March 23, 2010, healthcare reform entitled the "Patient Protection and
Affordable Care Act" (the "ACA") was signed into law. The new law was intended to increase
the rate of insured individuals by expanding insurance coverage while lowering the costs of
healthcare for both individuals and the government. Challenges to the law's constitutionality
were rejected by the Supreme Court on June 28, 2012.

19 65. One goal of the ACA was to reduce costs and improve the delivery of healthcare 20 services by focusing on the quality of healthcare service. The ACA attempts to accomplish this 21 through an increase in competition, regulation, and incentives to streamline the delivery of 22 healthcare. One such incentive is called "Hospital Consumer Assessment of Healthcare 23 Providers and Systems" also called "HCAHPS." HCAHPS is a survey reporting patients' 24 perspectives of hospital care. Beginning in October 2012, a part of hospital Medicare 25 reimbursement was tied to HCAHPS results. Several questions on the HCAHPS survey relate to 26 responsiveness of hospital staff, communication with nurses, and quietness of the hospital 27 environment. According to the Company, Vocera's products and solutions have been shown to 28 improve HCAHPS results. The ACA primarily affects Vocera's private hospital customers. In

general, the ACA did not cause any significant changes to Vocera's government hospital
 customers (the DOD or VA) because the ACA does not affect Tricare, the military's health
 insurance program.

4

2. Budget Control Act

5 66. The Budget Control Act ("BCA") was enacted in 2011 in order to bring resolution 6 to the debt ceiling crisis. The law was intended to reduce federal budget deficits by a total of 7 approximately \$2.1 trillion from 2012-2021. The reduction came in the form of automatic 8 spending cuts, otherwise known as "sequestration." Sequestration was scheduled to begin in 9 January 2013. However, in January 2013, enactment was delayed by an additional three months, 10 and the BCA ultimately came into effect on March 1, 2013. Medicare was subject to 11 sequestration, and provider payments were cut up to 2 percent. Government hospitals' fiscal 12 years end on September 30. Thus, in 2012, government hospitals began planning their new 2013 13 budget with the pending sequester in mind. Sequester mainly affected Vocera's government hospital customers. 14

15

28

F.

Vocera's Growth Strategy

16 67. Between 2007 and 2011, prior to the IPO, Vocera's revenue increased more than
17 two fold from approximately \$34 million to over \$79 million, and adjusted EBITDA increased
18 from negative \$2.6 million to over \$3 million.

				Yea	rs ended De	cember 31,
(in thousands)		2007	2008	2009	2010	2011
Consolidated stateme	nts of operations data:					
Revenue						
Product		\$ 27,332	\$ 28,352	\$ 25,985	\$ 35,516	\$ 50,322
Service		7,125	11,474	15,154	21,287	29,181
Total revenue	!	34,457	39,826	41,139	56,803	79,503
Adjusted EBITDA		\$ (2,688)	\$ (4,800)	\$ 578	\$ 3,821	\$ 3,020
1.	The IPO					
68. On A	ugust 1, 2011, the	Company file	ed a Regist	ration Stat	ement with	h the SEC
form S-1, in which i	t announced its inte	ention to hold	an IPO fo	r the sale	of Vocera	common

stock. The Company amended the Registration Statement several times, which ultimately

1	became effective on March 27, 2012. On March 28, 2012, Vocera filed a Form 424B4
2	Prospectus (which together with the registration statements make up the "IPO Offering
3	Materials"). 6,727,500 common shares were sold at \$16.00 per share in the IPO, which occurred
4	on or about March 28, 2012. The Company sold 5 million shares of common stock, existing
5	shareholders sold an aggregate of 1,727,500 shares, and underwriters sold an additional 877,500
6	shares as a result of the underwriters' exercise of their over-allotment option.
7	69. The IPO Offering Materials explained that several forces in the hospital industry,
8	including healthcare reform, were driving adoption of Vocera's product as most hospitals'
9	"legacy" communications systems were unreliable, inefficient and have a negative effect on
10	patient satisfaction. Moreover, the hospital industry faced a growing shortfall among nursing
11	staff. According to the IPO Offering Materials:
12	The inadequate coverage of patients by qualified nurses can detract
13	from the patient experience and impact hospitals' financial performance as patients are increasingly selecting hospitals and providers based on quality of care, cost and overall experience
14	with the provider. <i>The increasing focus on improving patients</i> '
15	experience is supported by the healthcare reform initiative, which incorporates financial incentives for hospitals to improve the quality of care and patient satisfaction. These forces are driving
16 17	hospitals to invest in technology and process improvements to manage their operations more efficiently and to improve staff and patient satisfaction.
17	70. Vocera claimed that its products and services helped improve hospitals' finances
19	and achieve the goals of healthcare reform by (1) providing improvements in patient safety, (2)
20	enhancing patient experience, (3) improving caregiver job satisfaction, and (4) increasing
20	hospital revenue while reducing expenses. Vocera also repeatedly expressed that hospitals were
21	seeking more effective ways of addressing their communications deficiencies and that Vocera's
22	products would provide those solutions.
23	71. In the IPO Offering Materials, Vocera estimated "the worldwide hospital market
24	opportunity for the full deployment of our Voice Communication solution to be over \$6 billion."
25 26	Indeed, Vocera stated that its communication systems were installed and used in only parts of
20	800 of the 6,000 hospitals in the U.S. Vocera told the market that it had a "growing U.S.
27	Customer base," and that in the eight months leading up to the IPO, this growing customer base
20	
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 19 MASTER FILE NO. 3:13-CV-03567 EMC

and current customer expansion had led Vocera's "quarterly revenue [to] increase[] each
 quarter."

On the day of the IPO, Zollars was interviewed by "The Street." When asked if 3 72. 4 he was concerned that the Company was too focused on the hospital industry, Zollars said "No," 5 and affirmed the Company's growth story, stating: "We're actually really excited about health 6 care because it's about a \$6 billion market for our solution, so we've got plenty of room to grow. 7 We're less than 10% penetrated today." When asked if Zollars was concerned about the effect of 8 the Supreme Court's upcoming decision on healthcare reform, Zollars answered that Vocera was 9 not being impacted by health care reform at all, stating: "So the reform really doesn't have much impact on us, and again, we've got great growth opportunity with about 90% of the market left to 10 11 go capture." 12 73 The IPO was a huge success, and the Company raised \$70.5 million in net 13 proceeds. By the next day, on March 29, 2012, Vocera's stock closed at \$24.91, an increase of 14 over 55% of the offering price of \$16.00. 15 **Vocera's Purported Class Period Success** 2. 16 74. On May 9, 2012, in the first reporting period after the IPO, Vocera filed a Form 8-17 K reporting revenue for the first quarter of \$23.1 million, an increase of 26% year over year. 18 Vocera's non-GAAP adjusted EBITDA was \$2.0 million, an increase of 44% year over year. 19 The Company also issued strong guidance for 2Q12 and for fiscal year 2012. 20 75 During an analyst call that day, Defendants touted the Company's "significant 21 growth opportunities" and affirmed that the type of growth the Company was seeing and 22 projecting for the future was "sustainable top line growth." Zerella stated, "[w]e committed to 23 25% top line growth over the longer time in the road show and frankly, our view has not 24 changed." Zerella also touted the "visibility" into future revenue streams because of the 25 reliability of Vocera's recurring revenues. 26 76. Defendants also told the market that the hospital capital spending environment 27 had not changed. Finally, Defendants affirmed analysts' perception that the Supreme Court's

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page26 of 141

review of healthcare reform was not affecting the Company, but rather, that there was a lot of
 "momentum []behind patient experience and the HCAHPS scores."

3 77. On this news, Vocera's stock price rose nearly 7% to close at \$23.35 on May 10
4 on heavy volume.

5 78. During 2012, Defendants' growth story for the Company seemingly remained 6 intact. Quarter after quarter, Defendants reported that Vocera met or beat its revenue and 7 adjusted EBITDA guidance and that the Company was on track to meet its fiscal year 2012 8 guidance. For the second and third quarters, Vocera came in at the high end of its guidance. In 9 the fourth quarter, 2012, Vocera came in at the midpoint of guided revenue and adjusted 10 EBITDA, allowing the Company to meet analysts' consensus expectation of annual revenues of 11 \$101 million. Vocera far surpassed its adjusted EBITDA guidance quarter after quarter by 12 millions of dollars. Vocera's reported results were also a marked increase year over year for 13 results in the same quarter for 2011.



20

21

22

23

24

25

26

27

28

Vocera Meets or Beats Revenue and EBITDA Guidance in 2012

5		1Q 2012	2Q 201	2	3Q 201	2	4Q 201	2
6		Actual	Guidance	Actual	Guidance	Actual	Guidance	Actual
7	Revenue	\$23.1 M	\$24 M to \$25 M	\$24.9 M	\$25 M to \$26 M	\$26.0 M	\$26 to \$28 M	\$27.0 M
8	Y/Y % Increase	26%		30%		27%		24%
10	Adjusted EBITDA	\$2.0 M	\$0.5 M to \$1.0 M	\$3.0 M	\$1.0 M to \$2.0 M	\$3.8 M	\$1.2 M to \$2.2 M	\$3.2 M
19	Y/Y % Increase	44%		650% ¹		3,700%²		166%³

¹ Non-GAAP Adjusted EBITDA of \$3.0 million, compared to \$0.4 million in the second quarter of 2011 ² Non-GAAP Adjusted EBITDA of \$3.8 million, compared to \$0.1 million in the third quarter of 2011

³ Non-GAAP Adjusted EBITDA was \$3.2 million, compared to \$1.2 million in the fourth quarter of 2011

79. In addition, Vocera increased its annual non-GAAP adjusted EBITDA guidance

significantly in 2012. Vocera also raised its earnings guidance substantially.

1 2

3

4

5

6

7

Annual 2012 - Increased EBITDA and EPS Guidance

	Form 8-K						
	May 9, 2012	August 2, 2012	November 5, 2012				
2012 Adjusted EBITDA Guidance	\$4 M to \$5 M	\$7 M to \$8 M	\$10 M to \$11 M				
2012 GAAP EPS Guidance	\$(0.06) to \$(0.11)	\$(0.03) to \$(0.08)	\$0.09 to \$0.11				
2012 Non-GAAP EPS Guidance	\$0.10 to \$0.14	\$0.20 to \$0.24	\$0.33 to \$0.35				

8 80. Vocera's growth story was also buoyed by Defendants' non-numerical statements 9 about the Company's performance and expectations. For example, on August 2, 2012, when the 10 Company announced second quarter results and increased guidance, Defendant Zollars 11 remarked: "[o]ur Voice communications solution continues to perform well." In the earnings call with analysts that day, Zollars touted the "strength of the second quarter" and "very solid 12 13 new customer growth." Defendants again assured the market that the strong results were driven 14 by the "visibility" of Vocera's business model. Defendants also continued to deny that 15 healthcare reform was impacting Vocera's business negatively and reiterated that they did not 16 see any impact on hospital buying patterns. On this news, Vocera's stock price rose over 7% to 17 close at \$29.18 on August 3.

18

3. Vocera's Secondary Offering

19 81. In the midst of this purported success, Vocera announced that it would be offering 20 additional common stock in a Secondary Offering. On August 24, 2012, the Company filed a 21 Form S-1 with the SEC and subsequently issued one amendment. On September 6, 2012, the 22 SEC declared the registration statement effective. On September 7, 2012 Vocera filed a Form 23 424B4 Prospectus (which together with the registration statements make up the "Secondary 24 Offering Materials"). Vocera's common shares were sold at \$28.75 per share in the Secondary 25 Offering, which occurred on or about September 7, 2012. The Company sold 1,337,500 shares, 26 existing stockholders sold 4,211,250 shares of common stock, and underwriters sold an 27 aggregate of 723,750 shares as a result of the underwriters' exercise of their over-allotment 28 option.

82. The Secondary Offering Materials repeated many of the statements made in the
 IPO Offering Materials, including that healthcare reform would spur demand for Vocera's
 products and services, and that the market opportunity for Vocera was over \$6 billion.

4 83. The Secondary Offering raised over \$36 million in net proceeds for the Company
5 and selling shareholders. Vocera's stock price rose over 5%, on September 7, 2012, the day of
6 the Secondary Offering, to close at \$30.42 on extremely heavy volume.

84. In connection with the Secondary Offering, Vocera issued a press release stating
that J.P. Morgan Securities LLC and Piper Jaffray & Co., the lead book-running managers of
Vocera's IPO and Secondary Offering, were releasing a lock-up restriction with respect to
certain shares of Vocera's common stock held by certain officers and directors of Vocera. The
release was scheduled to take effect concurrently with the completion of the Secondary Offering
on September 12, 2012. Zollars and Lang took advantage of this partial release and each sold
millions of dollars worth of stock as more fully discussed in Section III.H below.

14 85. Over the next several months, Defendants continued to tout strong demand for 15 Vocera's products and services, reassured the market that Vocera's growth story was intact, and 16 continued to tout "visibility" into Vocera's recurring revenue streams. For example, on 17 November 5, 2012, the Company announced earnings for the third quarter and increased revenue 18 guidance for the full year. Zerella told analysts that the growth level for the Vocera badge device 19 was "pretty consistent with historical trends...nothing out of the ordinary, really, in terms of 20 growth rate as compared to previous quarters." Both Zollars and Zerella emphasized ongoing 21 growth in the number of clients who purchased products and services from Vocera and that the 22 number continued to grow every quarter. Zollars again affirmed Defendants' "visibility" into 23 revenues, attributable to Vocera's recurring revenue business model.

86. In November 2012, Defendants informed the market during their third quarter
earnings call that several government contracts slipped outside the third quarter, but stated that
they "remained very, very optimistic about the opportunity to sell into the government space."
Defendants did not attribute the reason for these slipped bookings to federal budget issues
relating to the pending BCA sequestration and instead blamed other external forces. Analysts

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page29 of 141

1	were confider	nt that these issues were not affecting the Company's growth. For example, on					
2	November 5,	2012, a William Blair analyst wrote a report entitled: "Strong Software Sales Drive					
3	Another Beat-and-Raise Quarter; Growth Outlook Remains Robust" and on that same day, a J.P.						
4	Morgan analysts wrote: "Overall dynamics unchanged. We reiterate our Overweight rating on						
5	VCRA given	its strong competitive position and opportunities for growth."					
6	87.	On January 7, 2013, at the J.P. Morgan Healthcare Conference, Zollars told the					
7	market that V	ocera was a "good Healthcare IT stock to own," that healthcare reform was					
8	continuing to	have a positive effect on Vocera's sales, and that Vocera's market was "growing."					
9	Zerella in turi	n emphasized the "very large market opportunity," "good visibility and repeatability					
10	of [Vocera's]	revenue streams," and growing revenues.					
11	88.	At no time during the Class Period did Defendants disclose that that the ACA and					
12	uncertainties	surrounding its implementation were <i>already having</i> an effect on demand for					
13	Vocera's prod	luct.					
14	G.	The Negative Effects of the ACA and BCA on Vocera's Business Persist					
15		Throughout the Class Period and Are Known By Defendants But Hidden From Investors					
16	89.	Numerous high level former employees from the Company and internal Company					
17	documents sh	ow that contrary to Vocera's public statements, Vocera's business was actually					
18	suffering at th	he time of the IPO and throughout the Class Period. Quarter after quarter,					
19	Defendants to	outed Vocera's growth and visibility into current and expected revenue, while					
20	denying that a	any adverse impact was being felt from the ACA or the budget sequestration.					
21	However, beł	hind the scenes,					
22							
23							
24	90.	At meetings held at the end of each quarter during the Class Period, Defendants					
25	received repo	rts confirming that Vocera's quarterly revenue was					
26		In order to make quarterly guidance and continue the					
27	facade that V	ocera remained a "growth story," Defendants scoured Vocera's backlog and pushed					
28	hospitals to a	ccelerate the acceptance of shipments of Vocera products to an earlier quarter,					
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 24 D. 3:13-CV-03567 EMC					
	WIASTER FILE IN	J. J. 1J-C V-0JJ0/ LIVIC					

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page30 of 141

allowing Vocera to recognize revenue sooner and meet guidance. This tactic may have worked
for a while, but it (1) created an ever growing gap between expected quarterly revenue and what
the Company had guided the market, and (2) depleted the backlog going forward. Defendants
were essentially robbing revenue from future quarters to allow the Company to meet guidance in
the current quarter -- all without telling the market that new bookings were declining and
backlog was dropping. This smoothing of revenue also created the appearance that Defendants
were able to deliver consistent, on-target guidance and results.

8

9

91. Former employees and

Defendants became so desperate that they began shipping products to hospitals before the agreed upon shipping date, *without* customer authorization. ¶121-128. Further, numerous high level employees told Defendants, who were involved in the decision to accelerate backlog shipments, that Vocera's Class Period revenue forecasts (and the forecasts were not reasonable and that Vocera was going to "fall off a cliff" because it kept eroding the Company's backlog.

16

1. The Internal Audit Report

17 92. CW2, the former Senior Director of Internal Audit and Compliance, worked for 18 Vocera from November 2011 until August 2013. CW2 is an experienced internal auditor with 19 over 30 years of internal audit and compliance experience, particularly in Silicon Valley. CW2 20 reported to John McMullen, Chairman of the Audit Committee, and Zerella. CW2 maintained a 21 binder of internal Company documents which included documents and conclusions relating to 22 Vocera's booking practices, backlog management, and revenue recognition practices during the 23 Class Period, with a focus on expedited shipments (backlog pull-ins) that occurred in 4Q12 and 24 1Q13. Among these documents are a report entitled "Q1 Revenue Compliance Exception, 25 Backlog Management & Forecasting Practices - 2013" (the "Internal Audit Report") and a 26 supporting document with management comments to the Internal Audit Report and Internal 27 Audit's responses ("Management/Audit Response"). "Management" in the report refers to

Zerella, Mark O'Hagen (CAO), Michael Hutchinson (Vice President Finance), and Bob Flury
 (Senior Vice President of Sales).

3 93. The Internal Audit Report was prepared by CW2 (except for the sections with
4 management comments) and was informed by CW2's internal investigation, interviews with
5 numerous employees, and internal Company financial data. The Internal Audit Report was dated
6 June 18, 2013 and was sent to: Bill Zerella (CFO), Mark O'Hagan (CAO), Michael Hutchinson
7 (VP Finance), Bob Flury (Senior Vice President of Sales), Bob Zollars, (CEO), Brent Lang
8 (COO), Vocera Audit Committee Members, and PwC, Vocera's independent accountants.

2. The ACA Was Negatively Affecting Vocera's Growth at the Time of the IPO and Throughout the Class Period

94. According to CW1, the ACA (and BCA) were frequently discussed during the 16 Class Period in the senior management revenue meetings that CW1 attended. CW1 recalled that 17 during and after the IPO, concern about both laws and their impact on sales and the Company's 18 growth potential was expressed at the revenue meetings she attended with the executives. In 19 particular, CW1 recounted that leading up to and immediately following the IPO, much 20 discussion was held among management about the ability to achieve revenue forecasts and that 21 the rosy forecasts and statements related to future sales expectations did not comport with what 22 was being discussed internally. In terms of revenue growth, CW1 told Zerella and Martin Silver 23 [who was employed by the Company during the time period leading up to the IPO] that the 24 Company would not meet internal projections of future sales based on the realities of what was 25 going on with the business. CW1 concluded that the Company's projected growth was not 26 sustainable because of the ACA, and that the ACA was one of the factors that impacted Vocera's 27

28

9

10

11

12

13

14

sales [bookings]. CW1 specifically recalled VP of Sales Robert Flury mentioning the ACA as
 one of the reasons Vocera was having sales troubles.

3 95. CW3 also confirmed that the ACA was adversely impacting upon sales of 4 Vocera's communication systems. CW3 was employed by Vocera as a Health Systems Director 5 from January 2011 to January 2014. CW3 initially reported to Greg Young, Vice-President of 6 Health Systems, who was in charge of the federal government team, and after being shifted to the 7 enterprise side reported to Kelly Bechtel, the West Region Vice President. CW3 was responsible 8 for several large health systems in the west, including Kaiser, the VA and DOD, managing top 9 line sales, revenue growth and master purchasing contracts. CW3's focus was on new accounts, 10 adding new accounts in each of the health systems, helping to leverage national contracts and 11 funding.

96. CW3 explained that in order for a hospital to install a Vocera communications
system, it needed to commit to voice-over IP, wifi and access points throughout the hospital, and
including multiple servers. According to CW3, this was a huge commitment for "net-new"
hospitals. CW3 explained that the ACA caused hospitals to "hold onto cash" and focus on
"need" which made a Vocera communications system a tough sale. CW3 stated that the ACA
forced hospitals to be more conservative with capital expenditures, such as Vocera's system and
products, which in turn caused Vocera's sales to suffer.

97. According to CW3, because of questions related to implementation of the ACA,
hospitals were leery of spending their capital, and needed to hold on to cash - so there is no
question that every hospital tightened its belt. CW3 stated that he observed the actual, negative
effects of the ACA on Vocera's business by "mid-2012, Q2, Q3." In fact, CW3 stated that it was
clear, even before the Supreme Court ruling essentially affirming the legality of the ACA [which
was in June of 2012], that the ACA was going to impact negatively on hospitals' spending and in
turn Vocera's business.

- 26
- 27
- 28

2

3

4

5

6

7

8

9

1

3. The Effects of Sequestration Are Felt in 2012 **But Not Publicly Reported Until 2013**

98. In their notes to the Internal Audit Report, management admits that "federal budget issues" "impacted" the Company's growth "in our government business" in 2012. 99. CW1 stated that the government's budget sequestration slowed down the government hospital sales process at Vocera. CW1 recalled that in the fall of 2012, the sales process was slowed down by 20% or more. CW1 advised that Hutchinson kept a report (that CW1 reviewed) where he tracked the sales cycle (this is where they are, this is where we want to be, etc.). CW1 confirmed that Hutchinson would have shared this report with Zerella, O'Hagan, Perkins, Zollars, and Lang.

10 100. CW3 corroborates that federal budget issues affected Vocera during the Class 11 Period, stating that the BCA, or sequestration, took a toll on Vocera's business. CW3 noted the 12 effects of sequestration on Vocera's government business, stating that its impact on pending 13 deals was significant. CW3 explained that all DOD and VA hospital business "dried up." CW3 14 believed that VA and DOD hospitals made-up about 10% of Vocera's overall customers (he 15 estimated that they were about \$10-\$20 million of Vocera's overall revenue stream), the rest 16 being private hospitals. According to CW3, it was tough to get any dollars through and Vocera's 17 price point made it even more difficult. CW3 recalled that he had a \$1.5 million hospital deal 18 that was about to be booked and then fell through due to the sequestration. He continued to say 19 that sequestration forced government hospitals to "hang onto (their) cash." CW3 reiterated that 20 both pieces of legislation [ACA and BCA] affected hospitals' willingness to invest in capital 21 expenditures that were not a necessity.

22

101.

- 23
- 24 25

26

27

28

CW4 was employed by Vocera from September 2010 to April 2014 as a Senior Manager of Professional Services. CW4 reported to the Vice President of Professional Services, Andy Hayden, who first reported to Senior Vice President of Services, Victoria Perkins, and the directly to Lang. CW4's territories included the northeastern U.S., Canada, the U.K. and the Middle East, and CW4's responsibilities included developing new sales opportunities, assisting the sales team on selling services in his territories, and forecasting service revenue.

102. Corroborating CW3, CW4 stated that Veteran's Affairs bookings were "running dry" during the Class Period.

3

4.

1

2

Throughout the Class Period, the Company Cannibalized its Backlog in Order to Keep Its Growth Story Alive In the Minds of Investors

4 CW1 recalled that backlog became the focal point of the revenue meetings that 103. 5 CW1 attended with the executives. CW1 recalled sitting in the revenue meetings [which were 6 attended by the Individual Defendants ($\P61$) and listening to the executives discuss how they 7 were going to need to utilize the backlog to achieve revenue targets, and this occurred from the 8 time of the IPO through the end of CW1's tenure. According to CW1, during the revenue 9 meetings, the executives who attended were constantly asking "Can we pull it in?...Can we go 10 back (to a particular customer?...Are they (the salespeople) going to talk with the customer to 11 see if there is something we can do, maybe we can offer them some incentive." CW1 further 12 advised that about 20% of the Company's quarterly revenue during the Class Period came from 13 Vocera's pulling of revenue out of backlog, into an earlier quarter. According to CW1, Mike 14 Hutchinson, VP of Finance, spent the majority of his time trying to figure out how to utilize the 15 backlog to generate current revenue by accelerating shipments, or pulling backlog forward, to 16 compensate for the Company's shortfall in sales each quarter.

17

18

19

20

21

104. CW2 stated that prior to 1Q13, Vocera missed its forecasts in each quarters in 2012 by 20%. Consistent with CW1's account, CW2 stated: "We continually missed our forecasts quarter after quarter [but] Bill (Zerella) was insistent on growth and took from backlog to make up the shortfalls." Thus, for each quarter, Vocera would have missed its projections absent accelerating the backlog.

Vocera's quarterly revenue targets. According to CW1, at the end of the quarter, Defendants

executive was at these meetings...as I was - I never saw a group that was so intent to know every

number and involved in all of those decisions." CW1 continued that eventually, everyone except

decided what to ship and book as revenue. CW1 stated: "Zerella and every high-ranking

Defendants were intimately involved in the decision to use backlog to achieve

22

105.

23


24 25

- 20
- 26


27

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page35 of 141

the high echelon were excused from the revenue meetings and then, the word came down to his
 group as to what to ship and what to book.







and earnings, a quality prized by the investing public as reflective of management's perceived
 skill and credibility.

3 112. CW3 corroborates that declining sales caused Vocera to resort to cannibalizing its 4 backlog to make guidance. CW3 recalled that during the relevant time period, Defendants 5 "would have staff pull stuff through to make numbers." Corroborating CW2's conclusion, CW3 6 said that Vocera went so hard after quarterly numbers that it was routine to pull numbers 7 forward, and this process eventually caused quarterly sales goals to become completely 8 unrealistic. To that effect, the Internal Audit Report states "[o]verly optimistic bookings 9 forecasts can drive unnatural behavior in backlog management. If revenue targets are not 10 achievable on the merit of current booking trends, and backlog is depleted to help make the 11 numbers, succeeding quarters' revenue targets become increasingly more difficult to achieve."

12 CW3 stated that it did not matter if you had to "beg, steal and borrow" to make 113 13 numbers. The culture at Vocera was "sell my soul" just to achieve quarterly numbers and don't 14 worry about what sales were needed for future quarters. CW3 advised that the pressure came 15 directly from Robert Flury, Senior Vice President of Sales, who was definitely getting pressure 16 from the more senior executives to whom he reported. CW3 recalled that this pressure began in 17 2011 when he joined the Company but was exacerbated after the IPO through the end of his 18 tenure. CW3 stated that the Company was eating through backlog and "sucking the pipeline 19 dry."

20 CW3 provided an example of how Vocera would ship product early in order to 114. 21 make its numbers. CW3 was working on a hospital deal in Portland, Oregon, one of his "net-22 new" clients. According to CW3, a new Kaiser hospital was being built and expected to open in 23 early 2013. In June 2012, Kaiser committed to install a Vocera communications system at this 24 new hospital, but the hospital was not scheduled to open until February 2013. According to 25 CW3, around November 2012, he started to get pressure from Kathy Bechtel (Current Western 26 Region Vice President) to ship products to the hospital in Portland even through it had no need 27 for them since it had not opened yet. CW3 advised that Bechtel's directive likely came from 28 Robert Flury (Senior Vice President of Sales) since Bechtel did not do anything at Vocera

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page38 of 141

without Flury's oversight. CW3 was very concerned about accelerating this shipment because as 1 2 soon as the product was shipped, the warranty on the product would begin to run, even though 3 the hospital was not going to be using the products for months. CW3 was instructed to be a 4 "team player" and go along with the acceleration plan. According to CW3, ultimately, even with 5 his protests, the products were shipped by December 15, 2012, which in turn allowed Vocera to 6 recognize the revenue for this sale in 4Q12. CW3 explained that the Kaiser Portland hospital 7 situation was just one of many examples of how he and other sales personnel were pressured into 8 accelerating sales to make numbers for a particular quarter.

9 115 CW1 also described the pressure to make sales in order to meet quarterly 10 numbers. CW1 recalled sales personnel receiving directives from management to literally camp-11 out in the lobbies of hospitals to get a purchase order in time for a quarter end. CW1 recalled 12 that sales people would be forced to "badger" customers for the purchase orders, as product 13 could not ship without a signed purchase order. CW1 said "that's how it always was." CW1 14 also recalled one time when Kelly Bechtel became fed up and told Robert Flury that they were 15 not going to get the purchase order but that Flury (and his superiors) were relentless. The 16 pressure placed by management on the sales staff to make sales in order to meet guidance in the 17 summer of 2012 was particularly "intense" because it was important to meet guidance in the first 18 few quarters after the IPO, according to CW1.

19

20

26

27

28

5. Unable to Further Tap Into Backlog, The Company Violated Its Internal Revenue Recognition Policies In Order to Make It's 4Q12 and 1Q13 Numbers

21 116. The Company's practice of using backlog to make its quarterly numbers was
22 unsustainable, as backlog continued to be depleted and

23 CW2 stated that in 4Q12, Mike Hutchinson, VP of Finance, warned Zerella that the

24 Company was going to "fall off a cliff" because it was eroding backlog. By the end of 2012, and

25 moving into 1Q13, the Company was in a dire position.

Company's backlog had decreased from \$22 million just

⁸ See footnote 5.

CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS MASTER FILE NO. 3:13-CV-03567 EMC

a year ago to \$16 million.

1

2

3


4

5 Ultimately, Vocera met its 4Q12 guidance analysts' consensus
6 estimates of \$101 million by eating into backlog.

117. CW2 stated that Mike Hutchinson was very upset that the Company was burning
through backlog at the end of FY2012 and going into 1Q2013. CW2 recounted a discussion he
had with Hutchinson in 4Q2012 during which Hutchinson told CW2 that Zerella forbid him
(Hutchinson) from showing trending graphs at revenue meetings. According to CW2, the graphs
would have shown that the backlog was running out and that sales would not support the
Company's targets. Hutchinson told CW2 that the underlying data did not support the
Company's forecast for 1Q2013.

14 118. CW1 corroborated CW2's account. According to CW1, many insiders, including
15 Mike Hutchinson were concerned that the 1Q13 projections could not be achieved. CW1 noted
16 that Hutchinson challenged Bob Flury, SVP of Sales, over the projections and was quoted saying
17 to Flury, "[i]s this really going to happen?" CW1 stated that Flury replied to Hutchinson's
18 concerns in his typical fashion of "spinning things as if they were really going to happen." CW1
19 indicated that Hutchinson doubted whether the numbers Flury was reporting were accurate.

20 119. CW1 stated that in February 2013, one month before quarter close, people were 21 "frenzied," adding that there was a tremendous amount of pressure to make the numbers. CW1, 22 who attended the revenue meetings with the Individual Defendants, recounted that the top 23 executives, including the CFO, CEO, and CAO were so immersed in the numbers that they 24 viewed each deal in 1Q13 on a daily basis. CW1 noted that the C-suite [chief executives] was 25 always metrics driven but the intensity grew during 1Q13. CW1 stated that Zollars was 26 concentrating on additional strategic opportunities and Lang analyzed every single deal prior to 27 the close of 1Q13. According to CW1, CW1 had never seen a C-level team so close to the 28 details.



Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page41 of 141

was significant customer dissatisfaction that required attention by Vocera account managers in
 January and February 2013 to restore the injured customer relationship."

124. CW2 indicated that the shipment, which was over was sent
out on March 29, 2013, the last day of 1Q13, but the order was actually scheduled to ship on
June 30, 2013. If the shipment was returned which resulted in
"late accounting adjustments" of over the shipment in revenue. The Internal Audit Report notes that
there was displeasure and a negative impact on customer relations at the shipment.

8 125. CW1 confirmed that there were two occasions in 1Q13 where Vocera shipped
9 unauthorized products to two hospitals to make its numbers.

10 CW1 recalled that as the end of 1Q13 neared, the Company was "burning through 126. 11 backlog." CW1 described his experience on the expedited shipment. Right at the end 12 of 1Q13, CW1 received pressure from Michelle Goldman (Current Sales & Service Controller) 13 to ship the order to Around 4:30 pm on the last day of the quarter, CW1 was told to 14 ship the order. CW1 refused because CW1 did not have a signed purchase order. Goldman tried 15 to pressure CW1 to ship it out but CW1 refused unless CW1 received authorization from either 16 or Zerella.

17 127. According to CW1, after CW1 refused to ship the order, Goldman "stormed into" 18 a meeting in the executive conference room. This meeting was attended by Zerella, Mark 19 O'Hagen (Chief Accounting Officer) and others. O'Hagen then went to CW1 to get CW1 to 20 ship the products to . CW1 refused to do so without Zerella's written authorization. 21 Eventually, CW1 received Zerella's written authorization and begrudgingly sent out the order in 22 time to recognize the revenue for guarter end. According to CW1, sent the 23 unauthorized products back to Vocera upon receipt. CW1 recalled that there were definitely e-24 mails from the hospital to Vocera questioning the shipment and warning that there was never an 25 authorization for the shipment. CW1 was baffled as to how Vocera recognized the revenue 26 generated from that transaction. CW1 stated that this led to issues with satisfaction, 27 since it was upset about receiving product it did not authorize. As part of his investigation of the 28 backlog pull-ins, CW2 interviewed Michelle Goldman, Senior Manager of Sales Operations,

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page42 of 141

1	who, according to CW1, was involved in ordering the expedited shipment to
2	Goldman implied to CW2 that she was under pressure to make sure the shipments went out in
3	order for the Company to make its numbers. CW2 noted that there is a culture of fear at Vocera
4	evidenced by Goldman's statement to him while discussing backlog, "It's okay for you because
5	you are protected because you are in Internal Audit. Bill (Zerella) would just sack me if I didn't
6	do what I was told." CW2 further commented that people were scared to speak up at Vocera.
7	Indeed, the Company even discouraged employees from taking complete and accurate minutes at
8	meetings.
9	128. As part of his investigation, CW2 interviewed members of the Financial Planning
10	and Analysis ("FP&A") team which yielded evidence that the 1Q13 forecasts, and therefore the
11	related statements, made by the Company were not supportable with respect to 1Q13 forecasts.
12	CW2 noted that the forecasts did not factor in market trends and return trends.
13	129. CW2 also explained that the 2013 FY plan was not "aligned with historical trends
14	or validated with external environment/market conditions."
15	
16	
16 17	Particularly, CW2 concluded that:
	A growth goal was assessed to drive a stretch target for
17 18	A growth goal was assessed to drive a stretch target for revenue. The target revenue number was rationalized as achievable by hiring additional sales reps to wind the new Voice
17 18 19	A growth goal was assessed to drive a stretch target for revenue. The target revenue number was rationalized as achievable by hiring additional sales reps to win the new Voice customers, a new Messaging customers and a new ExperiaHealth customers to achieve and of the growth. In total
17 18 19 20	A growth goal was assessed to drive a stretch target for revenue. The target revenue number was rationalized as achievable by hiring additional sales reps to win the new Voice customers, a new Messaging customers and a new ExperiaHealth customers to achieve the of the growth. In total the plan assumed a new customers. This was a static increase over 2012 new customer achievement and ignored trends in this
 17 18 19 20 21 	A growth goal was assessed to drive a stretch target for revenue. The target revenue number was rationalized as achievable by hiring additional sales reps to win the new Voice customers, a new Messaging customers and a new ExperiaHealth customers to achieve and of the growth. In total the plan assumed and new customers. This was a sub-increase
 17 18 19 20 21 22 	A growth goal was assessed to drive a stretch target for revenue. The target revenue number was rationalized as achievable by hiring additional sales reps to win the new Voice customers, a new Messaging customers and a new ExperiaHealth customers to achieve and of the growth. In total the plan assumed new customers. This was a main increase over 2012 new customer achievement and ignored trends in this regard. There was no market research performed to evaluate whether the demand existed to achieve these numbers. The remaining growth was expected from the B3000 refresh
 17 18 19 20 21 22 23 	A growth goal was assessed to drive a stretch target for revenue. The target revenue number was rationalized as achievable by hiring additional sales reps to win the new Voice customers, in new Messaging customers and in new ExperiaHealth customers to achieve and of the growth. In total the plan assumed in new customers. This was a sub- over 2012 new customer achievement and ignored trends in this regard. There was no market research performed to evaluate whether the demand existed to achieve these numbers. The remaining growth was expected from the B3000 refresh opportunity together with National/regional account agreements to accelerate sales. No market research supports customer take up of
 17 18 19 20 21 22 23 24 	A growth goal was assessed to drive a stretch target for revenue. The target revenue number was rationalized as achievable by hiring additional sales reps to win the new Voice customers, a new Messaging customers and a new ExperiaHealth customers to achieve and of the growth. In total the plan assumed new customers. This was a minimum increase over 2012 new customer achievement and ignored trends in this regard. There was no market research performed to evaluate whether the demand existed to achieve these numbers. The remaining growth was expected from the B3000 refresh opportunity together with National/regional account agreements to
 17 18 19 20 21 22 23 24 	A growth goal was assessed to drive a stretch target for revenue. The target revenue number was rationalized as achievable by hiring additional sales reps to win the new Voice customers, in new Messaging customers and in new ExperialHealth customers to achieve the of the growth. In total the plan assumed in new customers. This was a stretch increase over 2012 new customer achievement and ignored trends in this regard. There was no market research performed to evaluate whether the demand existed to achieve these numbers. The remaining growth was expected from the B3000 refresh opportunity together with National/regional account agreements to accelerate sales. No market research supports customer take up of the B3000 opportunity or how much this would account for
 17 18 19 20 21 22 23 24 25 26 	A growth goal was assessed to drive a stretch target for revenue. The target revenue number was rationalized as achievable by hiring additional sales reps to win the new Voice customers, in new Messaging customers and in new ExperialHealth customers to achieve the of the growth. In total the plan assumed in new customers. This was a stretch increase over 2012 new customer achievement and ignored trends in this regard. There was no market research performed to evaluate whether the demand existed to achieve these numbers. The remaining growth was expected from the B3000 refresh opportunity together with National/regional account agreements to accelerate sales. No market research supports customer take up of the B3000 opportunity or how much this would account for
 17 18 19 20 21 22 23 24 25 	A growth goal was assessed to drive a stretch target for revenue. The target revenue number was rationalized as achievable by hiring additional sales reps to win the new Voice customers, in new Messaging customers and in new ExperialHealth customers to achieve the of the growth. In total the plan assumed in new customers. This was a stretch increase over 2012 new customer achievement and ignored trends in this regard. There was no market research performed to evaluate whether the demand existed to achieve these numbers. The remaining growth was expected from the B3000 refresh opportunity together with National/regional account agreements to accelerate sales. No market research supports customer take up of the B3000 opportunity or how much this would account for
 17 18 19 20 21 22 23 24 25 26 27 	A growth goal was assessed to drive a stretch target for revenue. The target revenue number was rationalized as achievable by hiring additional sales reps to win the new Voice customers, in new Messaging customers and in new ExperiaHealth customers to achieve the of the growth. In total the plan assumed in new customers. This was a stretch increase over 2012 new customer achievement and ignored trends in this regard. There was no market research performed to evaluate whether the demand existed to achieve these numbers. The remaining growth was expected from the B3000 refresh opportunity together with National/regional account agreements to accelerate sales. No market research supports customer take up of the B3000 opportunity or how much this would account for

2

3

23

1

6. Negative Information on Growth Is Known or Recklessly Disregarded By Defendants

130. The challenges facing the Company and its ability to meet guidance were known by Defendants at the time of the IPO and throughout the Class Period.

4 Both CW1, CW2, and VP of Finance Hutchinson told Defendants that their 131. 5 forecasts were unattainable. At the time of the IPO, CW1, who "handled every order and every 6 shipment," reported directly to the former CFO, Martin Silver, and then to Bill Zerella who 7 eventually succeeded Silver. CW1 stated that CW1 attended every revenue meeting as part of 8 CW1's duties, and was privy to everything that pertained to Vocera's orders and shipments. "I 9 saw every number, I gave booking numbers to the VP Sales Bob Flury and to Mike Hutchison 10 who gave the final numbers for revenues. I was privy to all of it..." In terms of revenue growth 11 at the time of the IPO, CW1 told Zerella and Silver that their rosy predictions on growth were 12 not achievable based on the realities of what was going on with the business.

- 13
 132. CW2 corroborates that Defendants were told their goals were not attainable.
 14
 15
 16
 17
 18
 19
 19
 10
 10
 11
 12
 132. CW2 corroborates that Defendants were told their goals were not attainable.
 132. CW2 corroborates that Defendants were told their goals were not attainable.
 14
 15
 16
 17
 18
 18
 19
 19
 10
 10
 10
 10
 11
 12
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 132
 133
 132
 133
 133
 133
 134
 134
 134
 134
 134
 134
 134
 134
 <li
- 17
 133. Defendants knew what the Company's revenue, bookings and backlog were
 because they were intimately involved in making decisions about these issues and attended
 revenue meetings where these issues were discussed. CW1, who attended the revenue meetings
 with the Individual Defendants, stated that the top tier at Vocera knew exactly what they were
 doing with the Road Show that was launched to support the IPO and that they knew what the
 numbers were. The Internal Audit Reports
 - Even after
- the IPO, Defendants continued to be involved in all the financial aspects of the Company. CW1
 recalled that after the IPO the Company swelled from about (80) employees to about (300), but
 oddly, the upper tier executives took a very unusual hands-on approach to everything revenuerelated.

	Case3:1	.3-cv-0356	67-EMC Docu	ment104 File	d09/19/14 Pa	ge44 of 141	
1 2	н	Defe		d Millions of D	ollars Worth of	vth Story" Is Int Company Stocl	
3	1. Defendant Zollars' and Lang's Stock Sales						
4	134. During the Class Period, Defendants Zollars and Lang benefitted handsomely						
5	from stock sales while Vocera's stock traded at artificially inflated prices, selling over 450,000						
6	shares an	d collective	ely netting over S	\$11 million in pr	coceeds from the	ir sales. ⁹ This is	
7	dramatica	ally disprop	oortionate to Zoll	lars' and Lang's	post-Class Perio	od sales of just 48	3,079 shares
8	totaling \$	34,072.					
9			Class 1	Period	Post Cla	ss Period	
10		Defendant	Number of Shares Sold	Net Proceeds	Number of Shares Sold	Net Proceeds	
11		Zollars	313,297	\$8,087,725	13,996	(\$285,741)	
		Lang	145,987	\$3,633,802	34,083	\$319,813	
12		Totals	459,284	\$11,721,527	48,079	\$34,072	
13 14 15				, ,	1	ls of \$8,087,725 nese were both di	C
16	indirect s	ales, but Zo	ollars benefitted	nonetheless, as t	the indirect owne	ership was by Zo	Co, LP, a
17	Company	owned by	Zollars and his	wife as general p	partners and thei	r children as limi	ted
18	partners.	In contrast	t, in the fourteen	months after the	e Class Period, Z	Collars sold 13,99	6 shares for
19	net proce	eds of nega	ative \$285,741. ¹¹	While several	of Zollars' sales	were made pursu	ant to a
20	10b5-1 tra	ading plan,	, this plan was er	ntered into on Au	ugust 27, 2012, a	at a time when	
21			and when the	he negative effect	ets of the ACA o	on the Company's	s current
22	financial	condition a	and effects on fut	ture growth were	e already known	. Notably, Zollar	rs most
23	significar	nt sale, with	n proceeds totalin	ng over \$5 millio	on, occurred on S	September 12, 20	12 as a
24	⁹ Beca	use the Cla	uss Period begins	with the IPO P	Plaintiffs cannot	compare Zollars'	and Lang's
25	pre-Class	Period sal	es to their Class	Period sales. Th	ius, as a way of o	comparison, Plai eriod with Zollar	ntiffs have
26	Lang's sa	les over th	e fourteen month	ns following the	Class Period.	a Zollars' Form 4	
27	the SEC t	that details	Zollars' Class P	eriod and post-C	Class Period sales	5.	
28	¹¹ Zoll purchase	ars exercis plan, whic	ed vested stock of h results in a neg	options and acqu gative proceeds r	uired stock under number.	the employee st	ock
	CONSOLIDA	TED CLASS A	ACTION COMPLAINT	FOR VIOLATIONS C)F THE FEDERAL SE	CURITIES LAWS	39

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page45 of 141

result of the partial release of the lock up during the Secondary Offering, and while the stock
 price was trading at \$27.24 as a result of the success of the Secondary Offering, and Defendants
 continued false and misleading statements.

- 4 136. Defendant Lang sold 145,987 shares for net proceeds of \$3,633,802 during the Class Period at stock prices well above the IPO price of \$16.00.¹² These were both direct and 5 6 indirect sales, but Lang benefitted nonetheless, as the indirect ownership was by the Lang Van 7 Schaack Revocable trust, his family's trust. In contrast, in the fourteen months after the Class 8 Period, Lang sold 34,083 shares for net proceeds of \$319,813. While several of Lang's sales 9 were made pursuant to a 10b5-1 trading plan, this plan was entered into on August 27, 2012, at a 10 time when and the negative effects of the ACA on the 11 Company's current financial condition and effects on future growth were already known. 12 Notably, Lang sold over \$2.7 million of Vocera stock on September 12, 2012 as a result of the 13 partial release of the lock up while the stock price was trading at \$27.24 as a result of the success 14 of the Secondary Offering, and Defendants' continued false and misleading statements.
- 15

2. The Individual Defendants Benefit From Inflating Revenue and EBITDA

16 Defendants also profited handsomely from their scheme to accelerate backlog into 137. 17 revenues, by exceeding certain incentive targets set by the Company for 2012. Vocera's 2012 18 executive bonus plan was based on the attainment of two Company-wide performance measures 19 - revenue and adjusted EBITDA. The target bonus attributable to revenues accounted for 50% of 20 an executive's target bonus while the target bonus attributable to adjusted EBITDA accounted 21 for 50%. Each Individual Defendant had an overall bonus percentage expressed as a percentage 22 of his salary. If both metrics were achieved at the target level, the Individual Defendant would 23 receive the target level of bonus.

- 24
 25
 26
 27
 28
 29
 29
 20
 20
 21
 21
 22
 23
 24
 24
 25
 26
 27
 28
 29
 29
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 20
 <
- 27

 ¹² Attached as Exhibit D is a chart with information obtained from Lang's Form 4s filed with the SEC that details Lang's Class Period and post-Class Period sales.

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page46 of 141

target. For performance on a Company-wide metric above 100%, a maximum bonus percentage
 of 200% of target could be earned for achievement at the 120% level. Bonus payments from
 100% to 200% of target could be earned for performance between 100% and 120% of the target
 metric. The target bonus for each of the Individual Defendants was: Mr. Zollars—\$405,000; Mr.
 Lang—\$203,000; and Mr. Zerella—\$201,000.

6 139. In February 2013, based on Vocera's 2012 performance, the compensation 7 committee determined that the Company had achieved the revenue target at approximately the 8 98% level and that the Company had achieved the adjusted EBITDA target at approximately the 9 196% level. These results, which were a consequence of the artificial backlog pull-ins, resulted 10 in bonus payments to the Individual Defendants of approximately 46% of the target bonus as a 11 result of achieving the revenue target and 100% of the target bonus as a result of achieving of the 12 adjusted EBITDA target, for an aggregate bonus payment of approximately 146% to each of the 13 Individual Defendants.

- 14 140. Defendants were essentially rewarded for their fraud with six figure bonuses.
 15 Notably, these bonuses dwarfed the bonuses they received in 2011. Zollars bonus was nearly
 16 double his salary. Zerella and Lang's bonuses exceeded their salaries.
- 17

				,		Non-equity		
18	Name and principal position	Year	Salary	Option Awards	Stock Awards	incentive plan compensation	All other compensation	Total
19	Robert J. Zollars	2012	\$ 385,000	\$ 866,708	\$ 869,400	\$ 590,652	\$ 785	\$ 2,712,545
20	Chief Execu ive Officer	2011	356,667	245,521	-	214,200	5,590	821,978
20	Brent D. Lang	2012	281,875	508,255	507,150	296,055	785	1,594,120
21	President & Chief	2012	256,667	150,227		121,550	5,148	533,592
<u>~1</u>	Operating Officer		200,007	,==.			0,0	000,002
22	William R. Zerella	2012	269 750	205 204	286 400	202.420	740	1 224 240
	Chief Financial	2012	268,750 65,000	385,204 990,600	386,400	293,138 30,388	718 1,571	1,334,210 1,087,559
23	Officer	2011	00,000	000,000		00,000	1,071	1,007,000
24								
2.5								
25								
26								
26								
27								
21								
28	¹³ Informatio	n take	from April	16 2013 1	Drovy			
20	Informatio	III take	пош дріп	10, 2013 1	IOXY.			
	CONSOLIDATED CL	ASS ACT	TION COMPLAT	INT FOR VIO	LATIONS OF	THE FEDERAL SE	ECURITIES LAWS	41
	MASTER FILE NO. 3						Leonaries Errivs	

Summary Executive Compensation Table¹³

1 2 I.

Defendants Eventually Admitted that Sequestration Was Affecting the Business But Continue to Mislead the Market About the Effects of the ACA on its Primary Business

141. On February 27, 2013, the Company announced that it had met fourth quarter and
annual guidance, but guided revenues slightly down for 1Q13. The Company blamed the light
1Q13 guidance on sequestration, for the first time telling the market that sequestration was
having a negative effect on sales to its government customer hospitals. However, Defendants
told the market that the "pipeline in the government remains very strong." Defendants also
announced that bookings and backlog were down, attributing the decline in part to the issues
with government hospitals.

10 142. Despite the impact of sequestration on Vocera's government related hospitals, 11 Defendants led the market to believe that demand from private hospitals, the main driver of 12 revenue, was still strong, claiming that "US healthcare business...is very healthy and performing 13 well." Defendants told the market that "we see no reason why we can't continue to grow this 14 business 25% on the top line over the next few years," and backed this statement up by providing 15 2013 annual guidance of \$120 to \$130 million, a 20% to 30% increase over 2012. Defendants 16 stated they were confident about meeting this range due to their "revenue model [which is] 17 highly recurring in nature."

18 143. On this news, despite the Defendants' attempts to blunt news about sequestration,
19 the Company's stock dropped over 9% on heavy volume to close at \$26.37 on February 28,
20 2012.

144. Analysts were surprised by the low guidance issued for 1Q13, but believed the
Company's growth story was still intact. For example, on February 28, 2013 a Piper Jaffray
analyst wrote "Distracting Quarter But We Believe In the Growth Story." On that same day, a
J.P. Morgan analyst wrote: "4Q12 Solid, 2013 Looks Good - 2013 guidance calls for 19-29%
top-line growth."

145. Indeed, in late March 2013, after the close of 1Q13, Vocera management,
including Zerella, communicated to Piper Jaffray and William Blair, statements that were later

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page48 of 141

published in analyst reports, including that the Company was "more confident than ever" on its
 growth outlook, particularly its 25% estimated growth for 2013. *See* ¶¶258-260.

3

J.

Vocera Finally Admitted that the ACA Was Negatively Affecting its Business and Reduced Annual Guidance Dramatically

4 On May 2, 2013, the Company shocked the market when it announced that first 146. 5 guarter revenues had fallen beneath the already lowered projected guidance range, and that the 6 Company was lowering its 2013 annual guidance to between \$100 and \$110 million. The 7 Company blamed this earnings miss and guidance reduction on "uncertainties surrounding the 8 effect of sequestration and the healthcare reform act...[v]irtually every health system we speak 9 of has put in place a large expense reduction initiatives as a result of reform." 10 147. On this news, the stock dropped over 37% to close at \$12.15 on May 3 on 11 extraordinarily high volume. 12 Analysts were shocked. For example, on May 2, 2013, a William Blair analyst 148. 13 stated "the magnitude of the shortfall (especially after providing guidance in late February) 14 clearly surprised us." The William Blair analyst also commented on the revelation about 15 Vocera's "visibility," into revenue showing that the market now understood that Vocera's 16 backlog was not providing that type of recurring revenue stream that Defendants had touted 17 during the Class Period: 18 Lastly, we also thought visibility was better for Vocera (e.g., 19 sizable recurring revenue stream, predictable customer reorders [until this quarter]), but after two straight quarters of disappointing results (and the large guidance reset) we clearly 20 overestimated the predictability in the business; clearly this will 21 cause a reset in the valuation multiple that investors afford the company. 22 23 24 25 26 27 28 CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 43 MASTER FILE NO. 3:13-CV-03567 EMC

IV.	DEFI STAT THEI	ENDANTS' MATERIALLY FALSE AND MISLEADING CLASS PERIO TEMENTS AND OMISSIONS AND ANALYST AND MARKET REACTION RETO ¹⁴
	A.	March 28, 2012 IPO
	149.	The Class Period begins on March 28, 2012, the date of Vocera's IPO. In the
Offerin	ng Mat	erials, Vocera laid out its business strategy and the seemingly limitless opportun
for gro	wth an	d expansion due, in part, to the pressures and incentives provided by the ACA.
	150.	The IPO Offering Materials explained that Vocera would be successful because
health	care ref	form initiatives were actually providing incentives to hospitals to purchase Voce
techno	logy ar	nd products to "improve the quality of care and patient satisfaction":
		Patients are increasingly selecting hospitals and healthcare
		providers based on quality of care, cost and overall experience with the provider. <i>In addition, healthcare reform initiatives</i>
		incorporate financial incentives for hospitals to improve the quality of care and patient satisfaction. These forces are driving
		hospitals to manage their operations more efficiently and to seek ways to improve staff and patient satisfaction through process
		<i>improvements and technology solutions.</i>

		The increasing focus on improving patients' experience is supported by the healthcare reform initiative, which incorporates
		financial incentives for hospitals to improve the quality of care and patient satisfaction. These forces are driving hospitals to
		invest in technology and process improvements to manage their operations more efficiently and to improve staff and patient satisfaction.
	151.	Vocera then suggested that traditional hospital communications often "degrad
patient	and ca	aregiver satisfaction," because they lead nurses away from the bedside, do not
always	reach	the appropriate caregiver in a timely manner, foster noisy environments and car
preven	t close	d loop communication.
	152.	Vocera touted its products as providing the "solution" to these problems
		To address these deficiencies, hospitals are seeking more effective alternatives for improving communication. <i>We believe hospitals will increasingly turn to communication technologies to help improve patient safety and satisfaction, productivity and</i>
statem	ents all	on IV, the statements made by Defendants that are in bold and italicized are the leged to be false and misleading. Additional statements that appear in bold (but e in bold for emphasis.

	Case3:13-c	v-03567-EMC Document104 Filed09/19/14 Page50 of 141
1 2		caregiver satisfaction and retention. We believe our solutions are at the convergence of the healthcare IT market and the enterprise communications and collaboration market.
3	153.	In particular, Vocera claimed that its products would address problems faced by
4	hospitals by in	mproving patient safety, enhancing patient experience, and improving caregiver job
5	satisfaction.	
6	154.	Vocera also explained the pressures that hospitals might face because of
7	healthcare ref	form, but touted Vocera as the solution that hospitals needed to alleviate these
8	pressures:	
9		Effective communication is extremely important among mobile
10		and widely dispersed healthcare professionals in hospitals. As of December 31, 2011, there were over 6,900 hospitals in the United
11		States. We believe that a combination of policy changes through healthcare reform, demographic trends and downward pressure on
12		healthcare reimbursement is increasing financial pressure on hospitals and other healthcare providers. Furthermore, the nursing
13		shortage in the United States, with over 115,000 openings, can detract from the patient experience and place further strain on
14		hospital operations.
15		
16		• Increase revenue and reduce expenses. Improved communication facilitated by our solutions can enable hospitals to increase revenue and reduce expenses through more efficient use
17		of their resources, directly impacting profitability. With our solutions, hospitals can reduce nurse overtime expense and
18		increase job satisfaction, thereby improving nurse recruiting and retention. In addition, improvements in patient safety and
19		reduction in errors can lead to reduced liability cost for hospitals.
20	155.	The Offering Materials further explained that because of the benefits and
21	"solutions" th	at Vocera provided to hospitals, Vocera's prospects for growth were enormous:
22		We estimate the worldwide hospital market opportunity for the full deployment of our Voice Communication solution to be over
23		\$6 billion on an aggregate basis.
24	156.	Vocera touted the Company's growth in 2011 and described its growth strategy to
25	increase the a	mount of new healthcare clients and continue to develop expansion into its existing
26	customer base	2:
27		In 2011, we generated revenue of \$79.5 million, representing growth of 40.0% over 2010.
28		***
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 45 0. 3:13-CV-03567 EMC

1	that the registrant reasonably expects will have a material favorable or unfavorable impact on net
2	sales or revenues or income from continuing operations." In addition, Instruction 3 of Item
3	303(a) of Regulation S-K requires that "[t]he discussion and analysis shall focus specifically on
4	material events and uncertainties known to management that would cause reported financial
5	information not to be necessarily indicative of future operating results." Moreover, pursuant to
6	SEC Regulation C, registrants have an overarching duty to disclose material information
7	necessary to ensure that representations in a registration statement are not misleading.
8	Specifically, Rule 408 states that, "In addition to the information expressly required to be
9	included in a registration statement, there shall be added such further material information, if
10	any, as may be necessary to make the required statements, in light of the circumstances under
11	which they are made, not misleading." 17 C.F.R. § 230.408(a).
12	159. On March 28, 2013, the same day of the IPO, Debra Borchart, a market analyst
13	from "The Street" interviewed Zollars about the IPO.
14	<u>Analyst</u> :
15	Any concern that you are too narrowly focused in the hospital sector?
16	Zollars:
17	
18	No. We're actually really excited about health care because it's about a \$6 billion market for our solution, so we've got plenty of room to grow. We're less than 10% penetrated today. The other
19	exciting thing about the technology, though, is we do sell it into other verticals. So we're in high end hotels. Here in New York
20	City, for instance, the Plaza, the Trump Soho, the Intercontinental in Times Square, all use Vocera in their hospitality setting.
21	Analyst:
22	The hearings that we have going on right now with the Supreme
23	Court and the Health Care laws, are you guys going to be affected at all by any decisions that are happening with the Supreme Court?
24	Zollars:
25	No. Fortunately for us we haven't been involved in any of the
26	stimulus money which has sort of created some artificial funding in the area of EMRs and Vocera doesn't participate this, and that goes
27 28	away it won't hurt us. So the reform really doesn't have much impact on us, and again, we've got great growth opportunity with about 90% of the market left to go capture.
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 47 MASTER FILE NO. 3:13-CV-03567 EMC 47

1	160.	These statements were materially false and misleading for the reasons stated in
2	¶157.	
3	161.	Vocera's stock price reacted favorably to Defendants' false statements, soaring to
1	\$24.91 on the	e day after the IPO.
5	162.	Analysts bought the Company's growth story. For example, on May 7, 2012, an
5	analyst at Wi	lliam Blair sang the Company's praises, stating in a report: "we expect Vocera to be
7	one of the stre	ongest growth stories in our coverage universe."
3	B.	Class Period Financials
)	163.	During the Class Period, Defendants issued quarterly and annual results for their
)	revenue, EBI	TDA, and earnings. These statements were false and misleading because
1	Defendants fa	ailed to disclose that the revenue and earnings as reported were only achieved by
2	pulling in rev	enue set for future quarters, out of backlog, and into the current quarter (revenue
3	and earnings	"smoothing"). See ¶¶103-128.
4		
5		
5		
7		
3		
)		
)		
2		
3		
4		
5 6		
7		
8		In each quarter, Defendants "smoothed" Vocera's revenue and
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 48 0. 3:13-CV-03567 EMC

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page54 of 141

1 earnings numbers, making it appear as though Vocera met its guidance organically, and

2 portrayed a misleadingly positive picture of the Company's (and management's) performance.

164. The chart below lists each false and misleading revenue and earnings figure

4 reported during the Class Period:

3

5	Source	Date	Revenue and Earnings
6	1012.0 K	5/0/2012	<u>Revenue</u> - \$23.1 million <u>Non-GAAP Adjusted EBITDA</u> - \$2.0 million <u>GAAP net loss</u> - \$0.8 million
7 8	1Q12 8-K	5/9/2012	GAAP loss per share: \$0.23 per diluted share Non-GAAP net income - \$1.4 million
9			Non GAAP EPS - \$0.06 per diluted share
10			<i>Zollars:</i> <u>Revenue</u> - \$23.1 million <u>Non-GAAP net income</u> - \$1.4 million
11		_ /_ /	<u>Non-GAAP adjusted EBITDA</u> - \$2 million <u>Non-GAAP EPS</u> - \$0.06
12	1Q12 call	5/9/2012	Zerella:
13			<u>Revenue</u> - \$23.1 million
14			<u>Non-GAAP net income</u> - \$1.4 million <u>Non-GAAP adjusted EBITDA</u> - \$2.0 million
15	1Q12 10-Q	5/14/2012	<u>Revenue</u> - \$23.1 million
16			
17			<u>Revenue</u> - \$24.9 million <u>GAAP net income</u> - \$1.2 million,
18	2Q12 8-K	8/2/2012	<u>GAAP EPS</u> - \$0.00 per diluted share <u>Non-GAAP net income</u> - \$2.3 million
19			<u>Non-GAAP EPS</u> - \$0.09 per diluted share <u>Non-GAAP Adjusted EBITDA</u> - \$3.0 million
20			Non-OAAT Adjusted EDITIDA - \$5.0 minion
21			
22			
23			
24			
25			
26			
27			
28			
	CONSOLIDATED MASTER FILE N		N COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 49

Source	Date	Revenue and Earnings
		<i>Zollars:</i> <u>Revenue</u> - \$24.9 million <u>Non-GAAP net income</u> - \$2.3 million <u>Non-GAAP Adjusted EBITDA</u> - \$3 million <u>Non-GAAP EPS</u> - \$0.09
2Q12 call	8/2/2012	Zerella:
		<u>Revenue</u> - \$24.9 million <u>GAAP net income</u> - \$1.2 million
		<u>GAAP EPS</u> - \$0.00 per diluted share <u>Non-GAAP net income</u> - \$2.3 million
		Non-GAAP EPS - \$0.09 per diluted share
		<u>Non-GAAP Adjusted EBITA</u> - \$3 million <u>Non-GAAP Adjusted EBITDA margins</u> - 12%
		S: // /// 20.2012
2Q12 10-Q	8/14/2012	Six months ended June 30, 2012: <u>Revenue</u> - \$48.0 million
		<u>Revenue</u> - \$26.0 million <u>GAAP net income</u> - \$1.7 million
3Q12 8-K	11/5/2012	GAAP EPS - \$0.07 per diluted share
		<u>Non-GAAP net income</u> - \$3.3 million <u>Non-GAAP EPS</u> - \$0.13 per diluted share
		Non-GAAP Adjusted EBITDA - \$3.8 million
		<i>Zollars:</i> Revenue - \$26 million
		Non-GAAP net income - \$3.3 million
		<u>Non-GAAP Adjusted EBITDA</u> - \$3.8 million <u>Non-GAAP EPS</u> - \$0.13
		Non-GAAP gross margin - 66.4%
3Q12 call	11/5/2012	Zerella:
		<u>Revenue</u> - \$26 million <u>GAAP net income</u> - \$1.7 million
		<u>Non-GAAP net income</u> - \$3.3 million <u>Non-GAAP EPS</u> - \$0.13 per diluted share
		Non-GAAP adjusted EBITDA - \$3.8 million Non-GAAP adjusted EBITDA margin - 14%
		Nine months ended September 30, 2012:
3Q12 10-Q	11/13/2012	<u>Revenue</u> - \$74.0 million
	CLASS ACTION	COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS
	0. 3:13-CV-035	

1	Source	Date	Revenue and Earnings
2 3 4			<i>4Q12:</i> <u>Revenue</u> - \$27.0 million <u>GAAP net income</u> - \$0.8 million <u>GAAP EPS</u> - \$0.03 per diluted share <u>Non-GAAP net income</u> - \$2.6 million <u>Non-GAAP EPS</u> - \$0.10 per diluted share
5	4Q12 and		$\frac{GAAP \text{ product gross margin}}{Non-GAAP \text{ product gross margin}} = 68.9\%$ in the quarter
6	FY 2012 8-K	2/27/2013	<u>Non-GAAP Adjusted EBITDA</u> - \$3.2 million
7 8			<i>FY 2012:</i> <u>Revenue</u> - \$101.0 million
9			<u>GAAP net income</u> - \$2.9 million <u>GAAP EPS</u> - \$0.08 per diluted share
10			<u>Non-GAAP net income</u> - \$9.6 million for 2012 <u>Non-GAAP EPS</u> - \$0.38 per diluted share
11			
12			Zollars:
13			<i>4Q12:</i> Revenue - \$27 million
14			Adjusted EBITDA - \$3.2 million Non-GAAP EPS - \$0.10
15			
16			<i>FY 2012:</i> <u>Revenue</u> - \$101 million <u>Adjusted EBITDA</u> - \$11.9 million
17	4Q12 call	2/27/2013	Non-GAAP EPS - \$0.38
18			Zerella:
19 20			<i>4Q12:</i> <u>Revenue</u> - \$27 million
20			<u>GAAP net income</u> - \$811,000 <u>GAAP EPS</u> - \$0.03 per diluted share
21			Non-GAAP net income - \$2.6 million Non-GAAP EPS - \$0.10 per diluted share.
22 23			Non-GAAP Adjusted EBITDA - \$3.2 million
23	L		
24 25	C.	Class Peri	od Guidance
26	165.	Beginning	g with the second quarter of 2012, Defendants provided the market with
27	quarterly and	annual reve	nue and earnings guidance. Statements concerning guidance were false
28	and misleadin	ng because tl	ney omitted to state (1) that the ACA was already a factor negatively
	Consolidated Master File N		A COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 51 567 EMC

impacting revenue and earnings and would continue to do so (¶¶94-97), (2) bookings were down,
 which caused backlog to decline (¶107), and (3) the Company had further depleted its backlog by
 accelerating backlog from future quarters, in order to meet its quarterly and annual revenue
 targets, thus robbing future quarters of this revenue. ¶¶103-129. Thus, the quarterly and annual
 guidance issued by Defendants lacked a reasonable basis based on known facts.

6 166. The chart below lists each false and misleading guidance figure reported during
7 the Class Period.

Source	Date	Guidance
1Q12 8K	5/9/2012	Full year 2012:Revenue - between \$100 million and \$102 millionGAAP loss per share - between \$(0.06) and \$(0.11)Non-GAAP earnings - between \$2.5 million and \$3.5 millionNon-GAAP EPS - between \$0.10 and \$0.14Non-GAAP Adjusted EBITDA - between \$4 million and \$5 million.2012:Revenue - between \$24 million and \$25 millionGAAP loss per share - between \$(0.03) and \$(0.05)Non-GAAP earnings - between \$0.1 million and \$0.5 millionNon-GAAP EPS - between \$0.00 and \$0.02Non-GAAP Adjusted EBITDA - between \$0.5 million and \$1.0 million
1Q12 call	5/9/2012	Zerella: Full year 2012: Revenue - between \$100 million and \$102 million Non-GAAP net income - between \$2.5 million and \$3.5 million Non-GAAP EPS - between \$0.10 and \$0.14 Non-GAAP adjusted EBITDA - between \$4 million and \$5 million GAAP net loss - between \$1 million and \$2 million GAAP net loss - between \$1 million and \$2 million GAAP net loss per share - \$0.06 and \$0.11 per share 2Q12: Revenue - between \$24 million and \$25 million Non-GAAP earnings - between \$0.1 million and \$0.5 million Non-GAAP EPS - between \$0.0 and \$0.2 per share Adjusted EBITDA - between \$0.5 million and \$1 million GAAP net loss - between \$0.6 million and \$1.1 million, or between \$0.03 and \$0.05 per share

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page58 of 141

1	Source	Date	Guidance
2		2400	Full year 2012:
			Revenue - between \$100 million and \$102 million
3			<u>GAAP loss per share</u> - between \$(0.03) and \$(0.08) <u>Non-GAAP earnings</u> - between \$5.0 million and \$6.0 million
4			<u>Non-GAAP EPS</u> - between \$0.20 and \$0.24 <u>Non-GAAP Adjusted EBITDA</u> - between \$7.0 million and \$8.0 million
5	2Q12 8-K	8/2/2012	
6			<i>3Q12:</i> <u>Revenue</u> - between \$25 million and \$26 million
7			<u>GAAP loss per share</u> - between \$(0.04) and \$0.00 <u>Non-GAAP earnings</u> - between \$0.5 million and \$1.5 million
8			Non-GAAP EPS - between \$0.02 and \$0.06
9			Non-GAAP Adjusted EBITDA - between \$1.0 million and \$2.0 million
			Zerella:
10			Full year 2012:
11			<u>Revenue</u> - between \$100 million and \$102 million <u>Non-GAAP net income</u> - between \$5 million and \$6 million
12			Non-GAAP EPS - between \$0.20 and \$0.24
13			<u>Non-GAAP Adjusted EBITDA</u> - between \$7 million and \$8 million <u>GAAP earnings</u> - loss of between \$500,000 and \$1.4 million
14	2Q12 call	8/2/2012	GAAP EPS - loss of \$0.03 and \$0.08 per share
15			<i>3Q12:</i>
16			<u>Revenue</u> - between \$25 million and \$26 million <u>Non-GAAP earnings</u> - between \$500,000 and \$1.5 million
17			<u>Non-GAP EPS</u> - between \$0.02 and \$0.06 <u>Non-GAAP Adjusted EBITDA</u> - between \$1 million and \$2 million
			GAAP net loss - between \$0 million and \$1 million
18			GAAP loss per share - between \$0.00 and a loss of \$0.04 per share.
19			<i>Full year 2012:</i> Revenue - between \$100 million and \$102 million
20	3Q12 8-K	11/5/2012	GAAP EPS - between \$0.09 and \$0.11
21			<u>Non-GAAP earnings per share</u> - between \$0.33 and \$0.35 Non-GAAP Adjusted EBITDA - between \$10.0 million and \$11.0 million
22			Zerella:
23			Full year 2012:
24	3Q12 call	11/5/2012	Revenue - between \$100 million and \$102 million
			<u>Non-GAAP 2012 EPS</u> - between \$0.33 and \$0.35 <u>Non-GAAP adjusted EBITDA</u> - between \$10 million and \$11 million
25			GAAP EPS - between \$0.09 and \$0.11
26			
27			
28			
	CONSOLIDATE	ED CLASS ACT	TON COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS
	MASTER FILE		

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page59 of 141

Source	Date	Guidance
4Q12 and		<i>Full year 2013:</i> <u>Revenue</u> - between \$120 million and \$130 million <u>GAAP earnings per share</u> - between a loss of \$0.10 and a profit of \$0.09 <u>Non-GAAP EPS</u> - between \$0.33 and \$0.51 <u>Non-GAAP Adjusted EBITDA</u> - between \$12 million and \$17 million
FY 2012 8-K	2/27/2013	<i>1Q13:</i> Revenue - between \$23 million and \$25 million
		<u>GAAP loss per share</u> - between \$0.08 and \$0.13 <u>Non-GAAP earnings</u> - between a loss of \$1.2 million and breakeven
		<u>Non-GAAP EPS</u> - between a loss of \$0.05 and \$0.00 <u>Non-GAAP Adjusted EBITDA</u> - between a loss of \$0.7 million and earnings of \$0.5 million
		Zerella:
		Full year 2013:
		<u>Revenue</u> - between \$120 million and \$130 million <u>Non-GAAP net income</u> - between \$9 million and \$14 million
		<u>Non-GAAP EPS</u> - between \$0.33 and \$0.51 <u>Non-GAAP adjusted EBITDA</u> - between \$12 million and \$17 million.
		GAAP (net) income - between a loss of \$2.5 million and a profit of \$2.5 million
4Q12 call	2/27/2013	<u>GAAP EPS</u> - between a loss of \$0.10 per share and a profit of \$0.09 per share.
		1 <u>0</u> 13:
		<u>Revenue</u> - between \$23 million and \$25 million <u>Non-GAAP earnings</u> - between a loss of \$1.2 million and break even.
		<u>Non-GAAP EPS</u> - between a loss of \$0.05 and \$0.00 per share <u>Non-GAAP Adjusted EBITDA</u> - between a loss of \$700,000 and a profit
		of \$500,000. <u>GAAP net loss</u> - between \$1.9 million to \$3.1 million <u>GAAP loss per share</u> - between \$0.08 and \$0.13 per share.
		<i>Full year 2013:</i> <u>Revenue</u> - between \$100 million and \$110 million
		<u>GAAP earnings per share</u> - between a loss of \$(0.47) and \$(0.22) <u>Non-GAAP earnings per share</u> - between a loss of \$(0.05) and a profit of
		\$0.18 <u>Non-GAAP Adjusted EBITDA</u> - between \$1.2 million and \$7.9 million
1Q13 8-K	5/2/2013	2Q13:
		<u>Revenue</u> - between \$23 million and \$25 million <u>GAAP loss per share</u> - between (0.17) and (0.12)
		<u>Non- GAAP earnings</u> - between a loss of (1.6) million and (0.4) million <u>Non-GAAP earnings per share</u> - between a loss of (0.06) and (0.02)
		$\frac{\text{Non-GAAP Adjusted EBITDA}}{\text{gain of $0.3 million}} - \text{between a loss of $(1.0) million and a gain of $0.3 million}$
		TION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page60 of 141

1	Source	Date	Guidance
2 3 4 5 6 7 8 9	1Q13 call	5/2/2013	Zerella: Full year 2013: Revenue - \$100 and \$110 million Non-GAAP net income - between a loss of \$1.3 million and a profit of \$5 million Non-GAAP EPS - between a loss of \$0.05 and a profit of \$0.18 Non-GAAP EBITDA - between \$1.2 million and \$7.9 million 2Q13: Revenues - between \$23 and \$25 million Non-GAAP EPS - between a loss of \$1.6 million and \$400,000 Non-GAAP EPS - between a loss of \$0.06 and \$0.02 per share Non-GAAP Adjusted EBITDA - between a loss of \$1 million and a gain of \$300,000
11	D.	May 9,	2012 - Form 8-K and Press Release
12	167.	-	9, 2012, after the market closed, Vocera filed a Form 8-K with the SEC
13	and attache	d a press rel	lease entitled "Vocera Reports First Quarter Results." Zerella signed the
14	Form 8-K.	For the firs	t quarter, Vocera reported the financials and guidance described in ¶164
15	and 166 ab	ove. Comm	enting on these results and future guidance, Zollars stated:
16 17 18 19	We are very pleased to report <i>strong results in our first quarter as</i> <i>a public company. Our business continues to perform well</i> and we are receiving great feedback on our recently released B3000 badge from initial users. <i>We believe 2012 is off to a great start</i> and we remain focused on executing on the numerous opportunities that are in front of us.		
20	168	. The stat	ements contained in the Form 8-K and Press Release were materially false
21	and mislead	ling. Stater	nents made by Zollars commenting on first quarter results and guidance,
22	concerning	the Compar	ny's allegedly "strong results in our first quarter" and that "[w]e believe
23	2012 is off	to a good st	art" were objectively false and misleading because first quarter results
24	were not "s	trong" and 2	2012 was not "off to a good start" for the reasons stated in \P 163 and 165,
25	and because	e at the time	e the statements were made,
26			
27	1	d. Zollars'	remarks were objectively verifiable and contradicted by this internal
28	financial da	ita. <i>See</i> Ex	s. A-B.
	Consolidate Master File		ION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 55 03567 EMC

1	Е.	May 9, 2012 - 1Q12 Earnings Conference Call
2	169.	The Company hosted an earnings conference call on May 9, 2012 to discuss the
3	first quarter re	esults after the market closed. Zollars, Zerella and Lang participated on the call.
4	Zollars and Zo	erella reiterated first quarter financial results and second quarter and annual
5	guidance. See	¶¶164, 166. The Individual Defendants all made positive statements concerning
6	the current sta	te of the Company's business and Vocera's growth prospects.
7	170.	For example, in his prepared remarks, Zollars commented on the Company's
8	"strong result	s for the first quarter" and the continuing success the Company was experiencing:
9		Zollars:
10		<i>We</i> 're really pleased with the first quarter results, and off to a great start for 2012These strong results continue to
11		demonstrate the high visibility of our business model, and were driven by several factors. First, the continued expansion and
12		acceptance of our voice communications solution. Second, higher than expected gross margins driven by a favorable product
13		mix, and increased leverage from our professional services investments. And third, lower than expected operating expense
14		driven by cost controls, and the timing of some engineering and sales spending.
15		***
16		And while we continue to have tremendous success in our core
17 18		<i>healthcare market, during Q1</i> we also delivered on a significant for a large casino operator who deployed the B3000, and then immediately placed an additional order to expand their usage to
10		more employees.
20		***
20		So, before turning the call over to Bill, <i>I'd just summarize Q1 as a good, solid start to 2012.</i> We're very pleased with the number of
21		initiatives we have underway, especially the uptake of the B3000, and we're also excited about the opportunities we have throughout
23		our business.
24	171.	In response to a question from an analyst, Zerella continued to tout the
25	Company's gr	rowth story:
26		Analyst:
27		Nicely done, guys. Thanks for taking the question. So, first a numbers question. Given the strong guidance for the year, are you
28		still looking at long-term 25% <u>sustainable</u> top line growth?
-	Coversion	Zerella:
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 56 D. 3:13-CV-03567 EMC

	Case3:13-cv	v-03567-EMC Document104 Filed09/19/14 Page62 of 141
1 2 3	150	Yes, Sean. We committed to 25% top line growth over the longer time in the road show, and frankly, our view has not changed. We continue to see significant growth opportunities for our business.
4	172.	Analysts were focused on Vocera's growth, and the same analyst immediately
5		a follow up question regarding Vocera's ability to achieve 25% sustainable top line
6	growth:	
7		<u>Analyst</u> :
8		So, when you think about the leverage that you need to pull from here to continuing to achieve that kind of growth it's penetrating your existing customers; it's adding new customers;
9		it's cross-selling. Bob, if you could just describe the leverage that you need to pull here to achieve that long-term top line growth .
10 11		What do you see as the opportunities, and what are the areas where you might have to put some more work into, such as, specifically secure messaging, to drive the growth in that market.
12		Zollars
13		Yes, great, Sean. So, I think if you think about our five growth
14		levers, as usual, our current installed base came through in a big way in Q1, so a big expansion quarter for us from the installed base. They drove the majority of growth, as they usually do.
15 16		Growth lever two is adding new names, new addresses. <i>We also had a very solid quarter in adding new hospitals to the mix.</i> This is something that I don't think I'll ever be satisfied with, though, as long as we're at such a low market share. <i>So, we did well in Q1.</i> I
17		think we can do lot better.
18	173.	An analyst asked defendants about "the big picture environment" and if there had
19	been any chan	nges to the capital spending environment. Zollars responded that there hadn't been
20	any changes to	o hospital spending:
21		<u>Analyst</u> :
22		Okay, perfect. And then, going back to the big picture environment. How's the any changes to the capital spending
23		environment? Hospitals still spending because I know there has been some turmoil in the healthcare IT space as we know it on the
24		HR side, and I'm not sure if you guys are seeing any effect or any correlation from that?
25		Zollars:
26 25		Yes, a good question. It looks like the forecasts that we're
27 28		reading still have healthcare IT budgets growing the next couple of years between 13% and 15%. So, what we're seeing some good funding there. We just had a board meeting yesterday, and we've got a couple of healthcare system executives, who
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 57 D. 3:13-CV-03567 EMC

Case3:13-c	v-03567-EMC Document104 Filed09/19/14 Page63 of 141
	interestingly enough, are cautious about the reform, and what it might do to their P&Ls, <i>but thus far, they haven't changed behavior.</i> And that's essentially what we're seeing.
	We're seeing a lot of talk out in the market, <i>but not much change in behavior</i> , and I think the small bite-size first sale of Vocera helps us there, because we're a lot different than the EMR. You can get started with us for \$100,000 to \$250,000, and you're off and running. <i>And so, we're seeing people using operating budgets, as well as capital budgets.</i>
174.	Another analyst reiterated his understanding from Defendants that capital
spending and	healthcare reform were not having an effect on Vocera, and asked about the eff
that HCAHPS	S would have:
	Analyst:
	Okay. Very helpful. Thank you. And then, let me ask another couple of big picture questions. I'm curious, it doesn't sound like you're spoing any impact from some of the constant
	you're seeing any impact from some of the consternation around capital budgets, or the Supreme Court review. I'm actually curious if you're seeing any increased momentum in some of your product lines with value-based purchasing and HCAHPS coming up. I think you have a pretty clear solution on how to improve scores, and also with some of the noise around readmission rates, I'm curious if any of your communications solutions and your new discharge solutions start to more traction in the market today than maybe six months ago.
	<u>Zollars</u> :
	Yes, Ryan, good question. I think we're seeing really positive feedback from our ExperiaHealth business. There seems to be a lot of momentum and a lot of effort behind patient experience and the HCAHPS scores. And I would say that we're on the front edge of that wave. I think people have been talking about that for awhile, but now they seem to be funding the effort. And so, we're seeing the Experia folks get engaged at a high level within some leading health systems around the country. So that's good.
	On the discharge product, we're seeing a lot of interest, but it hasn't shown up in revenue yet. It's still early. From the early days, we've got some beta tests going on that product. We're getting great feedback, but it hasn't turned into revenue per se.
	And then the last comment I would make, is that, more and more I think, we're talking about Vocera, not just as a communications solution, but as a clinical workflow solution.
175.	Another analyst asked about Vocera's growing customer base:
	Analyst:
	CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS

	Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page64 of 141
1 2 3	Okay. And then, just a customer wins, I'm curious if we could get any metrics around number of customers, maybe even mix of wins between large health systems, and small, and then maybe also, US, non-US, and non-healthcare as a percent of the total. <u>Zollars:</u>
4 5 6 7 8	 Yes, that's a good question. So, we don't disclose quarterly the number of new customers that we add. We're going to do that on an annual basis. But we had a good quarter in new names, especially on the voice communications solution. We got orders from customers of all sizes, so, large hospitals and small, which again continues to be a nice strength for the business. The solution works whether you're a couple-hundred bed hospital or thousand-bed hospital.
9 10 11 12	And, then as I mentioned, good traction outside of the US, and also outside of healthcare for the quarter. We had a handful of orders outside of healthcare. We mentioned the casino. We had a post off or not a post office, a library order the product. <i>Pretty</i> <i>diverse set of new customers that we added to the book of</i> <i>business.</i>
13	176. The statements Defendants made during the first quarter earnings conference call
14	were materially false and misleading for the following reasons:
15	(a) Statements made in \P 170 and 172 by Zollars' statements "strong results"
16	for the first quarter, a "great start for 2012," "Q1 as a good, solid start to 2012," a solid quarter"
17	and "we did well in Q1" were false and misleading for the reasons stated in ¶168;
18	(b) Statements made in ¶170 by Zollars concerning the "high visibility" of
19	Vocera's business model were false and misleading because they gave the false impression that
20	Vocera's backlog would provide consistent, predictable and growing revenue streams, when in
21	fact, Defendants' scheme to smooth its financial results by accelerating revenue and by depleting
22	backlog to make quarterly numbers caused future revenue to be organically unachievable, since
23	revenue that had been expected in future quarters was being pulled into earlier quarters and
24	because by smoothing revenue to meet quarterly guidance, it gave the false impression that
25	Defendants had visibility into and could accurately estimate the Company's revenues and
26	competently manage the business. ¶¶103-129;
27	(c) Statements made in $\P170-172$, 175 by Zerella and Zollars concerning
28	growth, including sustainable "top line growth," "we continue to see significant growth
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 59 MASTER FILE NO. 3:13-CV-03567 EMC 59

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page65 of 141

opportunities," growth in Vocera's customer base, and "expansion" were false and misleading
because contrary to these statements, the type of growth that Vocera was touting was not
attainable since the ACA was having a negative effect on the Company's ability to book deals
with private hospitals – the Company's main growth driver.
and was robbing from revenue scheduled
for recognition in future quarters by accelerating shipments into an earlier quarter. ¶¶94-97, 103-

129; 7 (d) 8 Statements made in ¶173-174 by Zollars concerning the positive effect of 9 healthcare reform, including statements that capital spending by hospitals was status quo and that 10 the Company had "tremendous success in our core healthcare market in Q1," were false and 11 misleading because at that time, the ACA was negatively affecting Vocera's ability to book deals 12 with private hospitals – the Company's main growth driver. ¶94-97. 13 177. The stock price reacted favorably to Defendants' false assurances during the 14 analyst call, jumping 6.86% to close at \$23.35. 15 178. Analysts were clearly comforted by Defendants' statements that healthcare reform 16 was not affecting growth and would not affect growth in the future. For example, a William 17 Blair analyst published a report following the earnings call on May 9, 2012 stating: 18 From an end-market perspective, management commented that the company has been relatively immune from the issues 19 confronting other [Healthcare] IT vendors—namely, elongating sales cycles in part resulting from the Supreme Court's review of 20 the healthcare reform legislation and battling for capital budget dollars with core clinical and financial systems tied to "meaningful 21 use" incentive payments. More specific, management commented that the Supreme Court decision does not affect 22 the vast majority of the company's return-on-investment (ROI) cases, such as increased operating room throughput or 23 fewer ED diversions 24 179. On May 10, 2012, another analyst from Piper Jaffray commented on the top line 25 growth the Company was touting: "we believe that the growth drivers (higher software mix, new 26 healthcare and non-healthcare customers and international expansion) are playing out well to 27 sustain 25%+ top-line growth for the company." 28 CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 60 MASTER FILE NO. 3:13-CV-03567 EMC

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page66 of 141

1 2 3

4

5

6

7

8

9

10

11

12

13

14

15

16

May 14, 2012 - Form 10-Q

	180.	On May 14, 2012, Vocera filed its Form 10-Q with the SEC for the first quarter
ended N	March	31, 2012. The Form 10-Q was signed by Zollars and Zerella.
	181.	The Form 10-Q stated:

Revenue grew 26.2% from \$18.3 million in March 2011 to \$23.1 million in March 2012.

F.

Total revenue increased \$4.8 million, or 26.2%, from the three months ended March 31, 2011 to March 31, 2012.

Product revenue increased \$3.0 million, or 25.8%. Device revenue increased \$2.1 million, or 25.4%, and software revenue increased \$0.9 million, or 26.9%. The increase in device revenue, which related entirely to our Voice Communication solution, was driven primarily by an increase in unit sales of badges and related accessories from new customers making initial purchases, existing customers expanding deployments within their facilities to new departments and users, and customers replacing badges. A portion of the increase in device revenue was a result of higher average selling prices as a result of lower discounts and a change in mix as customers move to the B3000 badge, which has a higher list price than the B2000 badge. The list prices for our products did not change substantially in 2012. The increase in software revenue was primarily a result of an increase in sales of Voice Communication software licenses, primarily to existing customers to support enterprise expansions.

17 Service revenue increased \$1.8 million, or 26.8% from the three 18 months ended March 31, 2011 to March 31, 2012. Software maintenance and support revenue increased \$1.1 million, or 22.8%, 19 and professional services and training revenue increased \$0.7 million, or 38.6%. The increase in software maintenance and 20 support revenue was primarily a result of a larger customer base increasing software maintenance revenue by \$0.9 million. The 21 increase in professional services and training revenue included \$0.4 million as a result of an increase in the number of new 22 deployments and expansions of our Voice Communication solution.

182. The Form 10-Q included certifications signed by Zollars and Zerella, required
under the Sarbanes-Oxley Act of 2002 ("SOX"), representing that the "report does not contain
any untrue statement of material fact or omitted to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report," and that the information contained

in the Form 10-Q "fairly present[s] in all material respects, the financial condition, results of
 operation and cash flows of the [Company]."

operation and	cash nows of the [Company].
183.	The statements made in the Form 10-Q were materially false and misleading.
Specifically,	the statements attributed growth and increases in revenue to an increase in sales of
devices and s	oftware, but omitted to state that the ACA was a factor adversely impacting sales
and growth a	nd that the revenue increases were actually driven by Defendants' scheme to pull
from backlog	and ship products early, essentially robbing the Company of future growth by
depleting reve	enue from backlog from future quarters, in order to make Vocera's quarterly
guidance. ¶¶	94-97, 103-129. The omitted information was required to be disclosed in the Form
10-Q pursuan	t to Item 2 of the instructions to Form 10-Q, which provides that companies
disclose infor	mation called for under Item 303 of Regulation S-K [17 C.F.R. §229.303].
G.	July 11, 2012 – J.P. Morgan Analyst Report
184.	On July 11, 2012, JP Morgan published an analyst report describing a meeting
with Vocera's	s COO Brent Lang in New York on July 10, 2012. Based on Lang's representations
to the J.P. Mo	organ analyst, J.P. Morgan reported that Vocera was "confident the company is
executing on	its growth goals as planned."
185.	Based on the meeting with Lang, J.P. Morgan parroted back to the market that
Vocera's grov	wth proposition continued unabated:
	Company remains committed to driving growth; focus is on new customer adds. While expansion into existing footprints,
	international sales, non-healthcare vertical sales, and new product launches all contribute to revenue growth, the leading
	driver of growth—and management's top priority—is new customer adds (new footprints).
186	Notably, the J.P. Morgan analyst reported that the ACA was not impacting
	ocera's product:
	Underlying market dynamics intact. The Supreme Court ruling
	on Health Reform and the period leading up to it did not have any marked effect on demand. EHR implementations continue to
	sap IT-personnel bandwidth at hospitals, but some hospitals have turned to Vocera to help with EHR go-live efforts (by setting up
	EHR task forces with the appropriate personnel easily accessible). Customers and prospects generally continue to be drawn to
	Vocera as the company's voice communication tool can help
	CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 62 0. 3:13-CV-03567 EMC
	183. Specifically, f devices and s and growth an from backlog depleting revo guidance. ¶¶ 10-Q pursuan disclose infor G. 184. with Vocera's to the J.P. Mo <i>executing on</i> 185. Vocera's grow 186. demand for V

	Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page68 of 141
1 2	 enhance patient safety, patient satisfaction and workflow efficiency. 187. The statements contained in the J.P. Morgan analyst reports attributable to Lang
3	
4	were materially false and misleading for the following reasons:
5	(a) Statements Lang made to the J.P. Morgan analyst concerning growth were
6	false and misleading for the reasons stated in $\P176(c)$. In the second quarter, which ended in
7	June, almost 2 weeks before these statements were made,
, 8	
9	
0	
1	(b) Statements Lang made concerning the effects of the ACA, including
2	claims that underlying market demand is intact and the Supreme Court decision did not have any
3	effect on demand were false and misleading for the reasons stated in ¶176(d).
4	H. August 2, 2012 - Form 8-K and Press Release
5	
	188. On August 2, 2012, after the market closed, Vocera filed a Form 8-K with the
	188. On August 2, 2012, after the market closed, Vocera filed a Form 8-K with the SEC and attached a press release entitled "Vocera Reports Second Quarter 2012 Results."
) 7	188. On August 2, 2012, after the market closed, Vocera filed a Form 8-K with the SEC and attached a press release entitled "Vocera Reports Second Quarter 2012 Results." Zerella signed the Form 8-K. For the second quarter, Vocera reported the financial results and
5 7 3	188. On August 2, 2012, after the market closed, Vocera filed a Form 8-K with the SEC and attached a press release entitled "Vocera Reports Second Quarter 2012 Results."
5 7 3 9	188. On August 2, 2012, after the market closed, Vocera filed a Form 8-K with the SEC and attached a press release entitled "Vocera Reports Second Quarter 2012 Results." Zerella signed the Form 8-K. For the second quarter, Vocera reported the financial results and
	188. On August 2, 2012, after the market closed, Vocera filed a Form 8-K with the SEC and attached a press release entitled "Vocera Reports Second Quarter 2012 Results." Zerella signed the Form 8-K. For the second quarter, Vocera reported the financial results and guidance listed in ¶¶164-166 above. Commenting on these results and future guidance, Zollars stated: <i>Our Voice Communication solution continues to perform well.</i>
6 7 8 9 0	188. On August 2, 2012, after the market closed, Vocera filed a Form 8-K with the SEC and attached a press release entitled "Vocera Reports Second Quarter 2012 Results." Zerella signed the Form 8-K. For the second quarter, Vocera reported the financial results and guidance listed in ¶¶164-166 above. Commenting on these results and future guidance, Zollars stated: Our Voice Communication solution continues to perform well. Our new B3000 badge is being well received in the marketplace and is driving healthy growth and improved profitability. As we enter the second half of 2012, we remain confident in our ability
6 7 8 9 0 1 2 3	188. On August 2, 2012, after the market closed, Vocera filed a Form 8-K with the SEC and attached a press release entitled "Vocera Reports Second Quarter 2012 Results." Zerella signed the Form 8-K. For the second quarter, Vocera reported the financial results and guidance listed in ¶¶164-166 above. Commenting on these results and future guidance, Zollars stated: Our Voice Communication solution continues to perform well. Our new B3000 badge is being well received in the marketplace and is driving healthy growth and improved profitability. As we
5 6 7 8 9 0 1 2 2 3 4	188. On August 2, 2012, after the market closed, Vocera filed a Form 8-K with the SEC and attached a press release entitled "Vocera Reports Second Quarter 2012 Results." Zerella signed the Form 8-K. For the second quarter, Vocera reported the financial results and guidance listed in ¶¶164-166 above. Commenting on these results and future guidance, Zollars stated:
6 7 8 9 0 1 2 3 4	 188. On August 2, 2012, after the market closed, Vocera filed a Form 8-K with the SEC and attached a press release entitled "Vocera Reports Second Quarter 2012 Results." Zerella signed the Form 8-K. For the second quarter, Vocera reported the financial results and guidance listed in ¶164-166 above. Commenting on these results and future guidance, Zollars stated: <i>Our Voice Communication solution continues to perform well. Our new B3000 badge is being well received in the marketplace and is driving healthy growth and improved profitability. As we enter the second half of 2012, we remain confident in our ability to execute on our growth opportunities.</i> 189. The statements contained in the Form 8-K and Press Release were materially false
6 7 8 9 0 1 2 3	 188. On August 2, 2012, after the market closed, Vocera filed a Form 8-K with the SEC and attached a press release entitled "Vocera Reports Second Quarter 2012 Results." Zerella signed the Form 8-K. For the second quarter, Vocera reported the financial results and guidance listed in ¶164-166 above. Commenting on these results and future guidance, Zollars stated: <i>Our Voice Communication solution continues to perform well. Our new B3000 badge is being well received in the marketplace and is driving healthy growth and improved profitability. As we enter the second half of 2012, we remain confident in our ability to execute on our growth opportunities.</i> 189. The statements contained in the Form 8-K and Press Release were materially false and misleading. Statements made by Zollars commenting on results and guidance, including statements that the Voice Communications solution (which was their main revenue driver),
6 7 8 9 0 1 2 3 4 5	 188. On August 2, 2012, after the market closed, Vocera filed a Form 8-K with the SEC and attached a press release entitled "Vocera Reports Second Quarter 2012 Results." Zerella signed the Form 8-K. For the second quarter, Vocera reported the financial results and guidance listed in ¶164-166 above. Commenting on these results and future guidance, Zollars stated: <i>Our Voice Communication solution continues to perform well. Our new B3000 badge is being well received in the marketplace and is driving healthy growth and improved profitability. As we enter the second half of 2012, we remain confident in our ability to execute on our growth opportunities.</i> 189. The statements contained in the Form 8-K and Press Release were materially false and misleading. Statements made by Zollars commenting on results and guidance, including statements that the Voice Communications solution (which was their main revenue driver), "continues to perform well", that the new badge was "driving healthy growth and improved
6 7 8 9 0 1 2 3 4 5 6	 188. On August 2, 2012, after the market closed, Vocera filed a Form 8-K with the SEC and attached a press release entitled "Vocera Reports Second Quarter 2012 Results." Zerella signed the Form 8-K. For the second quarter, Vocera reported the financial results and guidance listed in ¶164-166 above. Commenting on these results and future guidance, Zollars stated: <i>Our Voice Communication solution continues to perform well. Our new B3000 badge is being well received in the marketplace and is driving healthy growth and improved profitability. As we enter the second half of 2012, we remain confident in our ability to execute on our growth opportunities.</i> 189. The statements contained in the Form 8-K and Press Release were materially false and misleading. Statements made by Zollars commenting on results and guidance, including statements that the Voice Communications solution (which was their main revenue driver),

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page69 of 141

1	ability to exec	oute on our growth opportunities, " were false and misleading because the Voice
2	Communicati	on's solution was not continuing to "perform well," the Company was not
3	experiencing ^c	"healthy growth" and the remainder of 2012 would continue to be compromised for
4	the reasons sta	ated in ¶¶163 and 165 above, and because at the time the statements were made,
5		
6		¶¶103-129. Zollars' remarks were
7	objectively ve	rifiable and contradicted by this internal financial data. See Exs. A-B.
8	I.	August 2, 2012 - 2Q12 Earnings Conference Call
9	190.	The Company hosted an earnings conference call on August 2, 2012, after the
10	market closed	, to discuss Vocera's second quarter results. Zollars, Zerella and Lang participated
11	on the call. Z	ollars and Zerella reiterated second quarter financial results and third quarter and
12	annual guidan	ce. See ¶¶164, 166. The Individual Defendants all made positive statements
13	concerning the	e current state of the Company's business and Vocera's growth prospects.
14	191.	In his prepared remarks, Zollars discussed Vocera's "strong sales" and Vocera's
15	focus on conti	nued growth:
16		<i>We continue to be very pleased by our results of revenues in the second quarter coming in at the top end of our guidance range,</i>
17		while EBITDA and earnings-per-share exceeded our guidance as profitability continued to expand These strong results continue
18		to demonstrate the high visibility and operating leverage that's inherent in our business model.
19		I want to take a minute to review several factors that led to these
20		strong results. First, our revenue growth during the second quarter was driven by strong sales of our core voice
21		communication solution across all geographies, representing about 93% of our quarterly revenues.
22		***
23		While beyond the strength of the second quarter, we continue to
24 25		have multiple avenues of long-term growth in our business, I want to take a few minute []just to review those. First is the
25 26		addition of new customers. We were quite pleased this quarter with our progress and enjoyed a very solid new customer growth.
26 27		As we've mentioned before, these new customers have nice near term financial impact but will also have a longer time positive impact as they expand have our other solutions, and concrate
27 28		impact as they expand, buy our other solutions, and generate maintenance revenue.
20		$C_{LASS} \wedge C_{TION} C_{OMDLADIT} EOD WOLLTIONS OF THE EFFERTLY SECURITY ALTING (4)$
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 64 0. 3:13-CV-03567 EMC

	Case3:13-c	v-03567-EMC Document104 Filed09/19/14 Page70 of 141
1 2 3 4 5		Our second growth opportunity is within our existing customers as they continue to expand their deployments. We saw strong growth here at the end of the second quarter. And, in fact, the release of the B3000 has created additional interest from our install dates both for expansion as well as replacement business. About 75% of our B3000 shipments during the quarter were to our existing install-based customers. These first two growth strategies are driving the majority of our
6		near term revenue results
7		***
8		Before turning the call over to Bill, <i>I want to re-emphasize</i> Vocera's diversified approach to growth. During the first quarter we saw strength in revenues from our install based as
9		well as purchase outside the healthcare vertical. This quarter we surpasses our expectations for the number of new hospitals
10 11		<i>signed and have good existing customer expansions.</i> We also put in place traditional building blocks for future quarters with the solutions we announced.
12	192.	An analyst again asked Defendants if they had seen any impact on their business
13	from the Supr	reme Court health care reform decision:
14		Analyst:
15 16		OK, understood. Then was there any impact from the business from the Supreme Court health reform decision during the quarter? Did you guys see any changes to buying patterns?
17		Zollars:
18		Yes, Atif, this is Bob. No, we really don't. To the extent ruling
19		helps hospitals, that helps us to the extent it hurts them. Then we become a better source to drive costs down and become a more productive tool for them. I think either way we're OK there. As
20		it relates to sort of some of the subsidies that have been pushed into the market, we haven't participated in those in the past. We're
21 22		not dependent on a lot of the EMR sort of subsidy that's been funding a lot of purchases. <i>We're purely market driven, which I</i> <i>like our position at this point in that regard.</i>
23	193.	These statements during the second quarter earnings conference call were
24	materially fal	se and misleading.
25		(a) Statements made in ¶191 by Zollars concerning "strong results" for the
26	second quarte	er were false and misleading for the reasons stated in ¶189;
27		(b) Statements made in ¶191 by Zollars concerning "high visibility" of
28	Vocera's busi	iness model were false and misleading for the reasons stated in ¶176(b);
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 65 0. 3:13-CV-03567 EMC

1	(c) Statements made in ¶191 by Zerella concerning growth, including		
2	"revenue growth" was driven by strong sales, "we continue to have multiple avenues of long-		
3	term growth in our business," "[we] enjoyed a very solid new customer growth," existing		
4	customers "continue to expand their deployments" we saw strong growth at the end of the		
5	second quarter" and "these first two growth strategies [new and existing customers] are driving		
6	the majority of our near term revenue results, were false and misleading for the reasons stated in		
7	¶176(c);		
8	(d) Statements made in ¶192 by Zollars concerning the positive effect of		
9	healthcare reform, including that that the Supreme Court decision in health care did not affect		
10	Vocera's business negatively were false and misleading for the reasons stated in ¶176(d).		
11	194. In response to these materially false and misleading statements, Vocera's stock		
12	price soared over 7% to close at \$29.18 per share.		
13	195. Analysts continued to be reassured by Defendants' statements that healthcare		
14	reform was not having an adverse effect on its core hospital business and would not adversely		
15	affect growth. For example, on August 2, 2012 an analyst from William Blair reported:		
16	From an end-market perspective, management commented that		
10			
17	the company has been relatively immune from the issues confronting other [Healthcare] IT vendors, such as indecision		
	the company has been relatively immune from the issues confronting other [Healthcare] IT vendors, such as indecision surrounding the Supreme Court's review of the healthcare reform legislation or battling for capital budget dollars with		
17	the company has been relatively immune from the issues confronting other [Healthcare] IT vendors, such as indecision surrounding the Supreme Court's review of the healthcare reform legislation or battling for capital budget dollars with core clinical and financial systems tied to meaningful use incentive payments. More specific, management commented that		
17 18	the company has been relatively immune from the issues confronting other [Healthcare] IT vendors, such as indecision surrounding the Supreme Court's review of the healthcare reform legislation or battling for capital budget dollars with core clinical and financial systems tied to meaningful use incentive payments. More specific, management commented that the Supreme Court decision toward the end of the quarter provided no real impact to demand and that a very limited number of		
17 18 19	the company has been relatively immune from the issues confronting other [Healthcare] IT vendors, such as indecision surrounding the Supreme Court's review of the healthcare reform legislation or battling for capital budget dollars with core clinical and financial systems tied to meaningful use incentive payments. More specific, management commented that the Supreme Court decision toward the end of the quarter provided no real impact to demand and that a very limited number of customers have chosen a subscription model, as the up-front capital pressure for an initial Vocera deployment (later expansions		
17 18 19 20	the company has been relatively immune from the issues confronting other [Healthcare] IT vendors, such as indecision surrounding the Supreme Court's review of the healthcare reform legislation or battling for capital budget dollars with core clinical and financial systems tied to meaningful use incentive payments. More specific, management commented that the Supreme Court decision toward the end of the quarter provided no real impact to demand and that a very limited number of customers have chosen a subscription model, as the up-front capital pressure for an initial Vocera deployment (later expansions typically become operating budget expenses for a particular department) is minimal compared with meaningful-use-related		
 17 18 19 20 21 	the company has been relatively immune from the issues confronting other [Healthcare] IT vendors, such as indecision surrounding the Supreme Court's review of the healthcare reform legislation or battling for capital budget dollars with core clinical and financial systems tied to meaningful use incentive payments. More specific, management commented that the Supreme Court decision toward the end of the quarter provided no real impact to demand and that a very limited number of customers have chosen a subscription model, as the up-front capital pressure for an initial Vocera deployment (later expansions typically become operating budget expenses for a particular department) is minimal compared with meaningful-use-related [healthcare] IT projects.		
 17 18 19 20 21 22 	 the company has been relatively immune from the issues confronting other [Healthcare] IT vendors, such as indecision surrounding the Supreme Court's review of the healthcare reform legislation or battling for capital budget dollars with core clinical and financial systems tied to meaningful use incentive payments. More specific, management commented that the Supreme Court decision toward the end of the quarter provided no real impact to demand and that a very limited number of customers have chosen a subscription model, as the up-front capital pressure for an initial Vocera deployment (later expansions typically become operating budget expenses for a particular department) is minimal compared with meaningful-use-related [healthcare] IT projects. 196. A J.P. Morgan analyst reported on Defendants' representations that healthcare 		
 17 18 19 20 21 22 23 	 the company has been relatively immune from the issues confronting other [Healthcare] IT vendors, such as indecision surrounding the Supreme Court's review of the healthcare reform legislation or battling for capital budget dollars with core clinical and financial systems tied to meaningful use incentive payments. More specific, management commented that the Supreme Court decision toward the end of the quarter provided no real impact to demand and that a very limited number of customers have chosen a subscription model, as the up-front capital pressure for an initial Vocera deployment (later expansions typically become operating budget expenses for a particular department) is minimal compared with meaningful-use-related [healthcare] IT projects. 196. A J.P. Morgan analyst reported on Defendants' representations that healthcare reform was not affecting the Company and commented that Vocera expected its growth to 		
 17 18 19 20 21 22 23 24 	 the company has been relatively immune from the issues confronting other [Healthcare] IT vendors, such as indecision surrounding the Supreme Court's review of the healthcare reform legislation or battling for capital budget dollars with core clinical and financial systems tied to meaningful use incentive payments. More specific, management commented that the Supreme Court decision toward the end of the quarter provided no real impact to demand and that a very limited number of customers have chosen a subscription model, as the up-front capital pressure for an initial Vocera deployment (later expansions typically become operating budget expenses for a particular department) is minimal compared with meaningful-use-related [healthcare] IT projects. 196. A J.P. Morgan analyst reported on Defendants' representations that healthcare reform was not affecting the Company and commented that Vocera expected its growth to continue: 		
 17 18 19 20 21 22 23 24 25 	 the company has been relatively immune from the issues confronting other [Healthcare] IT vendors, such as indecision surrounding the Supreme Court's review of the healthcare reform legislation or battling for capital budget dollars with core clinical and financial systems tied to meaningful use incentive payments. More specific, management commented that the Supreme Court decision toward the end of the quarter provided no real impact to demand and that a very limited number of customers have chosen a subscription model, as the up-front capital pressure for an initial Vocera deployment (later expansions typically become operating budget expenses for a particular department) is minimal compared with meaningful-use-related [healthcare] IT projects. 196. A J.P. Morgan analyst reported on Defendants' representations that healthcare reform was not affecting the Company and commented that Vocera expected its growth to continue: Overall dynamics unchanged. The company did not see any effect (positive or negative) on its business from the Supreme Court 		
 17 18 19 20 21 22 23 24 25 26 	 the company has been relatively immune from the issues confronting other [Healthcare] IT vendors, such as indecision surrounding the Supreme Court's review of the healthcare reform legislation or battling for capital budget dollars with core clinical and financial systems tied to meaningful use incentive payments. More specific, management commented that the Supreme Court decision toward the end of the quarter provided no real impact to demand and that a very limited number of customers have chosen a subscription model, as the up-front capital pressure for an initial Vocera deployment (later expansions typically become operating budget expenses for a particular department) is minimal compared with meaningful-use-related [healthcare] IT projects. 196. A J.P. Morgan analyst reported on Defendants' representations that healthcare reform was not affecting the Company and commented that Vocera expected its growth to continue: Overall dynamics unchanged. The company did not see any effect (positive or negative) on its business from the Supreme Court health reform decision, and overall demand for its products remains robustIncreased prevalence of Wi-Fi in hospitals as 		
 17 18 19 20 21 22 23 24 25 26 27 	 the company has been relatively immune from the issues confronting other [Healthcare] IT vendors, such as indecision surrounding the Supreme Court's review of the healthcare reform legislation or battling for capital budget dollars with core clinical and financial systems tied to meaningful use incentive payments. More specific, management commented that the Supreme Court decision toward the end of the quarter provided no real impact to demand and that a very limited number of customers have chosen a subscription model, as the up-front capital pressure for an initial Vocera deployment (later expansions typically become operating budget expenses for a particular department) is minimal compared with meaningful-use-related [healthcare] IT projects. 196. A J.P. Morgan analyst reported on Defendants' representations that healthcare reform was not affecting the Company and commented that Vocera expected its growth to continue: Overall dynamics unchanged. The company did not see any effect (positive or negative) on its business from the Supreme Court health reform decision, and overall demand for its products 		

	Case3:13-cv	v-03567-EMC Document104 Filed09/19/14 Page72 of 141	
1 2		create favorable industry dynamics that should drive growth in coming years, we maintain our [overweight] rating.	
2	J.	August 14, 2012 - Form 10-Q	
	197.	On August 14, 2012, Vocera filed its Form 10-Q for the second quarter ended	
4	June 30, 2012.	. The Form 10-Q was signed by Zollars and Zerella.	
5	198.	The Form 10-Q stated:	
6		Revenue grew 28.3% from \$37.4 million for the six months	
7		ended June 30, 2011 to \$48.0 million for the six months ended June 30, 2012.	
8		Total revenue increased \$5.8 million, or 30.4%, from the three	
9		months ended June 30, 2011 to the three months ended June 30, 2012. Total revenue increased \$10.6 million, or 28.3%, from the	
10		six months ended June 30, 2011 to the six months ended June 30, 2012.	
11		Three months ended June 30, 2011 compared to three months	
12		ended June 30, 2012. Product revenue increased \$4.2 million, or	
13		35.5% from the three months ended June 30, 2011 to the three months ended June 30, 2012. Device revenue increased \$3.2	
14		million, or 35.6%, and software revenue increased \$1.0 million, or 35.2%. The increase in device revenue, which related entirely	
15		to our Voice Communication solution, was driven primarily by an increase in unit sales of badges and related accessories from	
16		new customers making initial purchases, existing customers expanding deployments within their facilities to new departments	
17		and users, and customers replacing badges and related accessories. A portion of the increase in device revenue was a	
18		result of higher average selling prices as a result of lower discounts and a change in mix, as customers purchase the B3000 badge,	
19		which has a higher list price than the B2000 badge. The list prices for our products did not change substantially in the three months	
20		ended June 30, 2012. The increase in software revenue was a result of an increase in sales of Voice Communication software	
20		licenses to new and existing customers.	
		Service revenue increased \$1.6 million, or 22.0% from the three	
22		months ended June 30, 2011 to the three months ended June 30, 2012. Software maintenance and support revenue increased \$1.2	
23		<i>million, or 22.4%, and professional services and training revenue increased \$0.4 million, or 20.9%. The increase in software</i>	
24		maintenance and support revenue was primarily a result of a larger customer base increasing software maintenance revenue	
25		<i>by \$0.9 million.</i> The increase in professional services and training revenue included \$0.3 million as a result of an increase in	
26		professional services related to our ExperiaHealth services, which are focused on helping customers improve the patient experience.	
27		and the particular of the particular of the particular.	
28			
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 67 MASTER FILE NO. 3:13-CV-03567 EMC 67		

П

199. The Form 10-Q included certifications signed by Zollars and Zerella, required
 under the Sarbanes-Oxley Act of 2002 ("SOX"), representing that the "report does not contain
 any untrue statement of material fact or omitted to state a material fact necessary to make the
 statements made, in light of the circumstances under which such statements were made, not
 misleading with respect to the period covered by this report," and that the information contained
 in the Form 10-Q "fairly present[s] in all material respects, the financial condition, results of
 operations and cash flows of the [Company]."

8 200. The statements made in the Form 10-Q were materially false and misleading. 9 Specifically, these statements attributed growth and increases in revenue to an increase in sales 10 of devices and software, but omitted to state that the ACA was a factor hurting sales and growth 11 and that the revenue increases were actually driven by Defendants' scheme to pull from backlog 12 and ship products early, essentially robbing the Company of future growth, in order to make its 13 quarterly guidance. ¶¶94-97, 103-129. The Form 10-Q also failed to disclose material 14 information that healthcare reform was already a factor adversely impacting the Company's 15 bookings and revenue. The omitted information was required to be disclosed in the Form 10-Q 16 pursuant to Item 2 of the instructions to Form 10-Q, which provides that companies disclose 17 information called for under Item 303 of Regulation S-K [17 C.F.R. §229.303]. 18 K. September 6, 2012 - Secondary Offering 19 201. The Secondary Offering Materials explained that Vocera would benefit from 20 healthcare reform because it provides incentives to hospitals to purchase Vocera's technology 21 and products to "improve the quality of care and patient satisfaction": 22 Patients are increasingly selecting hospitals and healthcare providers based on quality of care, cost and overall experience with the provider. *In addition, healthcare reform initiatives* 23 incorporate financial incentives for hospitals to improve the quality of care and patient satisfaction. These forces are driving 24 hospitals to manage their operations more efficiently and to seek ways to improve staff and patient satisfaction through process 25 improvements and technology solutions. 26 *** 27 The increasing focus on improving patients' experience is 28 supported by the healthcare reform initiative, which incorporates financial incentives for hospitals to improve the quality of care CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 68 MASTER FILE NO. 3:13-CV-03567 EMC

	Case3:13-cv	v-03567-EMC Document104 Filed09/19/14 Page74 of 141
1 2 2		and patient satisfaction. These forces are driving hospitals to invest in technology and process improvements to manage their operations more efficiently and to improve staff and patient satisfaction.
3	202.	Vocera also suggested that traditional hospital communications often "degrade
4	patient and ca	regiver satisfaction," because they lead nurses away from the bedside, do not
5	always reach	the appropriate caregiver in a timely manner, foster noisy environments and they
6		osed loop communication. According to Vocera, these impediments caused
7	inconvenience	e and frustration, medical errors and hospital inefficiencies, which led to lost
8	revenue oppoi	
9	203.	Vocera touted its products as providing the "solution" to these problems:
10	205.	
11		To address these deficiencies, hospitals are seeking more effective alternatives for improving communication. <i>We believe hospitals will increasingly turn to communication technologies to help</i>
12		<i>improve patient safety and satisfaction, productivity and caregiver satisfaction and retention. We believe our solutions are</i>
13 14		at the convergence of the healthcare IT market and the enterprise communications and collaboration market.
14	204.	In particular, Vocera claimed that its products would address problems faced by
	hospitals by in	mproving patient safety, enhancing patient experience, and improving caregiver job
16	satisfaction.	
17	205.	Vocera also laid out the pressures that hospitals might face because of healthcare
18	reform, but eq	ually touted the Company as the solution that hospitals needed to alleviate the
19	impact of thes	se proessures:
20		Effective communication is extremely important among mobile
21		and widely dispersed healthcare professionals in hospitals. As of December 31, 2011, there were over 6,900 hospitals in the United
22		States. We believe that a combination of policy changes through healthcare reform, demographic trends and downward pressure on
23		healthcare reimbursement is increasing financial pressure on hospitals and other healthcare providers. Furthermore, the nursing
24		shortage in the United States, with over 115,000 openings, can
25		detract from the patient experience and place further strain on hospital operations.
26		***
27		• Increase revenue and reduce expenses. Improved
28		communication facilitated by our solutions can enable hospitals to increase revenue and reduce expenses through more efficient use of their resources, directly impacting profitability. With our
		Class Action Complaint For Violations OF The Federal Securities Laws 69 0. 3:13-cv-03567 EMC
	WINGTER FILE INC	5. 5. 15 C Y 05 507 LIVIC

Case3:13-CV	-03567-EMC	Document104	Filed09/19/14	Page75 of 141	
	increase job sa retention. In a	tisfaction, thereby ddition, improven	urse overtime exp y improving nurse nents in patient sa educed liability co	recruiting and fety and	
206.	The Secondary	Offering Materia	als further explain	ed that because of	the benefi
and "solutions	" that Vocera p	rovided to hospita	als, Vocera's pros	pects for growth w	vere
enormous:					
	full deploymen		pital market oppo ommunication so s.		
207.	Vocera describ	ed its growth stra	tegy to increase t	he amount of new	healthcare
clients and cor	tinue to develo	p expansion into	its existing custor	ner base:	
	Our goal is to communicatio of our strategy	n solutions in the	rship position as e healthcare marl	a provider of ket. Key elements	
200	December 31, approximately expand our dif hospitals of all • Further pene Typically, our Communicatio gradually expa hospitals withi appreciate the strategy inclua Communicatio Messaging and customers.	2011, our solutio 9% of U.S. hosp rect sales force to l sizes. etrate our existing customers initial on solution in a fa and to additional in a healthcare sy value of our solu les promoting fun on solution and d d Care Transition	n solutions to our	in continue to ers among ner base. ce f a hospital and udditional ne to fully t of our sales our Voice value of our new existing	4
208.	Vocera also pro	ovided information	on showing its rep	orted growth over	the past ye
			Its of Operations	Marah	
(in thousands) (unaudited)		Quarterly Resu September 2011	Its of Operations December 2011	March 2012	
(in thousands) (unaudited) Revenue		September 2011	December 2011	2012	Ju 20 \$ 16 1
(in thousands) (unaudited) Revenue Product		September 2011 \$ 13,087	December 2011 \$ 13,674	2012 \$ 14,637	20 \$ 16,1
(in thousands) (unaudited) Revenue Product Service	revenue	September 2011	December 2011	2012	20

П

209. The statements made in the Secondary Offering Materials were materially false
 and misleading.

Statements made regarding the Company's growth and growth potential, 3 (a) 4 were false and misleading for the reasons stated in 176(c). 5 6 7 8 9 Statements concerning the positive effect that the healthcare reform (b) 10 initiative was having at the time of the Secondary Offering and would continue to have on 11 Vocera's business were false and misleading for the reasons stated in $\P176(d)$. 12 210 The Secondary Offering Materials also failed to disclose material information, 13 namely that that healthcare reform was already a factor impacting the Company's bookings and 14 revenue negatively. ¶¶94-97, 103-129. The omitted information was required to be disclosed in 15 the Form S-1 of the pursuant to Item 11(h) of the instructions to Form S-1, which provides that 16 companies disclose information called for under Item 303 of Regulation S-K [17 C.F.R. 17 [\$229.303]. Moreover, pursuant to SEC Regulation C, registrants have an overarching duty to 18 disclose material information necessary to ensure that representations in a registration statement 19 are not misleading. Specifically, Rule 408 states "In addition to the information expressly 20 required to be included in a registration statement, there shall be added such further material 21 information, if any, as may be necessary to make the required statements, in light of the 22 circumstances under which they are made, not misleading." 17 C.F.R. § 230.408(a). 23 L. November 5, 2012 - Form 8-K and Press Release 24 211. On November 5, 2012, after the market closed, Vocera filed a Form 8-K with the 25 SEC and attached a press release entitled "Vocera Reports Third Quarter 2012 Results." Zerella 26 signed the Form 8-K. For the second quarter, Vocera reported the results listed in ¶164 and 27 provided guidance for the third quarter, increasing its earnings guidance for the full year. See 28 ¶166. Commenting on these results and improved earnings guidance, Zollars stated: CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 71 MASTER FILE NO. 3:13-CV-03567 EMC

	Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page77 of 141
1 2 3 4 5 6 7 8 9 10	We continue to be very pleased with our financial results. We had a strong quarter with our existing customers expanding their Vocera footprint into additional departments. We experienced record gross margins due to continued strong software sales and further reductions in the unit cost of our B3000 badge. This drove record Adjusted EBITDA of \$3.8 million for the quarter. 212. The statements contained in the Form 8-K and press release were materially false and misleading. Statements made by Zollars commenting on third quarter results and fourth quarter guidance, stating "we had a strong quarter" were false and misleading because the quarter was not "strong" for the reasons stated in ¶163 and 165 above, and because at the time the statements were made, Zollars'
11	remarks were objectively verifiable and contradicted by this internal financial data. <i>See</i> Exs. A-B.
12 13	M. November 5, 2012 - 3Q12 Earnings Conference Call
13	213. The Company hosted an earnings conference call on November 5, 2012, after the
15	market closed, to discuss third quarter results. Zollars, Zerella and Lang participated on the call.
16	Zollars and Zerella reiterated third quarter financial results and annual guidance listed in ¶¶164
17	and 166 above. The Individual Defendants all made positive statements concerning the current
18	state of the Company's business and Vocera's growth prospects.
19	214. In his prepared remarks, Zollars discussed Vocera's current "strong results" and
20	Vocera's focus on continued growth:
21	So I thought I'd start the call today by sharing some of the highlights from our third quarter results. <i>We continue to be very</i>
22	pleased with our overall results, with revenues in the third quarter coming in at the top end of our guidance range.
23	EBITDA and earnings-per-share exceeded our guidance significantly as our gross margins continued to expand and we realized additional OpEx leverage
24	So these strong results continue to demonstrate the high visibility
25	and operating leverage inherent in our business model, and I
26	thought I'd take a few minutes just to review several factors that led to the strong results.
27	So first, let's chat about the drivers of our revenue growth for the quarter. We had a really positive quarter from our installed base
28	of customers, expanding their Vocera Voice Solution

	Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page78 of 141
1 2	deployments to additional departments. They're voting with their dollars as they expand Vocera across their enterprise. ***
3 4 5	We also saw a strong growth from our messaging solution and ExperiaHealth business, and although these are new businesses their contributions are still relatively small compared to voice. They both had great quarters.
6 7 8	Second, our profitability continued to improve with non-GAAP gross margins in the quarter of 66.4% versus 63.4% in the second quarter of this year, and 60.6% a year ago, well ahead of our expectations. This margin expansion was driven by continued strong software sales in the third quarter and further
9	reductions in unit costs for our B3000 badge.
10 11	All of these factors contributed to non-GAAP net income and non-GAAP adjusted EBITDA margins well above our guidance in the current quarter.
12 13	*** ***
14	Well beyond the strength of the third quarter, we continue to have multiple avenues of long-term growth in our business, and I'd like to just take a couple of minutes and talk about those a little bit more.
15 16	First is the addition of new customers. During the third quarter we continued to add to our network of customers. We also saw
17 18	the average sales price for Voice contracts move up sequentially, a result of customers electing to start with larger initial deployments. <i>As we told many of you, we'd expected a big bookings quarter</i>
19 20	from the Federal Government, yet some government contract bookings slipped outside the third quarter. I want to point out that we did not lose these contracts, however they pushed out for
20 21	a variety of reasons. In one case an order was pushed out as facilities wireless infrastructure was not yet completed, and another case 2012 fiscal year budget money allocated Vocera was pushed to 2013 fiscal year budgets, pushing out quarters out
22 23	beyond September 30th, the end of the government's 2012 fiscal year.
24	Now, some of these orders we hope to get in Q4, others may slide into early 2013. While this has been a little disappointing, we have remained very, very optimistic about the opportunity to sell
25 26	into the government space based on our recent certifications that we've received. We also added a number of new non-government health care customers during the quarter, but frankly I think we can do even better given the size of the market opportunity
27 28	can do even better given the size of the market opportunity. Our second growth opportunity lies within our existing customers as they continue to expand their deployments. And, as
_0	<i>I mentioned, this is a real strength for Q3, especially as it relates</i> Consolidated Class Action Complaint For Violations Of The Federal Securities Laws Master File No. 3:13-cv-03567 EMC

	Case3:13-cv	-03567-EMC Document104 Filed09/19/14 Page79 of 141
1 2		to our customers expanding their footprint with additional software licenses. Our Enterprise software license [lease] shipments were up 49% sequentially versus the second quarter of this year.
3		***
4		So while these first two growth avenues are driving a majority of
5		So while these first two growth avenues are driving a majority of our growth we have several exciting emerging opportunities
6		***
7		So, overall we had a very solid third quarter. We continue to feel really good about our near and long-term prospects. We
8 9		<i>continue to see nice growth out of our installed base. We're</i> <i>adding new customers. Our new solutions are getting traction.</i> And the creation of the mobility business unit should provide
10		additional revenue opportunities outside of healthcare.
11		
12		So, we're looking forward to continued success and strong performance to end 2012.
13	215.	An analyst asked about the growth levels for sales of the Vocera badge device,
14	and Zerella an	swered that the growth rate was consistent with historical trends:
15		<u>Analyst</u> :
16		Okay. And then maybe if you could just give us, Bill, maybe a feel within the device business I think it grew 26%, 27% year-
17 18		over-year, and the kind of supplies [versus] non-supplies, order, you know, was there an abnormally high growth for one or the other during the quarter, were they both relatively in line with that
19		26%? Zeneller
20		Zerella:
21		Yes. It was pretty consistent with historical trends, Jamie, nothing out of the ordinary, really, in terms of growth rate as
22	216.	<i>compared to previous quarters.</i>
23		Another analyst asked about the number of clients Vocera had, and Zollars and
24		the analyst that the numbers were "growing":
25		<u>Analyst</u> :
26 27		Hey. I just thought I had another one. I'm not sure if you can give this here in the third quarter but, could you possibly share with us your user numbers, whether it be US healthcare, non-healthcare, and then international?
28		Zollars:
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 74 . 3:13-CV-03567 EMC

1	218.	Analysts, however, were still enthralled by the growth story and the increasing
2	guidance, and	bought Defendants' story about the reasons that the government deals fell through.
3	For example, o	on November 5, 2012, in a report titled "Strong Software Sales Drive Another
4	Beat-and-Rais	e Quarter; Growth Outlook Remains Robust" William Blair commented that "the
5	year-to-date pe	erformance has been very strong":
6		Management commented that some deals with Department of Defense and VA hospital prospects slipped out of the quarter (but
7 8		were not lost) as the budget funds were pushed into the next federal fiscal year. We believe some of these deals have already closed, but some may not until next calendar year.
9	219.	On November 6, 2012 Leerink Swan reported:
10		While a few deals slipped from 3Q to 4Q, we believe VCRA is
11		doing a good job selling into its base, and we believe sales to the hospitality market, DoD, and international market represent
12		promising growth opportunities. While our 2013E EPS and 2014E EPS remain unchanged, we believe management guides
13		conservatively and there could be upside to expectations. We maintain our OP rating and \$31-32 valuation range.
14		Several Promising Opportunities: Management noted that one
15		federal government contract slipped due to Wi-Fi infrastructure delays and one got pushed due to FY2012 budget constraints, but they are still on track.
16	N.	November 13, 2012 - Form 10-Q
17	220.	On November 13, 2012, Vocera filed its Form 10-Q for the third quarter ended
18		
19		2012. The Form 10-Q was signed by Zollars and Zerella.
20	221.	The Form 10-Q stated:
21		<i>Revenue grew 28.0% from \$57.8 million for the nine months ended September 30, 2011 to \$74.0 million for the nine months</i>
22		ended September 30, 2012.
23		
24		Product revenue increased \$3.8 million, or 28.8% from the three months ended September 30, 2011 to the three months ended
25		September 30, 2012. Device revenue increased \$2.6 million, or 27.6%, and software revenue increased \$1.1 million, or 31.8%.
26		The increase in device revenue, which relates entirely to our Voice Communication solution, was driven primarily by existing
27		customers expanding deployments within their facilities to new departments and users, new customers making initial purchases,
28		<i>and customers replacing badges and related accessories</i> . A portion of the increase in device revenue was due to higher average selling prices as a result of lower discounts and a change in mix, as
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 76
	MASTER FILE NO	. 3:13-cv-03567 EMC

	Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page82 of 141
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page82 of 141 customers purchase the B3000 badge, which has a higher list price than the B2000 badge. The list prices for our products did not change substantially in the three months ended September 30, 2012. The increase in software revenue was a result of an increase in sales of Voice Communication software licenses to new and existing customers. Service revenue increased \$1.8 million, or 24.7% from the three months ended September 30, 2012. Software maintenance and support revenue increased \$1.2 million, or 20.8%, and professional services and training revenue increased \$1.2 million, or 50.7%. An increase of \$0.9 million in software maintenance and support revenue was primarily a result of a larger customer base. The increase in professional services and training revenue increased \$0.7 million, or 36.7%. An increase of \$0.9 million in software maintenance and support revenue was primarily a result of a larger customer base. The increase in professional services and training revenue included \$0.4 million as a result of an increase of \$1.0 classe of \$2002 ("SOX"), representing that the "report does not contain any untrue statement of a material fact or omitted to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report," and that the information contained in the Form 10-Q "fairly present[s] in all material respects the financial condition, results of operations and cash flows of the [Company]." 223. The statements attributed growth and increases in revenue to an increase in sales of devices and software, but omitted to state that the ACA was a factor that created a negative effect on sales and growth and that the revenue increases were actually driven by Defendants' scheme to pull from backlog and ship products early, essentially robbing the Company of future
20	of devices and software, but omitted to state that the ACA was a factor that created a negative
	scheme to pull from backlog and ship products early, essentially robbing the Company of future growth, in order to make Vocera's quarterly guidance. ¶¶94-97, 103-128.
24 25 26 27	224. The Form 10-Q also failed to disclose material information that healthcare reform was already a factor impacting the Company's bookings and revenue negatively. The omitted information was required to be disclosed in the Form 10-Q pursuant to Item 2 of the instructions to Form 10-Q, which provides that companies disclose information called for under Item 303 of
28	Regulation S-K [17 C.F.R. §229.303]. Consolidated Class Action Complaint For Violations Of The Federal Securities Laws 77 Master File No. 3:13-cv-03567 EMC

0.	November 28, 2012 – Piper Jaffray Report
225.	On November 28, 2012, Piper Jaffray reported that the Company hosted Zollars
	t the 24th annual Piper Jaffray Healthcare Conference for a fireside chat. Based of
	chat," Piper Jaffray reported:
	The company continues to exceed margin expectations because
	of the increasing software mix and faster B3000 adoption. Management noted there are several growth opportunities that
	should help the top-line growth including a \$150m upgrade opportunity in the current customer base, traction in non- healthcare verticals and international markets.
226.	Statements attributable to Zerella and Zollars concerning growth including
"several grov	wth opportunities that should help the top line growth" [which had been previous]
described as	25% growth] were false and misleading for the reasons stated in $\P176(c)$.
Р.	November 30, 2012 – J.P. Morgan Analyst Report
227.	On November 30, 2012, a J.P. Morgan analyst reported that he had "recently m
with Zollars	and Zerella and came away with a continued positive outlook for Vocera's growt
in its core ho	spital market and potential for additional growth in new areas." Specifically, the
"key takeawa	ays" from the meeting with Zollars and Zerella included comments on the
Company's c	continued growth, and the belief that government hospitals remained a strong area
for growth:	
	Company expects accelerating productivity from sales force. While expansion in existing footprints, international and non- healthcare verticals all contribute to revenue growth, the leading driver of growth and management's priority is new hospital customers. To this point management noted that as the sales force becomes more seasoned (average tenure is just ~18 months since VCRA went direct) and the ~15 new adds are trained it should see acceleration in new customer adds.
	DoD and VA hospitals remain an opportunity for further growth. On the company's 3Q call in October management noted that some government contract bookings had been pushed back due to budget changes. Management discussed with us that it has since closed two of those deals and expects to close the remainder in 4Q or early 2013. Management also noted that it would like to target multiple hospital deals (i.e. 25 at once vs. 1-2) with federal customers and we see this as a good area for growth going forward.
	CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS IO. 3:13-CV-03567 EMC

1	228.	Statements attributable to Zerella and Zollars concerning growth such as: the
2	"leading driv	er of growth" in new hospital customers and that "DoD and VA hospitals remain an
3	opportunity f	for further growth" were false and misleading because the ACA and now the BCA
4	were having a	and would continue to have a negative effect on new bookings, revenue and growth
5	for both priva	ate hospitals and government hospitals. See ¶¶176(c)-(d), 217.
6	Q.	January 7, 2013 – J.P. Morgan Healthcare Conference
7	229.	On January 7, 2013, Zollars, Zerella and Lang attended The 31st Annual JP
8	Morgan Heal	thcare Conference. During the conference, Zollars explained how health care
9	reform would	continue to have a positive effect on Vocera's sales:
10		And then very interestingly, this year – <i>two thousand, right at the</i>
11		end of twelve and into 2013 – reimbursement is going to begin to be affected by patient satisfaction scores via HCAHPS surveying that the government's doing for Medicare patients. And so, as
12		that the government's doing for Medicare patients. And so, as we think about how we can help a hospital and the issues we're
13		focused on, we're really dealing with top of mind issues for the hospital CEOs and their executive team. When you think about
14		patient safety, reimbursement, ROI, saving money and staff productivity, we're right there focused in on what they want us to
15	220	be focused in on.
16	230.	Zollars further touted the visibility into the Company's revenue streams, and
17	vocera s go	od" financial performance:
18		From an investment perspective we think this is a good Healthcare IT stock to own. We've got great visibility to revenue
19		<i>streams</i> and we've got a very unique solution. Brent will touch on this a little bit more in a few minutes, but there's nothing like this
20		in the market. The closest thing we get compared to is an in- building Wi-Fi phone which doesn't have the functionality or the
21		hands-free nature of our device, nor does it have the software. It's a multi-billion market opportunity. Although it seems kind of
22		niche-y when you first describe it as "healthcare communications" it's a big, big market – I'll define that for you in a minutes. This
23		really represents a good platform for us. We're now integrated into about 50 other clinical systems in and around the bedside,
24		including the EMRs, the IV pumps, etc. And so we're really setting up a software platform that we can grow and build upon.
25		We've got good, loyal customers who like the brand, like the company and so far so good on financial performance.
26	231.	Zollars also commented on Vocera's "growing" market and the tremendous
27	"growth oppo	ortunity" in light of healthcare reform:
28		For a market opportunity this is in the category of "I'd rather be
		lucky than good." We've got two nice growing markets that giveCLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS790. 3:13-cv-03567 EMC79
	WIASTEK FILE IN	0. J. 1 J-C V-0 J U / ENIC

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

us a nice tail wind as a business. One is Healthcare IT, and as all of you know being at the Healthcare Conference here, that's being funded pretty aggressively and continues to be funded aggressively, even post-Stimulus money that's going into a lot of the IT budgets. And so we're seeing a lot of investment going after things that can improve productivity, especially in light of *reform.* And we're also seeing nice growth in the enterprise communications market, which we participate in. And in this side of the market we either replace or enable devices. And so we're replacing old technologies like 2-way pagers, overhead paging, walkie-talkies – believe it or not those things still exist in hospitals today. And then we're enabling some of the newer technologies, like androids, smart phones, the Apple iPhone. We've got our own proprietary device as well. And so we find ourselves playing a really nice role as these two markets converge and really change how clinicians communicate with one another. So good growth opportunity.

And then I would say as we think about multiple avenues of growth there's really five things we're focused on. They're very straightforward. You probably already have 'em, just based on the previous four or five slides. [10:00] One is we just add new hospitals. So we're going out just adding new names, new addresses. It's the easiest way to grow and we're focused very much on that. Two is driving that 30% penetration rate up. And so we're further penetrating the hospitals that we have. That part of our business is doing really really well. Our customers are voting with their dollars and they continue to expand. Third is to develop and acquire products that we can then cross sell into the install base. And we've done a little bit of development and a little bit of acquisition as well. That part's working pretty well, as I mentioned earlier as well. Internationally, we continue to expand. That business we think can be a much bigger part of our overall revenue line, about 10% thus far this year. And then lastly we're expanding in non-healthcare.

232. Zerella commented on Vocera's current financials and "growth story":

Alright, thanks Brent. We'll wrap up here with the financials. So, starting with the profile of Vocera, as Bob described, *very large market opportunity measured in the billions. We've now recorded thirteen consecutive quarters of sequential revenue growth with records each quarter.* I'll take you through the revenue model here in a few minutes. *Good visibility and repeatability in terms of our revenue streams.* We have a very strong and diverse customer base, as Bob described, no customer concentration. Our gross margins continued to expand, actually north of 65% last quarter, with some other opportunities to continue that growth and we're generating strong cash flow.

So starting with the revenue model, a little less than half of our revenue stream is generated from the hardware side, which is primarily the sales of the Vocera badge. Also includes batteries, which we sell separately. Chargers, other related accessories.
17% of our revenue is derived from software and these are primarily user licenses that we sell. We typically sell perpetual

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

licenses, and that's obviously very high margin business. On the services side, our largest revenue stream is from software maintenance. This is ongoing technical support, updates and upgrades and what have you. And that's a little over a quarter of our total revenue streams. And finally, professional services, which represents about 10% of our revenue. This is our Services Group. We wrap services around the delivery and installation of our solution to help customers in terms of training and deployment.

In terms of the visibility of our revenue streams, however, we come into a guarter looking at our revenue streams in this fashion: with four blocks, if you will. So, first on the maintenance side, our customers typically pay us annually in advance for software maintenance. That all goes into deferred revenue, and we therefore come into the quarter with about 98% of our software maintenance revenue actually sitting in deferred revenue, just waterfalls into the P&L. The second block is our supplies business. This is daily flow of orders that we receive from the installed base. Badges get lost, they get broken or out of warranty, need to be replaced. Batteries wear out after about 18 months and need to be replaced. We get small software orders that just flow in over the transom. This is about 20% of our total revenues. It continues to grow as the installed base grows. And this slide is built to scale, so between these first 2 blocks here, just a little less than half of our total revenue streams are recurring in nature from maintenance and supplies. And our supplies revenues are very predictable. The third block here, which is the largest, is our expansions. And as Bob described, we have a land and expand strategy which we will initially get into a hospital, and typically we'll then go viral and customers will buy more badges, they'll need more user licenses, which will result in more maintenance, and so on. So that basically drives all the revenue streams with it. And lastly, new customers, which is about 15% of our total revenue.

So these first 3 blocks here represent the repeat business from the installed base, and that's about 85% of our revenue. And typically, we'll come into a quarter with a significant percent of this either sitting, again, in deferred revenue for maintenance, our supplies business, which is very predictable, or sitting in backlog. And as a result, as a public company, we've given very tight revenue guidance, typically plus or minus half a million dollars from a midpoint, on a quarterly basis.

So in terms of looking at our growth, again, as Bob described, growing very nicely are our revenues through the last nine months, approaching all of last year. We're also growing deferred revenue at a significant growth rate as well. And again, this is primarily associated with software maintenance.

So in terms of looking year on year, based on our results through September, we grew 28% year-to-date. But what you'll see at the bottom of the chart is that our earnings and EBITDA actually grew very rapidly. So we're seeing a lot of leverage in terms of the business model, and again, that's been driven by strong growth in terms of gross margins, but also significant OP-EX leverage. Last quarter in particular, we saw actually 49% sequential growth

	Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page87 of 141
1 2 3 4 5 6 7	from the previous quarter in terms of enterprise license seats that we shipped to our customers. And obviously, software is very high margin business, so to the extent that we continue to drive software, that will drive margins. So in looking at our target model, which is on the right here, you can see we've actually already exceeded our target gross margins at 66% last quarter. We articulated this model in the IPO last March, and indicated that we thought it would take us about 2 years or so to get there. So we made really great progress in terms of gross margins, we've had good OP-EX leverage as well, as I previously described. On the tax side, we do have an NOL, so that is shielding us from federal taxes, which we expect to continue for the next several years. When we do pay taxes, we see a 35%
 8 9 10 11 12 13 14 15 16 17 18 	 effective tax rate. And then, turn to the balance sheet, over 120 million in cash at the end of September. No debt. So, pristine balance sheet. We believe this does give us some dry powder to support any acquisitions that are synergistic, going forward. So, just finishing up here, again, going through the highlights. <i>This is a growth story. Again, we've got really diverse revenue streams with good visibility in terms of the model. Unique solution. Very large market opportunity which we're just scratching the surface of today.</i> Ultimately this is an IT platform; that's the way we look at ourselves. We have a recognized brand that just continues to grow in the market, a loyal customer base, and a strong track record of performance. That wraps us up, with 2 minutes to spare. 233. These statements were materially false and misleading for the following reasons: (a) Statements made in ¶230 by Zollars concerning "good [] financial
 19 20 21 22 23 24 25 26 27 28 	performance" were false and misleading because the Company's financial performance was not "good." "good." (b) Statements made in ¶230 and 232 by Zollars and Zerella concerning "great visibility" of Vocera's revenue streams were false and misleading for the reasons stated in ¶176(b); (c) Statements made in ¶231 and 232 by Zollars and Zerella concerning "growth," including the "growing market," the large market opportunity" and "this is a growth Consolidated Class Action Complaint For Violations Of The Federal Securities Laws 82 MASTER FILE NO. 3:13-CV-03567 EMC 82
	IVIASTER FILE NO. 5:15-CV-U550/ EMU

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page88 of 141

1	story" were false and misleading for the reasons stated in 176(c), and additionally because the			
2	BCA along with the ACA were negatively affecting Vocera's business;			
3	(d) Statements made in ¶229 and 231 by Zollars and Zerella concerning			
4	positive effects of healthcare reform were false and misleading for the reasons stated in ¶176(d).			
5	R. February 27, 2013 – Form 8-K and Press Release			
6	234. On February 27, 2013, after the market closed, Vocera filed a Form 8-K with the			
7	SEC and attached a press release entitled "Vocera Reports Fourth Quarter and Full-Year 2012			
8	Results." Zerella signed the Form 8-K. For the fourth quarter and full year, Vocera reported the			
9	financial information listed in ¶164 and provided first quarter and 2013 annual guidance listed in			
10	¶166. Zollars commented on the current results and guidance stating:			
11	We are very pleased with our fourth quarter results and our financial performance during our first year as a public company.			
12	We made good progress across all five of our growth strategies and believe we are well positioned for 2013 and beyond. In			
13	addition, our profitability continued to expand during 2012 and we are increasing our long-term profitability target. Contract			
14	wins with key healthcare national accounts, as well as in our Mobility business towards the end of the year, are also quite			
15	exciting.			
16	235. The statements contained in the Form 8-K and press Rrlease were materially false			
17	and misleading. Statements made by Zollars commenting on fourth quarter and 2012 annual			
18	results and first quarter and 2013 annual guidance stating "Webelieve we are well positioned			
19	for 2013 and beyond" were false and misleading because the Company was not "well positioned			
20	to meet 2013 guidance for reasons stated in ¶¶163 and 165 above, and because at the time the			
21	statements were made,			
22	Zollars' remarks were			
23	objectively verifiable and contradicted by this internal financial data. See Exs. A-B.			
24	S. PARTIAL DISCLOSURE – February 27, 2013 Earnings Conference Call			
25	236. The Company hosted an earnings conference call after the market closed on			
26	February 27, 2013 to discuss the third quarter results. Zollars, Zerella and Lang participated on			
27	the call. Zollars and Zerella reiterated third quarter financial results and annual guidance. See			
28	¶¶164, 166. The Individual Defendants all made positive statements concerning the current state			
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 83 MASTER FILE NO. 3:13-CV-03567 EMC			

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page89 of 141

of the Company business and Vocera's growth prospects, and for the first time disclosed "one lingering challenge" involving government contracts facing the Company. Defendants, however failed to disclose the effect on their core business resulting from the ACA and the Company's smoothing of revenue and earnings by pulling in revenue from future quarters out of backlog. 237. During his prepared remarks, Zollars discussed both Vocera's growth and the "very good year" the Company had in 2012. Zollars also discussed for the first time the effect of sequestration on their government contracts: As we look deeper into the fourth quarter, there are several positive factors that impacted our numbers, <i>and one lingering challenge</i> . On the positive side, <i>we saw a nice growth from our Voice business with strong new customer acquisition in the fourth quarter. Additionally, we saw significant expansions within our existing install base, which continued the strength we saw in Q3. *** In terms of challenges, government orders have continued to slip. As we mentioned in our last call, government hospital orders that we expected in Q3 got pushed out. We were able to close a couple of those deals in Q4, but the majority of these orders have slipped into 2013. The government has slowed its funding due to the debt ceiling and sequestration issues. <i>But, despite the contract delays, we still expect to close these deals. And believe the delay is a macro- funding issue.</i></i>
 failed to disclose the effect on their core business resulting from the ACA and the Company's smoothing of revenue and earnings by pulling in revenue from future quarters out of backlog. 237. During his prepared remarks, Zollars discussed both Vocera's growth and the "very good year" the Company had in 2012. Zollars also discussed for the first time the effect or sequestration on their government contracts: As we look deeper into the fourth quarter, there are several positive factors that impacted our numbers, and one lingering challenge. On the positive side, we saw a nice growth from our Voice business with strong new customer acquisition in the fourth quarter. Additionally, we saw significant expansions within our existing install base, which continued the strength we saw in Q3. *** In terms of challenges, government orders have continued to slip. As we mentioned in our last call, government hospital orders that we expected in Q3 got pushed out. We were able to close a couple of those deals in Q4, but the majority of these orders have slipped into 2013. The government has slowed its funding due to the debt ceiling and sequestration issues. But, despite the contract delays, we still expect to close these deals. And believe the delay is a macro-
 smoothing of revenue and earnings by pulling in revenue from future quarters out of backlog. 237. During his prepared remarks, Zollars discussed both Vocera's growth and the "very good year" the Company had in 2012. Zollars also discussed for the first time the effect of sequestration on their government contracts: As we look deeper into the fourth quarter, there are several positive factors that impacted our numbers, <i>and one lingering challenge</i>. On the positive side, <i>we saw a nice growth from our Voice business with strong new customer acquisition in the fourth quarter. Additionally, we saw significant expansions within our existing install base, which continued the strength we saw in Q3.</i> *** In terms of challenges, government orders have continued to slip. As we mentioned in our last call, government hospital orders that we expected in Q3 got pushed out. We were able to close a couple of those deals in Q4, but the majority of these orders have slipped into 2013. The government has slowed its funding due to the debt ceiling and sequestration issues. But, despite the contract delays, we still expect to close these deals. And believe the delay is a macro-
 237. During his prepared remarks, Zollars discussed both Vocera's growth and the "very good year" the Company had in 2012. Zollars also discussed for the first time the effect or sequestration on their government contracts: As we look deeper into the fourth quarter, there are several positive factors that impacted our numbers, and one lingering challenge. On the positive side, we saw a nice growth from our Voice business with strong new customer acquisition in the fourth quarter. Additionally, we saw significant expansions within our existing install base, which continued the strength we saw in Q3. *** In terms of challenges, government orders have continued to slip. As we mentioned in our last call, government hospital orders that we expected in Q3 got pushed out. We were able to close a couple of those deals in Q4, but the majority of these orders have slipped into 2013. The government has slowed its funding due to the debt ceiling and sequestration issues. But, despite the contract delays, we still expect to close these deals. And believe the delay is a macro-
 "very good year" the Company had in 2012. Zollars also discussed for the first time the effect of sequestration on their government contracts: As we look deeper into the fourth quarter, there are several positive factors that impacted our numbers, and one lingering challenge. On the positive side, we saw a nice growth from our Voice business with strong new customer acquisition in the fourth quarter. Additionally, we saw significant expansions within our existing install base, which continued the strength we saw in Q3. *** In terms of challenges, government orders have continued to slip. As we mentioned in our last call, government hospital orders that we expected in Q3 got pushed out. We were able to close a couple of those deals in Q4, but the majority of these orders have slipped into 2013. The government has slowed its funding due to the debt ceiling and sequestration issues. But, despite the contract delays, we still expect to close these deals. And believe the delay is a macro-
sequestration on their government contracts: As we look deeper into the fourth quarter, there are several positive factors that impacted our numbers, and one lingering challenge. On the positive side, we saw a nice growth from our Voice business with strong new customer acquisition in the fourth quarter. Additionally, we saw significant expansions within our existing install base, which continued the strength we saw in Q3. *** In terms of challenges, government orders have continued to slip. As we mentioned in our last call, government hospital orders that we expected in Q3 got pushed out. We were able to close a couple of those deals in Q4, but the majority of these orders have slipped into 2013. The government has slowed its funding due to the debt ceiling and sequestration issues. But, despite the contract delays, we still expect to close these deals. And believe the delay is a macro-
As we look deeper into the fourth quarter, there are several positive factors that impacted our numbers, <i>and one lingering challenge</i> . On the positive side, <i>we saw a nice growth from our Voice business with strong new customer acquisition in the fourth quarter. Additionally, we saw significant expansions within our existing install base, which continued the strength we saw in Q3.</i> *** In terms of challenges, government orders have continued to slip. As we mentioned in our last call, government hospital orders that we expected in Q3 got pushed out. We were able to close a couple of those deals in Q4, but the majority of these orders have slipped into 2013. The government has slowed its funding due to the debt ceiling and sequestration issues. But, despite the contract delays, we still expect to close these deals. And believe the delay is a macro-
factors that impacted our numbers, and one lingering challenge. On the positive side, we saw a nice growth from our Voice business with strong new customer acquisition in the fourth quarter. Additionally, we saw significant expansions within our existing install base, which continued the strength we saw in Q3. *** In terms of challenges, government orders have continued to slip. As we mentioned in our last call, government hospital orders that we expected in Q3 got pushed out. We were able to close a couple of those deals in Q4, but the majority of these orders have slipped into 2013. The government has slowed its funding due to the debt ceiling and sequestration issues. But, despite the contract delays, we still expect to close these deals. And believe the delay is a macro-
 business with strong new customer acquisition in the fourth quarter. Additionally, we saw significant expansions within our existing install base, which continued the strength we saw in Q3. *** In terms of challenges, government orders have continued to slip. As we mentioned in our last call, government hospital orders that we expected in Q3 got pushed out. We were able to close a couple of those deals in Q4, but the majority of these orders have slipped into 2013. The government has slowed its funding due to the debt ceiling and sequestration issues. But, despite the contract delays, we still expect to close these deals. And believe the delay is a macro-
In terms of challenges, government orders have continued to slip. As we mentioned in our last call, government hospital orders that we expected in Q3 got pushed out. We were able to close a couple of those deals in Q4, but the majority of these orders have slipped into 2013. The government has slowed its funding due to the debt ceiling and sequestration issues. <i>But, despite the contract delays, we still</i> <i>expect to close these deals. And believe the delay is a macro-</i>
As we mentioned in our last call, government hospital orders that we expected in Q3 got pushed out. We were able to close a couple of those deals in Q4, but the majority of these orders have slipped into 2013. The government has slowed its funding due to the debt ceiling and sequestration issues. <i>But, despite the contract delays, we still</i> <i>expect to close these deals. And believe the delay is a macro-</i>
 we expected in Q3 got pushed out. We were able to close a couple of those deals in Q4, but the majority of these orders have slipped into 2013. The government has slowed its funding due to the debt ceiling and sequestration issues. <i>But, despite the contract delays, we still expect to close these deals. And believe the delay is a macro-</i>
The government has slowed its funding due to the debt ceiling and sequestration issues. <i>But, despite the contract delays, we still expect to close these deals. And believe the delay is a macro-</i>
<i>Our pipeline in the government remains very strong,</i> especially with our certifications with both the VA and DOD. And because the government buys big, it only takes a couple of orders to be completed or deferred to impact our total revenue line one way or the other at our current size.
Turning to the full year 2012 results, we had a very good year.
238. During his prepared remarks, Zerella also commented on the Company's
disappointing bookings growth rate, but assured the market that its core non-government
business was still very much intact:
During the IPO road show, we committed to providing bookings on an annual basis. And while Bill will discuss backlog and
revenue visibility coming into 2013, I wanted to touch on bookings and provide some perspective on our bookings performance.
Bookings were \$101 million for 2012, compared to \$90 million in 2011, representing about a 12% year-over-year increase. And
CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 84 MASTER FILE NO. 3:13-CV-03567 EMC 84

	Case3:13-cv	-03567-EMC Document104 Filed09/19/14 Page90 of 141
1 2		while we were disappointed with that bookings growth rate, it's important to understand the underlying trends behind the different components of our business.
3		Bookings for our Voice solution in the US healthcare market,
4		excluding government, grew by 20%, which is actually an acceleration in growth versus 2011 growth of 17%. This segment
5		represents over 75% of our total business. Even better, new customer bookings for Voice in the US Market, excluding
6		government, grew 27%, which puts us in a great position to drive expansion revenue in 2013.
7		US government bookings, however, declined 21% from the prior
8		year due to contract delays. International bookings grew marginally in 2012 due to smaller expansions in Canada and Australia-New Zealand coming off very strong growth in 2011.
9		While our overall bookings growth rate was below our revenue
10		growth rate, our US healthcare business, excluding government, is very healthy and performing well. And we expect government,
11		Canada and Australia-New Zealand growth rates to bounce back this year in 2013.
12	239.	Zollars also commented on the Company's purported success in 2012 and
13	reiterated Voc	era's commitment to long term growth of 25% on the top line:
14 15		2012 was a solid year, and we have plans in place to do even better this year in 2013.
16		So, looking forward, we want to reiterate our commitment to long
17 18		term growth of 25% on the top line. We're fortunate to have a very large market opportunity, a unique solution, a healthy and growing install based, and numerous investment initiatives underway, as I just described.
19		That said, with the uncertainty of the government business in the
20		short term, you'll note the guidance that Bill gives in a few minutes will provide a slightly broader range than we usually
21		would. As we progress through the year, we plan to tighten that range as we deliver on our results.
22	240.	In Zerella's prepared remarks, he discussed the Company's financial results:
23		Thank you, Bob. And good afternoon, everyone. I would like to
24		spend my time detailing our fourth quarter results and our 2013 outlook. <i>Revenue [results]was driven by continued strength in</i>
25		our voice communications solution, including sales of our new B3000 badge and our service software.
26	241.	Zerella also discussed the decline in the Company's backlog, attributing it to
27	factors other th	han the Company's deceptive plan to pull orders out of backlog and ship them in
28	earlier quarters	3:
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 8 . 3:13-CV-03567 EMC

	Case3:13-cv	v-03567-EMC Document104 Filed09/19/14 Page91 of 141
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26	and reminded	 Backlog at year end 2012 was \$16 million compared to \$22 million a year ago. The decline in backlog is due to three factors. First, with the successful launch of the B3000, a larger percentage of our bookings in the second half of 2012 were badge upgrades, which are typically book and ship and don't ever get backlogged. As you think of year-over-year comparison, badge upgrades were not a meaningful portion of our business in 2011, and somewhat distorts the backlog number. Second, the delay we've experienced in booking new government deals has impacted our backlog. These deals tend to be big in nature and have a meaningful impact. Third, our professional services team did an outstanding job of completing projects on time and recognizing the associated revenue, further reducing our year end backlog. Finally Zerella provided guidance for 2013, and providing a range of \$120 to a 20% to 30% increase over 2012, despite the issues with the government business, the market about Vocera's high "recurring revenue": Turning to guidance we are providing our initial guidance for the full year 2013 and the first quarter of this year. As Bob mentioned, we see no reason why we can't continue to grow this business 25% on the top line over the next few years. That said, the lack of clarity of the government business in Q3 and Q4 of last year has made that portion of our business less visible and predictable that we would like. As a result, we are providing a revenue range for 2013 that is somewhat wider than we normally would provide. And as were whore through the year, we will tighten *** The backlog entry in 2013 as deferred revenue, the full impact of our sales force expansion, our mobility business is beginning to gain traction, continued uptake of the B3000 by our customers, additional national account opportunities, and finally, as a reminder, our revenue model is highly recurring in nature due to software maintenance and our supplies business, which
27 28		And then the big focus, probably, is going to be on the Q1 guidance. Obviously a little bit weaker on both the sales and FRITDA then I think individuals were expecting. And I'm
28		EBITDA than I think individuals were expecting. And I'm curious if you could talk a little bit more about that. Is that
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 86 0. 3:13-CV-03567 EMC

	Case3:13-cv-	03567-EMC Document104 Filed09/19/14 Page92 of 141	
1 2 3		really just more in the government business that you're seeing weakness there as you enter the year? And not expecting those contracts to come in and so you're just kind of pushing those out of the Q1? Or anything more behind that?	
4		Zerella:	
5		Hi, Ryan. Yes. That's actually precisely the answer in terms of the revenue guidance.	
6 7		We are entering the year with a lower backlog than we expected because a lot of those government deals we expected to book before the end of the year. And those would have turned into revenue in Q1 or Q2.	
8 9		So, that's certainly causing us to be cautious in terms of the guidance for Q1, in terms of revenue.	
10		On the OpEx side, we're going to continue to invest on that side	
11		of the business because we firmly believe that the growth opportunities are in front of us. So, we'll continue to focus on that investment. And that's what's driving the bottom line for the	
12		quarter.	
13	2	Zollars:	
14 15		Let me add one comment to that. The government tends to buy big. And when you look at even our full year 2012 results, we were one government deal away from being at the top end of our (technical difficulty) versus hitting right in the middle. So, it	
16		does have a big impact. And that's the reason Q1 is what it is.	
17		Given the weak 1Q13 guidance, analysts asked Defendants how they planned on	L
18	meeting their re		
19		<u>Analyst</u> :	
20		But, you know, maybe if we could talk about the second half of 2013, the guidance implies a pretty strong acceleration as far	
21 22	£	as revenue growth is concerned. And I hear you guys that the government business you expect to get stronger as the rest of the	
22	y	year progresses. Could you talk, maybe, about when you think you'll see the inflection point of the newer sales people really becoming productive? Are we going to see that in the second	
23		quarter, do you think? Or is more of a third quarter phenomenon?	
25	2	Zollars:	
26		Yes. Hi, Jamie. Good question. We've used a model that's been pretty predictive on new sales reps. And it's sort of a 30%, 60%,	
27	ġ	90% productivity rating by quarter. So, the first quarter calendar, they're at about a 30% productivity level. They move to 60% and	
28	t	then 90%. And then when they hit their stride, sort of in their fourth calendar quarter, their fourth quarter in their territory,	
		LASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 87 3:13-CV-03567 EMC	,

	Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page93 of 141
1 2 3 4 5 6 7	 they're pretty much fully productive. And we've seen exceptions to that on the front end and the back end. Interestingly, as we're speaking, right below us here at our headquarters we've got a boot camp going on with about 14 new reps in it. They're going through pretty extensive training for a two-week period. And then we turn them loose. So, I think it's one of the reason that the back half is a little bit more heavily weighted, three to four percentage points more heavily weighted than what we saw in 2012. I think when you combine both the bookings issue and this new sales rep productivity, that's why we feel confident in the back half.
8 9 10	And these national agreements you know, we're working these national agreements both at the street level and at the corporate level. And I think we'll see some acceleration within Ascension, Dignity and CHI and others.
10	245. Defendants admitted for the first time during the call that the government had
11	"slowed its funding due to the debt ceiling and sequestration issues," which resulted in lower
12	than expected first quarter guidance, however, they continued to mislead the market about the
13	Company's current growth and growth potential, touting private hospital business and telling the
15	market that "our pipeline to the government remains very strong."
16	246. Despite Defendants' attempts to blunt the effects of this news, Vocera's stock
10	dropped from \$29.07 to \$26.37, or over 9%, on heavy volume.
18	247. The statements made during the fourth quarter earnings conference call were
19	materially false and misleading for the following reasons:
20	(a) Statements made in \P 237 and 239 by Zollars including "2012 was a solid
21	year" and a "very good year" were false and misleading for the reasons stated in ¶235;
22	(b) Statements made in \P 237, 239 and 240 by Zerella and Zollars concerning
23	growth, including "nice growth," "strong new customers," the "significant expansions which
24	continued strength we saw in Q3," "continued strength," "commitment to top line growth of
25	25%" were false and misleading for the reasons stated in $176(c)$;
26	(c) Statements made in ¶237 by Zollars concerning government customers,
27	including "our pipeline to the government remains very strong" were false and misleading for the
28	reasons stated in ¶217;
	Consolidated Class Action Complaint For Violations Of The Federal Securities Laws 88
	MASTER FILE NO. 3:13-CV-03567 EMC

1		(d) Statement made in ¶238 by Zerella concerning private hospital customers
2	including that	"our US healthcare business, excluding government, is very healthy and
3	performing we	ell" were false and misleading for the reasons stated in $176(d)$.
4	248.	Analysts were concerned about the effects of sequestration but were comforted
5	that the growt	h story was intact because Defendants provided 2013 guidance of 20-30% growth
6	once again.	
7	249.	On February 28, 2013, an analyst from William Blair stated in a report:
8		Management also gave a first look at 2013 sales and adjusted
9		EBITDA guidance, which bracketed the consensus outlook but indicates that sales will be more back-end loaded than anticipated,
10		as a result of delays in large government hospital purchases (as the pending sequestration cuts and broader deficit reduction talks have frazen government purchases). Of note these government hospital
11		frozen government purchases). Of note, these government hospital contracts should still hit in 2013, as the company is actively
12		engaged with the facilities—all of which still desire the Vocera solution, yet are waiting for budget clarity before making the
13		purchase orders.
14		The new national account contracts also reinforce the strength of the company's core U.S. hospital business and represent one of
15		several reasons the company's back-half-loaded guidance is achievable, in our view.
16	250.	On February 28, 2012 a Piper Jaffray analyst wrote:
17		Distracting Quarter But We Believe In the Growth Story
18		Vocera delivered a solid quarter, beat EPS, delivered in-line revenue growth of 24% reitorated 25% ton line growth guideneous
19		revenue growth of 24%, reiterated 25% top-line growth guidance, raised their profile gross margin and EBITDA targets, guided 2013
20		in-line, and signed four new national accounts worth \$150 million in potential new business. So what's the worry? Bookings growth decelerated due to decreased deal flow from government accounts
21		decelerated due to decreased deal flow from government accounts, Q1 guidance is weak, and a CEO succession plan is a surprise. We think the good outweighs the bad.
22	251.	
23	231.	On February 27, 2013, a J.P. Morgan analyst wrote:
24		4Q12 Solid, 2013 Looks Good
25		2013 guidance calls for 19-29% top-line growth. Management reiterated its confidence in the potentiality of the government
26		revenues and noted that the wide earnings guidance range (adj. EPS of $0.33-0.51$, -13% to $+34\%$ y/y) was largely driven by the timing around the recognition of these revenues
27		timing around the recognition of these revenues.
28		
	CONSOLIDATED (CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 89

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page95 of 141

1	Т.	March 12, 2013 – Form 10-K
2	252.	On March 12, 2013 Vocera filed its Form 10-K for the 2012 fiscal year ended
3	December 31,	2011, with the SEC. The Form 10-K was signed by Zollars and Zerella, and
4	contained mat	erially false and misleading statements about the current effect of health care
5	reform on Voo	cera's business and Vocera's prospects for growth:
6		Improving communication among the mobile and highly dispersed
7		healthcare professionals in hospitals is extremely important. Hospital communications are typically conducted through
8		disparate components, including overhead paging, pagers and mobile phones, often relying on written records of who is serving in specific roles during a particular shift. These legacy
9		communication methods are inefficient, often unreliable, noisy and do not provide "closed loop" communication (in which a caller
10		knows if a message has reached its intended recipient). These communication deficiencies can negatively impact patient safety,
11		delay patient care and result in operational inefficiencies. Additionally, <i>the increasing focus on improving patients</i> '
12		experience is supported by the healthcare reform initiative, which incorporates financial incentives for hospitals to improve the
13		quality of care and patient satisfaction. These forces are driving hospitals to invest in technology and process improvements to
14		manage their operations more efficiently and to improve staff and patient satisfaction.
15		Our communication platform helps hospitals increase productivity
16 17		and reduce costs by streamlining operations, and improves patient and staff satisfaction by creating a differentiated "Vocera hospital" experience.
18	253.	The Form 10-K also described Vocera's strategy for growth which, among other
19	thing, include	d:
20		• Expand our business to new U.S. healthcare customers. As of December 31, 2012, our solutions were deployed in
21		<i>approximately 10% of U.S. hospitals.</i> We believe our unified communication platform can provide significant value to both
22		large and small hospitals that currently do not deploy our solutions. We plan to continue to expand our direct sales force to win new
23		customers among hospitals of all sizes. We have structured and incentivized our sales organization to focus on sales to new
24		customer sites, particularly within large health systems.
25		• <i>Further penetrate our existing installed customer base.</i> Typically, our customers initially deploy our Voice
26		Communication solutions in a few departments of a hospital and gradually expand to additional departments as they come to fully
27		appreciate the value of our solutions. We recognize the significant opportunity to up-sell and cross-sell to our existing customers,
28		including into new hospitals that are part of healthcare system where our systems are deployed in one or more other hospitals.
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 90 0. 3:13-CV-03567 EMC 90

Key sales strategies include promoting a further adoption of our Voice Communication solution and demonstrating the value of our Secure Messaging and Care Transition solutions to our existing customers. We plan to continue expanding the number of account managers focused on our existing customers in order to grow our revenue and maintain and improve customer experience.

254. The 10-K also commented on growth:

1

2

3

4

5

19

21

23

Our growth in 2012 was primarily due to increased product sales of our Voice Communication solution, and, to a lesser extent, to 6 an increase in services sales. We had balanced growth in 7 product sales in 2012, with increases in sales to new customers and expanded deployments by existing customers, as well as sales 8 of replacement badges due, in part, to favorable reception of our new B3000 badges. We believe that we have the ability to 9 continue to grow in each of these areas in 2013. In addition, we are continuing to invest to accelerate the development of new 10 products for our healthcare and targeted non-healthcare markets. In the fourth quarter of 2012 and continuing into the first quarter of 11 2013, we expanded and, we believe, upgraded our sales organization with the addition of new sales personnel and 12 bifurcating sales roles between obtaining new customers and managing the installed customer base. In recent months, we also 13 entered into sales contracts with four national health systems. A potential challenge in 2013 are sales to US government 14 customers, which have experienced a slowdown and deferral of orders due to the ongoing effects of and uncertainty around 15 sequestration and debt ceiling issues. We believe that our business to US government customers will continue to be less 16 visible and predictable in 2013 as we experienced in the third and fourth quarters of 2012. 17 255. The 10-K also commented on the 27% increase, year over year, in sales: 18

Total revenue increased \$21.5 million, or 27.0%, from 2011 to 2012.

20 256. The statements in $\P253-255$, were materially false and misleading:

- (a) Statements made regarding the Company's growth and growth potential
- 22 were false and misleading for the reasons stated in $\P176(c)$;
 - (b) Statements made concerning the positive effect that the healthcare reform

24 initiative was having and would continue to have on Vocera's business were false and

- 25 misleading for the reasons stated in $\P176(d)$;
- 26 257. In addition, the 2011 Form 10-K failed to furnish information about the true,
- 27 negative impact that the ACA had and continued to have on Vocera's bookings and revenues,
- and the impact it would have on Vocera's future. ¶¶94-97, 103-128. This information was

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page97 of 141

required to be disclosed in the 2011 Form 10-K pursuant to Item 7 of the instructions to Form 1 2 10-K, which provides that companies disclose information called for under Item 303 of 3 Regulation S-K. 4 U. March 2013 – Statements to Analysts 5 258. On March 19, 2013, nearly three weeks after the first quarter closed, Piper Jaffray 6 published an analyst report entitled "Meetings with Management Strengthen our Resolve." In 7 the report, the Jaffray analyst stated that Vocera management was "more confident than ever" on 8 their growth outlook, particularly their 25% estimated growth for 2013: 9 We traveled with Vocera management and learned of some incremental datapoints to strengthen our resolve on VCRA. We 10 believe the market is pricing in a nonexistent deceleration of the business. Management is confident that the government deals will 11 come, momentum continues in the core U.S. healthcare business, and there are sufficient growth drivers in place to give us more 12 confidence in a 25% top-line growth rate in 2013 and beyond. Reiterate Overweight rating, \$34 Price Target. 13 Management more confident than ever on their 25% growth 14 outlook. Management said it has a >50% visibility on the midpoint of 2013 revenues, in line with historical forward 15 visibility. Management stated they are more confident in their 25% growth outlook now than they ever have been. 16 259. On this news from Vocera, the stock price increased over 3.5%. 17 260 Three days later, on March 22, 2013, William Blair published an analyst report 18 entitled "Solid Growth Outlook Despite Government-Related Headwinds; Highlights From 19 Management Meetings." The report described the information that Zerella provided to the 20 analyst, which comported with the information that Piper Jaffray had reported only three days 21 earlier. 22 We recently had the opportunity to travel with William Zerella, 23 CFO of Vocera. In our view, the timing of our trip was opportunistic, as it allowed us more time with management to 24 assess the company's fiscal 2013 outlook (following back-endloaded fiscal 2013 guidance, which has since caused uncertainty 25 among investors and placed selling pressure on the company's stock). 26 While we provide a more detailed analysis in the pages that follow, 27 our main conclusion is that—despite some government-related spending headwinds that are affecting the company's near-term 28 federal business—the long-term growth outlook, unique CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 92 MASTER FILE NO. 3:13-CV-03567 EMC

		npetitive position, and strong industry drivers are all very uch intact.
	Sti	ll, we believe management's full year forecast of \$120 million
		\$130 million in sales appears reasonable (based on a number specific growth initiatives, which should manifest in strong
	sal	es going forward) and remain comfortable with the Street's I-year target of \$122.8 million.
		ain Investor Focus: The 2013 Growth Outlook
		thout a doubt, the main focus of investors is related to
	ma	nagement's fiscal 2013 sales outlook. As discussed above,
	Str	nagement's initial sales guidance was generally in line with eet expectations at the midpoint of guidance (\$125 million);
	\$2:	wever, based on first-quarter guidance (of only \$23 million to 5 million, or roughly 4% year-over-year growth at the
		dpoint), the organization needs a strong back half of the year to intain its 25% growth trajectory (its long-term objective).
	Мо	preover, investors seem particularly concerned about the second-
		arter growth outlook, which—because of weaker first-quarter es expectations—now requires the company to have a very
	ma	terial uptick in sequential sales to meet the current consensus get (e.g., it would require the largest percentage [and absolute
		llar] sequential growth increase in at least five years).
	La	stly, the company acknowledged that the government business nains unpredictable, but believes that recent sequestration cuts
	<i>co</i> 1	uld be a good thing, as government clients at least can move ward with more-certain budgets. Management also noted that
	the	e government pipeline remains very strong (with clinical
	sol	pport high) and reminded investors that its communication ution is the only approved technology of its kind for the
	Dej (cr	partment of Defense and Veterans Affairs (VA) hospitals eating a large market opportunity).
	261. Th	e statements attributable to Zerella in ¶260 were materially false and
r	nisleading for the	e following reasons:
	(a)	Statements made regarding the Company's growth and growth poten
i	ncluding that the	Company's growth story was "intact," bolstered by 2013 full year guidan
۲	were false and mi	sleading for the reasons stated in ¶¶165 and 176(c);
	(b)	Statements that the government pipeline remains very strong and that
5	sequestrations "co	ould be a good thing" were false and misleading because the BCA was
		e negative effects on government bookings, revenues, and growth. See ¶21
(0	

	Case3:13-cv	v-03567-EMC Document104 Filed09/19/14 Page99 of 141
1	V.	FINAL CORRECTIVE DISCLOSURE – May 2, 2013 - Form 8-K and Earnings Conference Call
2	262.	On May 2, 2013, after the market closed, Vocera filed a Form 8-K with the SEC
3		press release entitled "Vocera Reports First Quarter 2013 Results." Zerella signed
4		For the first quarter, Vocera reported:
5		Revenue for the quarter was \$22.4 million, a decrease of 3.1%
6		compared to \$23.1 million in the first quarter of 2012. For the first quarter of 2013, GAAP net loss was \$3.5 million, or \$(0.14) per
7		diluted share, compared to a net loss of \$0.8 million, or \$(0.23) per diluted share, in the first quarter of 2012. Non- GAAP net loss
8		was \$1.6 million for the first quarter of 2013, or \$(0.07) per diluted share, which compares to non-GAAP net income of \$1.4 million or
9		\$0.06 per diluted share, for the first quarter of 2012. A reconciliation of GAAP to non-GAAP financial measures is
10		provided in the schedules included below.
11		***
12		• Product revenue decreased 11.5% compared to the first quarter of 2012 and was directly impacted by U.S. healthcare expansion
13		contracts that were delayed. Product revenue in the first quarter of 2013 was comprised of \$3.0 million from software sales and \$10.0
14		million of device sales.
15		GAAP product gross margin of 64.4% in the quarter increased 150 basis points compared to the year ago period. Non-GAAP product
16		gross margin of 65.6% in the quarter increased 200 basis points compared to the year ago period.
17		• Service revenue increased 11.4% compared to the first quarter of
18		2012 and was driven by maintaining and supporting existing customers. Service revenue in the first quarter of 2013 was
19 20		comprised of \$7.3 million of software maintenance and \$2.1 million of professional services. GAAP services gross margin of 56.8% in the quarter decreased 110 basis points compared to the
21		year ago period. Non-GAAP services gross margin of 58.5% in the quarter increased 40 basis points compared to the year ago
22		period.
23	263.	The Company also lowered revenue guidance for 2013 and provided
24	disappointing	guidance for 2Q13, finally admitting that the growth the Company had been
25	touting all alor	ng was simply not sustainable:
26		2013 Guidance
27		For the full year 2013, we are lowering revenue guidance to between \$100 million and \$110 million. We expect a GAAP
28		earnings per share between a loss of \$(0.47) and \$(0.22), non- GAAP earnings per share between a loss of \$(0.05) and a profit of \$0.18, and non-GAAP Adjusted EBITDA between \$1.2 million
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 94 0. 3:13-cv-03567 EMC

	Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page100 of 141
1 2	and \$7.9 million. Our full year 2013 non-GAAP guidance excludes estimated stock compensation expense of \$9.5 million to \$10.0 million and estimated amortization of intangibles of
3	approximately \$0.7 million. Non-GAAP earnings per share guidance is based on a fully diluted share count for the full year 2013 of 25.0 million shares in the event of a loss and 27.3 million
4	shares in the event of a profit and expected income tax of \$0.3 million to \$0.6 million.
5	For the second quarter of 2013, Vocera expects revenues between \$23 million and \$25 million, a GAAP loss per share between
6 7	\$(0.17) and \$(0.12), non- GAAP earnings between a loss of \$(1.6) million and \$(0.4) million, non-GAAP earnings per share between
8	a loss of (0.06) and (0.02) , and non-GAAP Adjusted EBITDA between a loss of (1.0) million and a gain of 0.3 million. Our
9	second quarter 2013 non-GAAP guidance excludes stock compensation expense of approximately \$2.4 million and
10	amortization of intangibles of \$0.2 million. Non-GAAP earnings per share guidance is based on a fully diluted share count of 24.8 million shares, for the second guarter 2013. Income tax for the
11	million shares, for the second quarter 2013. Income tax for the second quarter of 2013 is expected to be \$100,000 to \$200,000.
12	264. Zollars commented on the disappointing results and guidance, revealing for the
13	first time that health care reform was having a serious effect on the Company's business:
14 15	We were disappointed with this quarter's results. Although the first quarter saw a very nice increase in new customer signings,
15	several significant expansion deals for U.S. hospitals that we expected to sign in the quarter were not completed. We believe this shortfall was driven by two factors: (1) increased financial
17	scrutiny from our hospital customers as a result of <u>lower</u> <u>utilization and reduced reimbursement rates under reform</u> ,
18	and (2) inconsistent sales execution across market segments. To address our sales execution issue, we are creating three new
19	leadership positions: EVP – Worldwide Sales and Service, VP-US Healthcare Sales, and VP-International Sales. Based on these
20	results and market dynamics, we're reducing our full year 2013 outlook.
21	265. The Company hosted an earnings conference call after the market closed on May
22	2, 2013 to discuss first quarter results. Zollars, Zerella and Lang participated on the call. In
23	Zollars' prepared remarks, he explained the reasons for the disappointing first quarter, and the
24 25	lowered guidance for the full year and second quarter:
25 26	Well, let me start by saying that we're disappointed with our first quarter results. We generated revenue of \$22.4 million, an adjusted EBITDA loss of \$1.2 million and a non-GAAP EPS loss
20	of \$0.07. Recent macro developments in the health care industry had a more profound effect on our existing customer base than we
28	anticipated. And as a result of that and some inconsistent sales execution, we didn't close a number of expansions during the
	quarter that we expected. Consolidated Class Action Complaint For Violations Of The Federal Securities Laws 95 Master File No. 3:13-cv-03567 EMC 95

	Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page101 of 141
1 2	While our field sales teams are quite optimistic, they've noticed that increased pressure on hospital budgets is delaying some of our larger expansion deals and increasing scrutiny on any spending in
2	these facilities.
4	We believe uncertainties surrounding the effect of sequestration and the health care reform act is affecting both
5	our government and now our commercial business. The impact this is having on our business seems to be enlongating the sales cycle.
6	In the first quarter, none of the new government purchase orders
7	we had been waiting for were received. And while we continue to be disappointed with the pace of getting these new government
8 9	facility contracts finalized, we believe these delayed deals are still included in the new federal budget. We did receive bookings for two government expansions, one in a VA hospital and another in a
10	DOD hospital. And as a result, we remain optimistic that we can close these deals this year, although the timing still remains
11	uncertain.
12	In the non-government health care segment, we saw several large expansions we had expected would close in Q1 not get
13	consummated . We thought it might be helpful to provide a little more color on what we're hearing as well as a description of a handful of these deals in order to better provide transparency on
14	what drove the revenue miss.
15	Virtually every health system we speak to has put in place large expense reduction initiatives as a result of reform. Just
16 17	this week, we heard expense reduction targets at two of our existing customers. One needs to cut \$200 million and the other \$120 million of expension
17	\$120 million of operating expense. Every quarter, we have a number of significant expansion deals in
19	the pipeline. And it's normal that we complete some in the quarter and the rest fall into future quarters. This past quarter however
20	was very rare in that sizeable expansion deals we were looking to close in the last ten days of the quarter were delayed. Because
21	these deals were expansions at existing customers, our expectation had that these would be book ship deals that could immediately
22	turn into revenue. And when they didn't materialize, our revenue fell off track.
23	Digging further into these delays, we believe we were impacted by both the macro issues I mentioned as well as a number of deal-
24	specific events that caused their delay. For example, one deal increased meaningfully in size during the contracting phase as the
25	health system wanted to expand the deployment to two additional hospitals in their system. That caused additional approval to be
26 27	bumped up to the next level of management and ultimately delayed closing.
27 28	Another deal was approved by the hospital capital committee only to later get caught in a temporary across the board spending freeze
20	by the hospital CEO as a result of reduced Medicare Consolidated Class Action Complaint For Violations Of The Federal Securities Laws
	MASTER FILE NO. 3:13-CV-03567 EMC

	Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page102 of 141
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 reimbursement. We underestimated the approval process in another. I want to point out that we're confident that none of these deals mentioned above can be attributed to competitive losses. We're frustrated by these booking delays and we recognize that we have to improve our forecasting ability and sales execution, which had inconsistent quarter performance by territory and geography. Zerella's prepared comments included the following: Finally, I would like to review the update to our outlook. In light of the factors discussed today that impacted our business in the first quarter, we are adopting new guidance ranges that reflect a more cautious stance on both revenues and earnings. As Bob described, we are seeing pressure on hospital budgets weighing on our ability to close deals. This is combined with the lack of visibility on the timing of closing government business. According[ly], our second quarter guidance reflects flat to down revenue and lower carnings year-over-year. *** For the full year of 2013, we now expect revenues between \$100 and \$110 million, non-GAAP earings per share between a loss of \$0.05 and a profit of \$0.8, and non-GAAP earings per share between a loss of \$0.05 and a profit of \$3.9, million. Our full year 2013 non-GAAP guidance excludes stock compensation expense of \$9.0, 510 million and a mortiziton of intangibles of approximately \$0.7 million. We expect income taxes of approximately \$0.7 million. We expect revenues between \$23 and \$25 million, non-GAAP Exp between a loss of \$1.6 million and \$400,000, non-GAAP Exp between a loss of \$1.0 million and a gain of \$30.000. We expect income taxes in the second quarter 2013, we expect revenues between \$23 and \$25 million and again of \$30.000. We expect income taxes in the second quarter to be \$100,000 to \$200,000. The market finally learned the full truth: both the BCA and ACA were negatively affecting both government and commercial business,
25	sustainable. The Company also admitted that its visibility into future revenue was compromised.
26	268. In reaction to these latest revelations, Vocera's stock price fell over 37% or \$7.23
20 27	per share, to close at \$12.15 per share on May 3, 2013 on extremely heavy volume.
27	
20	Consolidated Class Action Complaint For Violations Of The Federal Securities Laws 97 Master File No. 3:13-cv-03567 EMC 97

1	269.	Analysts were shocked by the huge reduction and guidance and the revelation that	
2	Vocera's growth story was in shambles and that visibility into future revenues was not as		
3	predictable as the market had learned to expect. For example, on May 2, 2013 a William Blair		
4	analyst commented:		
5		Still, given the weak start to the year, management also made two significant announcements. First, it reduced its 2013 sales	
6	Į	guidance markedly—from a range of \$120 million to \$130 million to a new range of \$100 million to \$110 million (flat to up roughly	
7		10% from the prior year).	
8	v	While we expected first quarter growth to be somewhat weak (and were worried about the revenue ramp up anticipated in 2013), the	
9	i	magnitude of the shortfall (especially after providing guidance in late February) clearly surprised us. Moreover, we are	
10	· · · · · · · · · · · · · · · · · · ·	surprised to hear that "increased investment scrutiny" is hitting Vocera so acutely because the company has never seen this	
11 12		phenomenon before and it offers a fairly low cost, high value solution.	
12		Lastly, we also thought visibility was better for Vocera (e.g., sizable recurring revenue stream, predictable customer	
13	1	reorders [until this quarter]), but after two straight quarters of disappointing results (and the large guidance reset) we clearly	
15		coverestimated the predictability in the business; clearly this will cause a reset in the valuation multiple that investors afford the company.	
16		On May 3, 2013, an analyst from Leerink Swann published a report, commenting	
17	that he had met	with management throughout the quarter and that there was no indication that the	
18	reduction in gui	idance would be so drastic:	
19 20]	Lack of Visibility Highly Concerning - Downgrade to MP	
20 21		Bottom Line: We are downgrading shares of VCRA to Market Perform on a significant deceleration in the company's 2013E	
21	1	growth rate and a lack of management visibility into sales. Earnings and revenue in 1Q:13 were well below our expectations	
23	8	and consensus, 2Q guidance is also well below expectations, and nanagement reduced its 2013 outlook dramatically. 2013 revenue	
24	i	s expected to grow +0-10% y/y (vs. +20-30% y/y previously) and 2013E adjusted EPS are now expected to be in the range of (\$0.05)	
25	t	to \$0.18, (vs. \$0.33-\$0.51 previously). One of our biggest concerns about this business model has been the lack of clarity	
26	ł	around recurring revenue. While \sim 70% of clients may "plan to buy more" products from VCRA, we estimate that the true	
27	I	'recurring revenue'' portion of the business is ~30% or less. As a result, product revenue can be very lumpy, and visibility can be	
28	low. We spoke and met with management several times throughout 1Q, and there was no indication there would be		
		ASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 98	

MASTER FILE NO. 3:13-CV-03567 EMC

	Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page104 of 141			
1 2 3 4 5 6 7	 such a drastic reduction in 2013 guidance. We are not buyers of the stock. On the call management highlighted that sequestration is putting significant pressure on hospital budgets and there have been "freezes" placed on some prospective clients' budgets which have caused delays in purchases. Furthermore, revenue generated from "inselling" this quarter was below expectations, possibly due to the new sales structure that was put in place earlier this year. While all of these factors likely play a significant role in the slow-down, we are concerned by: (1) management's lack of visibility into revenue and earnings and (2) hospital budgets have always been under pressure and we are not entirely convinced that this business decline can be blamed entirely on sequestration. 			
8 9	V. LOSS CAUSATION			
9 10	271. During the Class Period, as detailed herein, Defendants engaged in a scheme to			
11	deceive the market and a course of conduct that artificially inflated the price of Vocera securities			
12	and operated as a fraud or deceit on Class Period purchasers of Vocera securities by failing to			
12	disclose and misrepresenting the adverse facts detailed herein. As Defendants' prior			
13	misrepresentations and fraudulent conduct were disclosed and became apparent to the market,			
15	the price of Vocera securities declined significantly as the prior artificial inflation was removed			
16	from the Company's stock price.			
17	272. As a result of their purchases of Vocera securities during the Class Period,			
18	Plaintiffs and the other Class members suffered economic loss, i.e., damages, under the federal			
19	securities laws. Defendants' false and misleading statements had the intended effect and caused			
20	Vocera securities to trade at artificially inflated levels throughout the Class Period, with Vocera's			
21	common stock reaching as high as \$32.97 per share on September 25, 2012.			
22	273. By concealing from investors the adverse facts detailed herein, Defendants			
23	presented a misleading picture of Vocera's business and prospects. As the truth about the			
24	Company was revealed to the market and/or as the risks concealed by Defendants materialized,			
25	the price of Vocera securities fell significantly. These declines removed the inflation from the			
26	price of Vocera securities, causing real economic loss to investors who had purchased Vocera			
27	securities during the Class Period.			
28				
~				

1	274. The decline in the price of Vocera securities after the corrective disclosures came		
2	to light were a direct result of the nature and extent of Defendants' fraudulent misrepresentations		
3	and omissions being revealed to investors and the market. The timing and magnitude of the		
4	price declines in Vocera securities negate any inference that the loss suffered by Plaintiffs and		
5	the other Class members was caused by changed market conditions, macroeconomic or industry		
6	factors or Company-specific facts unrelated to Defendants' fraudulent conduct.		
7	275. During the Class Period, the price of Vocera stock declined as the true state of		
8	Vocera's operations was revealed to the investing public.		
9	276. The economic loss, i.e., damages, suffered by Plaintiffs and the other Class		
10	members, was a direct result of Defendants' fraudulent scheme to artificially inflate the price of		
11	Vocera securities and the subsequent significant decline in the value of Vocera securities when		
12	Defendants' prior misrepresentations and other fraudulent conduct were revealed.		
13	VI. APPLICABILITY OF PRESUMPTION OF RELIANCE: FRAUD ON THE MARKET DOCTRINE		
14	277. Plaintiffs are entitled to a presumption of reliance under <i>Affiliated Ute Citizens of</i>		
15	<i>Utah v. United States</i> , 406 U.S. 128 (1972), because the claims asserted herein against		
16	Defendants are predicated upon omissions of material fact which there was a duty to disclose.		
17	278. In the alternative, Plaintiffs are entitled to a presumption of reliance on		
18	Defendants' material misrepresentations and omissions pursuant to the fraud-on-the-market		
19	theory:		
20	(a) Vocera's common stock was actively traded on the NYSE, an		
21	informationally efficient market, throughout the Class Period.		
22	(b) Vocera's common stock traded at high weekly volumes during the Class		
23	Period.		
24	(c) As a regulated issuer, Vocera filed periodic public reports with the SEC.		
25	(d) Vocera regularly communicated with public investors by means of		
26	established market communication mechanisms, including through regular dissemination of		
27	press releases on the major news wire services and through other wide-ranging public		
28			
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 100 MASTER FILE NO. 3:13-CV-03567 EMC		

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page106 of 141

disclosures, such as communications with the financial press, securities analysts and other
 similar reporting services.

3 (e) The market reacted promptly to public information disseminated by
4 Vocera.

(f) Vocera securities were covered by numerous securities analysts employed
by major brokerage firms who wrote reports that were distributed to the sales force and certain
customers of their respective firms. Each of these reports was publicly available and entered the
public marketplace.

9 (g) The material misrepresentations and omissions alleged herein would tend
10 to induce a reasonable investor to misjudge the value of Vocera's securities.

(h) Without knowledge of the misrepresented or omitted material facts alleged
herein, Plaintiffs and other members of the Class purchased shares of Vocera's securities
between the time Defendants misrepresented or failed to disclose material facts and the time the

14 true facts were disclosed.

15 VII. NO SAFE HARBOR

16 The statutory safe harbor provided for forward-looking statements under certain 279. 17 circumstances does not apply to any of the materially false and misleading statements alleged in 18 this Complaint. First, many of the statements alleged herein to be false and misleading relate to 19 historical facts or existing conditions. Second, to the extent any of the false statements alleged 20 herein may be characterized as forward-looking, they were not adequately identified as 21 "forward-looking" statements when made. Third, any purported "forward looking statements" 22 were not accompanied by meaningful cautionary language because risks that Defendants warned 23 of had already come to pass. Fourth, to the extent that there were any forward-looking 24 statements that were identified as such, Defendants are liable because, at the time each of those 25 forward-looking statements was made, the speaker knew the statement was false when made. 26

- 27
- 28

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page107 of 141

A.	Many of Defendants' False and Misleading Statements Were Not Forward- Looking	
280.	For example, the alleged false and misleading statements below (1) relate to	
historical or current fact; (2) implicate existing conditions; and (3) do not contain projections of		
future performance or future objectives:		
	(a) Statements concerning financial results , i.e., ¶163;	
	(b) Statements concerning visibility, i.e., ¶¶170, 191, 214, 230, 232;	
	(c) Statements made concerning the then-current effect of the ACA and/or	
sequestration, i.e., ¶¶150, 159, 173-175, 185, 192, 201, 214, 227, 229, 237-238, 252;		
281.	To the extent any of these statements might be construed to touch on future intent,	
they are mixed statements of present facts and future intent and not entitled to safe harbor		
protection with respect to the part of the statement that refers to the present.		
В.	Several False and Misleading Statements are Not Properly Identified as "Forward-Looking"	
282.	The PSLRA imposes an additional burden on "oral" forward looking statements,	
requiring defendants to include a cautionary statement that the particular oral statement is a		
forward-looking statement, and that "actual results might differ materially from those projected		
in the forward-looking statement." 15 U.S.C. § 78u-5(c)(1)(A)(i)-(ii). The following oral		
statements ma	ade by Defendants were not appropriately identified as forward-looking pursuant to	
the Reform Act requirements and are therefore not protected by the safe harbor:		
	(a) Zollars' statements made to "The Street" on March 28, 2012, the date of	
IPO. ¶159.		
	(b) Lang's statements made to a J.P. Morgan analyst, which were published in	
a July 11, 201	2 J.P. Morgan analyst report. ¶¶184-186;	
	(c) Zollars' and Zerella's statements made to a Piper Jaffray analyst, which	
were published in a November 28, 2012 Piper Jaffray analyst report. ¶225;		
	(d) Zollars' and Zerella's statements made to a J.P. Morgan analyst, which	
were published in a November 30, 2012 J.P. Morgan analyst report. ¶227;		
	CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 102 D. 3:13-CV-03567 EMC	

(e) Zollars' and Zerella's statements made on January 7, 2013 at the J.P. 1 2 Morgan Healthcare Conference. ¶229-232; 3 (f) Zerella's statements made to a William Blair analyst, which were 4 published in a March 22, 2013 William Blair report. ¶260. 5 С. Defendants' False and Misleading Statements Were Not Accompanied by **Meaningful Cautionary Language** 6 283 None of Defendants' statements were accompanied by meaningful cautionary 7 language that identified important factors that could cause actual results to differ materially from 8 any results projected. 9 284. To the extent Defendants included any cautionary language, that language was not 10 meaningful because any potential risks identified by Defendants had already manifested. As 11 detailed herein, at the time Defendants were touting strong results, "top line growth of 25%" and 12 demand for Vocera's products, Defendants knew that the ACA was already negatively impacting 13 the business causing the Company to Thus, vague 14 warnings regarding, for example, how: health care reform "*could*" adversely affect Vocera's 15 business, were insufficient because they failed to warn that the risks had already occurred when 16 Defendants made their false and misleading statements.

17

D. Defendants Knew that the Risks they Warned of Had Already Come to Pass

18 285. To the extent there were any forward-looking statements that were identified as 19 such at the time made, Defendants are liable for those statements because at the time each 20 statement was made, the particular speaker knew that the particular forward-looking statement 21 was false, or, by reason of what the speaker failed to note, was materially false and/or 22 misleading, and/or that each such statement was authorized and/or approved by a director and/or 23 executive officer of Vocera who actually knew that each such statement was false and/or 24 misleading when made. 25

26 27

FIRST CLAIM FOR RELIEF Violation of § 10(b) of the Exchange Act and Rule 10b-5 Promulgated Thereunder Against All Defendants

286. Plaintiffs repeat and reallege each and every allegation set forth above in ¶¶25 to
285 as if fully set forth herein, as well as those allegations set forth in Section XII, ¶¶408 to 414
set forth below.

6

7

8

287. This Count is asserted pursuant to Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder by the SEC against all Defendants in "Part I: The Fraud Claims Under the Exchange Act."

9 288. As alleged herein, throughout the Class Period, Defendants, individually and in 10 concert, directly and indirectly, by the use of the means or instrumentalities of interstate 11 commerce, the mails and/or the facilities of national securities exchanges, made untrue 12 statements of material fact and/or omitted to state material facts necessary to make their 13 statements not misleading and carried out a plan, scheme and course of conduct, in violation of 14 Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder. Defendants 15 intended to and did, as alleged herein, (i) deceive the investing public, including Plaintiffs and 16 members of the Class; (ii) artificially inflate and maintain the prices of Vocera securities; and 17 (iii) cause Plaintiffs and members of the Class to purchase Vocera securities at artificially 18 inflated prices.

19 289. The Individual Defendants were individually and collectively responsible for
20 making the false and misleading statements and omissions alleged herein and having engaged in
21 a plan, scheme and course of conduct designed to deceive Plaintiffs and members of the Class,
22 by virtue of having made public statements and prepared, approved, signed and/or disseminated
23 documents that contained untrue statements of material fact and/or omitted facts necessary to
24 make the statements therein not misleading.

25 290. As set forth above, Defendants made their false and misleading statements and
26 omissions and engaged in the fraudulent activity described herein knowingly and intentionally,
27 or in such a deliberately reckless manner as to constitute willful deceit and fraud upon Plaintiffs
28 and the other members of the Class who purchased Vocera Securities during the Class Period.

1				
1	291. In ignorance of the false and misleading nature of Defendants' statements and			
2	omissions, and relying directly or indirectly on those statements or upon the integrity of the			
3	market price for Vocera securities, Plaintiffs and other members of the Class purchased Vocera			
4	securities at artificially inflated prices during the Class Period. But for the fraud, Plaintiffs and			
5	members of the Class would not have purchased Vocera securities at such artificially inflated			
6	prices. As set forth herein, when the true facts were subsequently disclosed, the price of Vocera			
7	securities declined precipitously and Plaintiffs and members of the Class were harmed and			
8	damaged as a direct and proximate result of their purchases of Vocera securities at artificially			
9	inflated prices and the subsequent decline in the price of that stock when the truth was disclosed.			
10	292. By virtue of the foregoing, Defendants are liable to Plaintiffs and members of the			
11	Class for violations of Section 10(b) of the Exchange Act and Rule 10b-5 promulgated			
12	thereunder.			
13	SECOND CLAIM FOR RELIEF			
14	Violation of § 20(a) of the Exchange Act Against the Individual Defendants			
15	293. Plaintiffs repeat and reallege each of the allegations set forth above in \P 25 to 292			
16	as if fully set forth herein, as well as those allegations set forth in Section XII, ¶¶408 to 414 set			
17	forth below.			
18	294. This Count is asserted pursuant to Section 20(a) of the Exchange Act against each			
19	of the Individual Defendants in "Part I: The Fraud Claims Under the Exchange Act."			
20	295. As alleged above, Vocera violated Section 10(b) of the Exchange Act and Rule			
21	10b-5 promulgated thereunder by making false and misleading statements in connection with the			
22	purchase and sale of Vocera's securities and by participating in a fraudulent scheme and course			
23	of business or conduct throughout the Class Period. This fraudulent conduct was undertaken			
24	with scienter and the Company is charged with the knowledge and scienter of each of the			
25	Individual Defendants who knew of or acted with deliberate and/or reckless disregard of the			
26	falsity of the Company's statements and the fraudulent nature of its scheme during the Class			
27	Period.			
28				

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page111 of 141

296. As set forth above, the Individual Defendants were controlling persons of Vocera
 during the Class Period, due to their senior executive positions with the Company and their direct
 involvement in the Company's day-to-day operations, including direct involvement with
 Vocera's revenue, bookings, and backlog.

5 297. By virtue of the foregoing, the Individual Defendants each had the power to
6 influence and control, and did influence and control, directly or indirectly, the decision-making
7 of Vocera, including the content of its public statements with respect to its financial condition
8 and the effect of legislation on its hospital customers.

9 298. These Individual Defendants acted knowingly and intentionally, or in such a
10 deliberately reckless manner as to constitute willful fraud and deceit upon Plaintiffs and the other
11 members of the Class who purchased Vocera securities during the Class Period.

12 299. In ignorance of the false and misleading nature of the Company's statements and 13 omissions, and relying directly or indirectly on those statements or upon the integrity of the 14 market prices for Vocera securities, Plaintiffs and other members of the Class purchased Vocera 15 securities at an artificially inflated price during the Class Period. But for the fraud, Plaintiffs and 16 members of the Class would not have purchased Vocera securities at artificially inflated prices. 17 As set forth herein, when the true facts were subsequently disclosed, the price of Vocera 18 securities declined precipitously and Plaintiffs and members of the Class were harmed and 19 damaged as a direct and proximate result of their purchases of Vocera securities at artificially 20 inflated prices and the subsequent decline in the price of that stock when the truth began to be 21 disclosed.

300. By reason of the foregoing, the Individual Defendants are liable to Plaintiffs and
the members of the Class as controlling persons of Vocera in violation of Section 20(a) of the
Exchange Act.

- 25
- 26

PART TWO: THE STRICT LIABILITY AND NEGLIGENCE CLAIMS UNDER THE SECURITIES ACT

301. In this part of the Complaint, The Securities Act Plaintiff asserts strict liability
and negligence claims based on violations of §§ 11, 12(a)(2) and/or 15 of the Securities Act, 15

U.S.C. §§ 77k, 77l and 77(o), on behalf of the Class (as defined herein). These claims are 1 2 asserted based on allegedly untrue statements and omissions made in the IPO Offering Materials 3 (defined herein) and in the Secondary Offering Materials (defined herein) in connection with the 4 IPO and Secondary Offering, respectively. The Securities Act Plaintiff expressly disclaims any 5 allegations of fraud, scienter, or recklessness for their Securities Act Claims because these claims 6 are not based on any allegations of knowing or reckless misconduct on behalf of the Defendants, 7 nor do they allege, or sound, in fraud. Any challenged statements of opinion or belief made in 8 connection with the IPO and Secondary Offering alleged in this part of the Complaint are alleged 9 to have been materially misleading statements of opinion or belief when made and at the time of 10 the Offerings.

302. This action was brought within one year after the discovery of the untrue
statements and omissions (and within one year after such discovery should have been made in
the exercise of reasonable diligence) and within three years after each of the two offerings
described herein.

303. The Securities Act claims set forth in this section of the Complaint concern two
separate offerings of securities registered by Vocera with the SEC during the Class Period.

17 304. The Securities Act Plaintiff asserts Section 11, 12(a)(2) and Section 15 claims 18 against the defendants specified below, on behalf of (1) all persons and entities, other than the 19 defendants and certain related persons and entities, who purchased or acquired shares of Vocera's 20 common stock pursuant or traceable to the IPO Offering Materials in connection with Vocera's 21 IPO and/or (2) all persons and entities, other than the defendants and certain related persons and 22 entities, who purchased or acquired shares of Vocera's common stock pursuant or traceable to the 23 Secondary Offering Materials in connection with Vocera's Secondary Offering, and suffered 24 damages thereby.

25

VIII. JURISDICTION AND VENUE

305. The claims asserted herein arise under and pursuant to §§ 11, 12 and 15 of the
Securities Act, 15 U.S.C. §§ 77k, 77l, and 77o.

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page113 of 141

1	306. This Court has jurisdiction over the subject matter of this action pursuant to § 22				
2	of the Securities Act, 15 U.S.C. § 77v.				
3	307. Venue is proper in this District pursuant to § 22 of the Securities Act, 15 U.S.C. §				
4	77v; Vocera is headquartered in this District.				
5	308. Many of the acts and omissions giving rise to the violations of law complained of				
6	herein, including the preparation and dissemination to the investing public of the materially				
7	untrue and misleading Offering Materials and Secondary Offering Materials, took place in this				
8	District.				
9	309. In connection with the allegations herein, the Securities Act Defendants (defined				
10	herein), directly or indirectly, used the means and instrumentalities of interstate commerce,				
11	including, but not limited to, the mails, interstate telephone communications and the facilities of				
12	the national securities markets.				
13	IX. PARTIES RELATING TO THE SECURITIES ACT CLAIMS				
14	A. The Securities Act Plaintiff ¹⁵				
15	310. Arkansas Teacher Retirement System ("ATRS" or "Plaintiff" in Part Two) is a				
16	public pension fund organized in 1937 for the benefit of the current and retired public school				
17	teachers of the State of Arkansas. ATRS is headquartered in Little Rock, Arkansas and has over				
18	\$14 billion dollars in assets under management. As set forth in Docket No. 42-1, ATRS				
19	purchased shares of common stock of Vocera pursuant or traceable to the IPO, and suffered				
20	damages as a result of the violations of the federal securities laws. ATRS also purchased Vocera				
21	common stock pursuant to the IPO Offering Materials from J.P. Morgan and was damaged				
22	thereby.				
23	B. The Securities Act Defendants				
24	311. Vocera is a Delaware corporation with its principal executive offices located at				
25	525 Race Street, San Jose, California 95126. Vocera describes itself as a provider of mobile				
26	$\frac{15}{15}$ At this time, the board of an institutional investor that nurshood shares of Vecera in the				
27	Secondary Offering is considering whether to join the action as an additional plaintiff and proposed class representation. No decision has been made at this time. If the board elects to				
28	proceed, a motion to add it as an additionally named plaintiff will be promptly filed.				
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS108MASTER FILE NO. 3:13-CV-03567 EMC108				

communication solutions focused on addressing critical communications challenges facing
 hospitals.

	1
3	1. The Officer Defendants
4	312. Robert J. Zollars ("Zollars") was Chairman of the Board and Chief Executive
5	Officer ("CEO") of the Company at the time of the IPO and Secondary Offering. Zollars signed
6	the registration statements in connection with the IPO and Secondary Offering.
7	313. Brent D. Lang ("Lang") was the President and Chief Operating Officer of the
8	Company at the time of the IPO and Secondary Offering.
9	314. William R. Zerella ("Zerella") was the Chief Financial Officer ("CFO") of the
10	Company at the time of the IPO and Secondary Offering. Zerella signed the registration
11	statements in connection with the IPO and Secondary Offering.
12	315. Zollars, Lang and Zerella are collectively referred to in Part Two as the "Officer
13	Defendants."
14	2. The Director Defendants
15	316. Defendant Brian D. Ascher ("Ascher") is a director of Vocera and has served in
16	that capacity since 2002. Defendant Ascher signed the registration statements in connection with
17	the IPO and Secondary Offering.
18	317. Defendant John B. Grotting ("Grotting") is a director of Vocera and has served in
19	that capacity since 2010. Defendant Grotting signed the registration statements in connection
20	with the IPO and Secondary Offering.
21	318. Defendant Jeffrey H. Hillebrand ("Hillebrand") is a director of Vocera and has
22	served in that capacity since 2010. Defendant Hillebrand signed the registration statements in
23	connection with the IPO and Secondary Offering.
24	319. Defendant Howard E. Janzen ("Janzen") is a director of Vocera and has served in
25	that capacity since 2007. Defendant Janzen signed the registration statements in connection with
26	the IPO and Secondary Offering.
27	
28	
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 109
	MASTER FILE NO. 3:13-CV-03567 EMC

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page115 of 141

1	320. Defendant John N. McMullen ("McMullen") is a director of Vocera and has				
2	served in that capacity since 2011. Defendant McMullen signed the registration statements in				
3	connection with the IPO and Secondary Offering.				
4	321. Defendant Hany M. Nada ("Nada") is a director of Vocera and has served in that				
5	capacity since 2003. Defendant Nada signed the registration statements in connection with the				
6	IPO and Secondary Offering.				
7	322. Defendant Donald F. Wood ("Wood") was a director of Vocera, having served in				
8	that capacity through May 2012. Defendant Wood signed the registration statement in				
9	connection with the IPO.				
10	323. The Defendants listed in paragraphs 316 to 322 are collectively referred to as the				
11	"Director Defendants":				
12	3. The Underwriter Defendants				
13	324. Defendant J.P. Morgan Securities LLC ("J.P. Morgan") was an underwriter of the				
14	Company's IPO and Secondary Offering and served as a financial advisor and assistant in the				
15	preparation and dissemination of Vocera's false and misleading registration statements for both				
16	offerings. J.P. Morgan along with Piper Jaffray & Co. ("Piper Jaffray") acted as the lead book				
17	runners for the IPO and the Secondary Offering.				
18	325. Defendant Piper Jaffray was an underwriter of the Company's IPO and Secondary				
19	Offering and served as a financial advisor and assistant in the preparation and dissemination of				
20	Vocera's false and misleading registration statements for both offerings. Piper Jaffray along				
21	with J. P Morgan acted as the lead book runners for the IPO and the Secondary Offering.				
22	326. Defendant Robert W. Baird & Co., Inc. was an underwriter of the Company's IPO				
23	and Secondary Offering and served as a financial advisor and assistant in the preparation and				
24	dissemination of Vocera's false and misleading registration statements for both offerings.				
25	327. Defendant William Blair & Company, L.L.C. was an underwriter of the				
26	Company's IPO and Secondary Offering and served as a financial advisor and assistant in the				
27	preparation and dissemination of Vocera's false and misleading registration statements for both				
28	offerings.				
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 110				

MASTER FILE NO. 3:13-CV-03567 EMC

328. Defendant Wells Fargo Securities, LLC was an underwriter of the Company's
 IPO and served as a financial advisor and assistant in the preparation and dissemination of
 Vocera's false and misleading registration statements for the IPO.

- 329. Defendant Leerink Swann LLC was an underwriter of the Company's IPO and
 served as a financial advisor and assistant in the preparation and dissemination of Vocera's false
 and misleading registration statement for the IPO.
- 7 330. The Defendants enumerated in paragraphs 324 through 329 are collectively
 8 referred to herein as the "Underwriter Defendants." Allegations against the Underwriter
 9 Defendants are made in connection with the respective offerings in which they participated.

10 331. The Company, the Officer Defendants, the Director Defendants, and the
11 Underwriter Defendants are collectively referred to herein in "Part Two" as the "Securities Act
12 Defendants."

- 332. Pursuant to the Securities Act, the Underwriter Defendants are liable for the false
 and misleading statements in the IPO Offering Materials and the Secondary Offering Materials.
 The Underwriter Defendants' failure to conduct adequate due diligence investigations was a
 substantial factor leading to the harm complained of herein.
- 17 333. The Underwriter Defendants are investment banking houses which specialize, *inter alia*, in underwriting public offerings of securities. They served as the underwriters of the
 19 IPO and the Secondary Offerings and collectively received millions of dollars in fees in
 20 connection with the IPO and Secondary Offering.
- 334. Representatives of the Underwriter Defendants also assisted Vocera and the
 Individual Defendants in planning the IPO and the Secondary Offerings, and purportedly
 conducted an adequate and reasonable investigation into the business and operations of Vocera,
 an undertaking known as a "due diligence" investigation. The due diligence investigation was
 required of the Underwriter Defendants in order to engage in the IPO and the Secondary
 Offerings. During the course of their "due diligence," the Underwriter Defendants had
 continuous access to confidential corporate information concerning Vocera's business, sales
- 28

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page117 of 141

model, financial condition, internal controls, and its future business plans and prospects,
 including bookings, backlog and revenue forecasts.

r

3 335. In addition to availing themselves of access to internal corporate documents, 4 agents of the Underwriter Defendants, including their counsel, met with Vocera's lawyers, 5 management, and top executives to determine: (i) the strategy to best accomplish the IPO and 6 Secondary Offering; (ii) the terms of the IPO and Secondary Offering, including the price at 7 which shares of Vocera common stock would be sold; (iii) the language to be used in the 8 registration statements for the IPO and Secondary Offering; (iv) what would be disclosed and 9 what would not be disclosed in the registration statements for the IPO and Secondary Offering; 10 and (v) how to respond to questions raised by the SEC in connection with its review of the 11 registration statements for the IPO and Secondary Offering. As a result of those constant 12 contacts and communications between the Underwriter Defendants' representatives and Vocera's 13 management, top executives and counsel, a reasonable due diligence would have revealed 14 Vocera's existing problems, and the misleading statements and omissions contained in the 15 registration statements and prospectuses for the IPO and Secondary Offering, as detailed herein. 16 336. The Underwriter Defendants caused the registration statements for the IPO and

Secondary Offering to be filed with the SEC and declared effective in connection with offers andsales thereof, including to the Plaintiff and the Class.

19

X.

FACTUAL ALLEGATIONS RELATING TO THE SECURITIES ACT CLAIMS

337. In connection with the offering materials for the IPO and Secondary Offering, the
Securities Act Defendants negligently made untrue statements and omitted material facts
regarding the current state of Vocera's finances and Vocera's future potential for growth,
including the known, adverse impact healthcare reform was having and would continue to have
on the Company's ability to sell communications systems to hospitals.

25

A.

Vocera Business Overview

338. Defendant Vocera is a provider of mobile communications solutions. The
majority of Vocera's customers consist of healthcare systems and hospitals. Vocera's main
product, referred to as its "Voice Communications" solution is a wearable badge and software

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page118 of 141

platform that enables users to connect instantly with other members of the hospital staff. This
 communications device is meant to assist hospitals in improving patient safety and satisfaction
 on the one hand, and increasing hospital efficiency on the other. Vocera obtains substantially all
 of its revenue from the sale of its Voice Communications solution.

339. Vocera also provides (1) a Secure Messaging System that securely delivers text
messages, alerts and other information directly to and from smartphones, and is designed to
replace paging and unsecured short messaging service, or SMS systems, and (2) a Care
Transition solution, which consists of a hosted voice and text based software that captures,
manages and monitors patient information when a patient is transferred from one caregiver to
another.

340. Vocera also offers services to complement its products. These services include
consulting services under the name "ExperiaHealth," professional services, which help the
customer deploy, manage and update their Vocera systems, and 24 hour a day Technical
Support.

15

B. Hospital Revenues Drive Vocera's Business

341. Substantially all of Vocera's revenue is derived from sales of the Voice
Communications solution to the healthcare market and, in particular, hospitals. Sales of the
Voice Communications solution to the healthcare market accounted for 91%, 92% and 91% of
the Company's revenue for the three months ended March 31, 2013 and the year ended 2012,
and 2011 respectively.

342. Private hospitals make up the bulk of the Company's hospital clients. Vocera's
products require that a hospital have installed a voice grade wireless or a Wi-Fi network
throughout the hospitals, including in access points in stairwells. Vocera also requires hospitals
to install system servers to operate the hardware and software. Installing these systems requires
a substantial, upfront capital investment by the hospitals. The sales cycle for a Vocera
installation and roll out could take anywhere from nine to twelve months.

- 27
- 28

3

4

5

6

7

1

C. **Relevant Legislation Affecting the Hospital Industry - The Affordable Care** Act

On March 23, 2010, healthcare reform entitled the "Patient Protection and 343. Affordable Care Act" (the "ACA") was signed into law. The new law was intended to increase the rate of insured individuals by expanding insurance coverage while lowering the costs of healthcare for both individuals and the government. The law's constitutionality was challenged by certain states and on June 28, 2012, three months after Vocera's IPO, the Supreme Court found the vast majority of the ACA to be constitutional.

8 9 10

344. The ACA was designed, in part, to reduce costs and improve healthcare by focusing the delivery of healthcare services on quality care over quantity of care. The ACA attempts to accomplish this by providing incentives to increase competition and to streamline 11 the delivery of care, and through regulation. One such incentive is called Hospital Consumer 12 Assessment of Healthcare Providers and Systems, also called HCAHPS. HCAHPS is a survey 13 reporting patients' perspectives of hospital care. Beginning in October 2012, a part of hospital 14 Medicare reimbursement was tied to HCAHPS results. Several questions on the HCAHPS 15 survey relate to responsiveness of hospital staff, communication with nurses, and the quietness of 16 the hospital environment. According to Vocera, the Company's technology, products and 17 services are designed to improve HCAHPS results for hospitals using its solutions.

18

19

20

21

23

24

The Importance of Bookings and Backlog to Revenue Visibility D.

345. "Bookings" are orders that are placed for Vocera's products and services. Because Vocera requires that a hospital have certain infrastructure in place in order to operate the Vocera communication system, there is oftentimes a delay in rolling out Vocera's product. 22 Even after the infrastructure is in place, and Vocera ships badges and software, Vocera must also train its customers to use the badge. Bookings convert to revenue when hospitals are ready to implement a new system and when Vocera ships the product.

25 346. New bookings from new customers, and at least a portion of the bookings of 26 repeat business, will initially go into backlog. Backlog refers to products or services that have 27 been ordered but that have not yet been delivered or provided. Backlog typically contains orders 28

that have specific delivery dates for different aspects of Vocera's product (*i.e.*, training,
 installation, software, badges). Since a customer roll out can take nine to 12 months during
 which time revenue is not recognized, a healthy, or high, backlog signals robust future revenue

which time revenue is not recognized, a healthy, or high, backlog signals robust future revenues,

4 and visibility into growth.

5

16

E. Vocera's Growth Strategy

347. In the years leading up to the IPO, Vocera's sales increased exponentially.
Between 2007 and 2011, revenue increased more than two fold from approximately \$34 million
to over \$79 million, and adjusted EBITDA increased from negative \$2.6 million to over \$3
million.

			Years ended Decembe		
(in thousands, except per share data)	2007	2008	2009	2010	2011
Consolidated statements of operations data:					
Revenue					
Product	\$ 27,332	\$ 28,352	\$ 25,985	\$ 35,516	\$ 50,322
Service	7,125	11,474	15,154	21,287	29,181
Total revenue	34,457	39,826	41,139	56,803	79,503
Adjusted EBITDA	\$ (2,688)	\$ (4,800)	\$ 578	\$ 3,821	\$ 3,020

F. The IPO


17 On August 1, 2011, the Company filed a Registration Statement with the SEC on 348. 18 Form S-1, in which it announced its intention to hold an IPO for the sale of Vocera common 19 stock. The Company amended the registration statements several times, which ultimately 20 became effective on March 27, 2012. Vocera also filed a Form 424B4 Prospectus (which 21 together with the registration statements make up the "IPO Offering Materials"). 6,727,500 22 common shares of Vocera common stock were sold at \$16.00 per share in the IPO, which 23 occurred on or about March 28, 2012. The Company sold 5 million shares of common stock, 24 existing shareholders sold an aggregate of 1,727,500 shares, and underwriters sold an additional 25 877,500 shares as a result of the underwriters' exercise of their over-allotment option. 26 349. The IPO Offering Materials explained that several forces in the hospital industry,

- ²⁷ lincluding health care reform, were driving adoption of Vocera's product. Most hospitals have
- 28

"legacy" communications systems such as overhead paging, pagers and mobile phones, systems 1 2 which are often unreliable and inefficient and have a negative effect on patient satisfaction. 3 Moreover, the hospital industry faced a growing shortfall among nursing staff. According to the 4 **IPO Offering Materials:** 5 The inadequate coverage of patients by qualified nurses can detract from the patient experience and impact hospitals' financial performance as patients are increasingly selecting hospitals and 6 providers based on quality of care, cost and overall experience 7 with the provider. The increasing focus on improving patients' experience is supported by the healthcare reform initiative, 8 which incorporates financial incentives for hospitals to improve the quality of care and patient satisfaction. These 9 forces are driving hospitals to invest in technology and process improvements to manage their operations more efficiently and 10 to improve staff and patient satisfaction. (Add page cite) 11 350. Vocera touted its solution as (1) providing improvements in patient safety, (2)12 enhancing patient experience, (3) improving caregiver job satisfaction, and (4) increasing 13 hospital revenue while reducing expenses. Vocera also repeatedly expressed that hospitals were 14 seeking more effective ways of addressing their communications deficiencies and that Vocera's 15 products would provide those solutions. 16 351. Vocera touted the opportunity it had to grow, stating in the Offering Materials 17 that "the worldwide hospital market opportunity for the full deployment of our Voice 18 Communication solution to be over \$6 billion." Indeed, Vocera stated that while its products 19 and communications systems were being utilized in over 800 hospitals, there was a market of 20 over 6,000 hospitals in the U.S. available for its products. Vocera stated in the Offering 21 Materials that it had a "growing U.S. Customer base," and that in the eight months leading up to 22 the IPO, this growing customer base and current customer expansion had led Vocera's "quarterly 23 revenue [to] increase[] each quarter." The total number of shares that each of the Underwriter Defendants sold in the 24 352 25 IPO is set forth in the table below. 26 27 28 CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 116 MASTER FILE NO. 3:13-CV-03567 EMC

	Under	writing			
Name		Number of Share			
Piper Jaffray	Securities LLC	2,340,000			
	& Company, L.L.C.	585,000			
	aird & Co. Incorporated	585,000			
Wells Fargo S	Securities, LLC	468,000			
Leerink Swar	n LLC	117,000			
Total		5,850,000 ¹			
353.	The Company raised \$70.5 millio	n in net proceeds through the IPO. By the nex			
day, on Marc	h 29, 2012, the stock closed at \$24.	91, an increase of over 55% of the offering pri			
of \$16.00.					
G.	Vocera's Secondary Offering				
354.		y filed a Form S-1 with the SEC and			
subsequently filed one amendment, which became effective on September 6, 2012. On					
September 7, 2012 Vocera filed a Form 424B4 Prospectus (which together with the registration statements make up the "Secondary Offering Materials"). The common shares were sold at \$28.75 per share in the Secondary Offering, which occurred on or about September 7, 2012.					
			Unlike the IPO, where the majority of shares sold were offered by the Company, in the		
			Secondary O	ffering, the majority of the shares w	vere offered by existing stockholders, including
Company exe	ecutives. In the Secondary Offering	g, the Company sold 1,337,500 shares, existing			
stockholders	sold 4,211,250 shares of common s	tock, and underwriters sold an additional			
723,750 share	es as a result of the underwriters' ex	tercise of their over-allotment option.			
355. The Secondary Offering Materials reiterated the statements made in the IPO Offering Materials, including those claiming that healthcare reform would spur demand for					
			Vocera's products and services, and that the market opportunity for Vocera was over \$6 billion.		
356. The total number of shares that each of the Underwriter Defendants sold in the					
Secondary O	ffering is set forth in the table below	₹.			
¹⁶ These figures do not include the 877,500 shares sold as a result of the underwriters' exercise of their over-allotment option.					
Consolidated Master File N	CLASS ACTION COMPLAINT FOR VIOLATIO	ONS OF THE FEDERAL SECURITIES LAWS 11			

	Under	writing
Name		Number of Sha
J.P. Morgan S Piper Jaffray	Securities LLC	2,050,6
. ,	& Co. & Company, L.L.C.	1,688, ⁻ 603, ⁻ _603, ⁻
	ird & Co. Incorporated	482,5
Total		4,825,00
357.	Vocera and the existing sharehol	ders raised over \$36 million in net proceeds
the Secondary	v Offering.	
Н.	The Negative Effects of the AC IPO and Secondary Offering	A Affect Vocera's Business at the Time of
358.	Numerous high level employees	from the Company, supported by internal
Company doc	uments, state and show that contra	ary to statements contained in the IPO Offeri
Materials and	Secondary Offering Materials, the	e ACA and uncertainties regarding its provis
and its likelih	ood for approval were already fact	ors adversely impacting upon demand for th
		or Vocera to sell its products and services at
time of the IP		si vocciu to sen na producta una services at
359.	C	er Administration at Vocera stated that at the
time of the IP	O, Vocera executives were already	concerned about the impact of health care
reform on sale	es and growth potential and discus	sed these concerns at internal revenue meeting
This employe	e stated that the ACA was one of t	he factors affecting Vocera's sales [bookings
A former Hea	lth Systems Director at Vocera als	o confirmed that by "mid-2012, Q2, Q3" (at
time of the Se	condary Offering) he observed the	e actual negative effects of the ACA on Voce
business.		
17 Thoras fu	and a not include the 722 750 a	hares sold as a result of the underwriters'



Case3	:13-cv	v-03567-EMC Document104 Filed09/19/14 Page125 of 141		
	363.	Thus, statements made in the IPO and Secondary Offering misstated and omitted		
the cur	rent tru	ue financial health and the growth prospects for Vocera.		
XI.	FAC	OFFERING MATERIALS CONTAINED UNTRUE STATEMENTS OF Γ AND OMITTED MATERIAL FACTS NECESSARY TO MAKE THE ERING MATERIALS NOT MISLEADING		
	364.	In connection with each of the Offerings, Vocera filed offering materials with the		
SEC th	at incl	uded misstatements and omissions of material facts.		
	A.	The IPO		
	365.	In the Offering Materials for the IPO Vocera laid out its business strategy and the		
seemin	gly lin	nitless opportunities for growth and expansion due, in part, to the pressures and		
incenti	ves pro	ovided by the ACA:		
		Patients are increasingly selecting hospitals and healthcare		
		providers based on quality of care, cost and overall experience with the provider. <i>In addition, healthcare reform initiatives</i> <i>incorporate financial incentives for hospitals to improve the</i>		
		quality of care and patient satisfaction. These forces are driving hospitals to manage their operations more efficiently and to seek ways to improve staff and patient satisfaction through process improvements and technology solutions.		

		The increasing focus on improving patients' experience is supported by the healthcare reform initiative, which incorporates		
		financial incentives for hospitals to improve the quality of care and patient satisfaction. <i>These forces are driving hospitals to invest in</i> <i>technology and process improvements to manage their operations</i> <i>more efficiently and to improve staff and patient satisfaction.</i> (add cite)		
	366.	Vocera then laid out a myriad of impediments that traditional hospital		
commu	unicatio	ons posed that can "degrade patient and caregiver satisfaction," including as nurse		
time away from bedside, the inability to reach the appropriate caregiver in a timely manner,				
noisy e	environ	ments and the lack of closed loop communication. According to Vocera, these		
impedi	impediments caused inconvenience and frustration, medical errors and hospital inefficiencies,			
which	lead to	lost revenue opportunities.		
	367.	Vocera touted its products as providing the "solution" to these problems		
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 120 0. 3:13-CV-03567 EMC		

	Case3:13-cv	-03567-EMC Document104 Filed09/19/14 Page126 of 141
1 2 3 4		To address these deficiencies, hospitals are seeking more effective alternatives for improving communication. <i>We believe hospitals</i> <i>will increasingly turn to communication technologies to help</i> <i>improve patient safety and satisfaction, productivity and</i> <i>caregiver satisfaction and retention. We believe our solutions are</i> <i>at the convergence of the healthcare IT market and the</i> <i>enterprise communications and collaboration market.</i> (add cite)
5	368.	In the IPO Offering Materials, Vocera also laid out the pressures that hospitals
6	might face be	cause of healthcare reform, but equally touted the Company as the solution that
7	hospitals need	led to alleviate these pressures:
8		Effective communication is extremely important among mobile and widely dispersed healthcare professionals in hospitals. As of
9		December 31, 2011, there were over 6,900 hospitals in the United States. We believe that a combination of policy changes through
10 11		healthcare reform, demographic trends and downward pressure on healthcare reimbursement is increasing financial pressure on hearitals and other healthcare providers. Furthermore, the pursing
11		hospitals and other healthcare providers. Furthermore, the nursing shortage in the United States, with over 115,000 openings, can detract from the patient experience and place further strain on
13		hospital operations.
14		***
15		• Increase revenue and reduce expenses. Improved communication facilitated by our solutions can enable hospitals to increase revenue and reduce expenses through more efficient use
16 17 18		of their resources, directly impacting profitability. With our solutions, hospitals can reduce nurse overtime expense and increase job satisfaction, thereby improving nurse recruiting and retention. In addition, improvements in patient safety and reduction in errors can lead to reduced liability cost for hospitals.
19	369.	The IPO Offering Materials further explained that because of the benefits and
20	"solutions" th	at Vocera provided to hospitals, Vocera's prospects for growth were enormous:
21		We estimate the worldwide hospital market opportunity for the full deployment of our Voice Communication solution to be over
22	270	\$6 billion on an aggregate basis.
23	370.	Vocera touted the Company's growth in 2011 and provided reasons that Vocera
24	expected to co	ontinue that growth, and rate of growth, going forward:
25 26		<i>In 2011, we generated revenue of \$79.5 million, representing growth of 40.0% over 2010.</i>
27		***
28		
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 121 D. 3:13-CV-03567 EMC

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page127 c	of 141		
Our goal is to extend our leadership position as a provider of communication solutions in the healthcare market. Key electron for our strategy include:			
• Expand our business to new U.S. healthcare customers. A	s of		
December 31, 2011, our solutions were deployed in approximately 9% of U.S. hospitals. We plan to continue to			
expand our direct sales force to win new customers among hospitals of all sizes.			
• Further penetrate our existing installed customer base.			
Typically, our customers initially deploy our Voice Communication solution in a few departments of a hospital gradually expand to additional departments, or additional	and		
gradually expand to additional departments, or additional hospitals within a healthcare system, as they come to fully appreciate the value of our solutions. A key part of our sale	g		
strategy includes promoting further adoption of our Voice Communication solution and demonstrating the value of ou			
Messaging and Care Transition solutions to our existing customers.	i new		

We have a growing U.S. customer base			
371. The statements in the IPO Offering Materials (1) regarding th	e Company's		
growth and growth potential, and (2) concerning the positive effect that the healthcare reform			
initiative was having at the time of the IPO and would continue to have on V	ocera's business,		
were materially untrue and omitted to state that at the time of the IPO, healthcare reform was			
already a factor negatively impacting upon demand for the Company's produ	acts and would		
continue to do so and as a result,			
that the Company needed to achieve in order to sustain the impression that it	was a "growth		
company."			
<i>See also</i> ¶¶358-362.			
372. The omitted information was required to be disclosed in the F	form S-1 of the		
pursuant to Item 11(h) of the instructions to Form S-1, which provides that c	ompanies disclose		
information called for under Item 303 of Regulation S-K [17 C.F.R. §229.30	03]. Item 303(a) of		
Regulation S-K requires issuers to "[d]escribe any known trends or uncertain	nties that have had o		
that the registrant reasonably expects will have a material favorable or unfav	orable impact on ne		
sales or revenues or income from continuing operations." In addition, Instru	ction 3 of Item		
CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES MASTER FILE NO. 3:13-CV-03567 EMC	Laws 122		
WASTER FILE INC. 5.15-UV-05507 EIVIU			

1	303(a) of Regulation S-K requires that "[t]he discussion and analysis shall focus specifically on			
2	material events and uncertainties known to management that would cause reported financial			
3	information not to be necessarily indicative of future operating results." Moreover, pursuant to			
4	SEC Regulation C, registrants have an overarching duty to disclose material information			
5	necessary to ensure that representations in a registration statement are not misleading.			
6	Specifically, Rule 408 states "In addition to the information expressly required to be included in			
7	a registration statement, there shall be added such further material information, if any, as may be			
8	necessary to make the required statements, in light of the circumstances under which they are			
9	made, not misleading." 17 C.F.R. § 230.408(a).			
10	B. The Secondary Offering			
11	373. The Secondary Offering Materials explained that Vocera would be successful			
12	because healthcare reform initiatives, by then with Supreme Court approval, were actually			
13	providing incentives to hospitals to purchase Vocera's technology and products to "improve the			
14	quality of care and patient satisfaction:"			
15	Patients are increasingly selecting hospitals and healthcare providers based on quality of care, cost and overall experience			
16	with the provider. In addition, healthcare reform initiatives incorporate financial incentives for hospitals to improve the			
17	quality of care and patient satisfaction. These forces are driving hospitals to manage their operations more efficiently and to seek			
18	ways to improve staff and patient satisfaction through process improvements and technology solutions.			
19	***			
20	The increasing focus on improving patients' experience is			
21	supported by the healthcare reform initiative, which incorporates financial incentives for hospitals to improve the quality of care			
22	and patient satisfaction. These forces are driving hospitals to invest in technology and process improvements to manage their			
23	<i>operations more efficiently and to improve staff and patient satisfaction.</i> (add cite)			
24	374. Vocera then laid out a myriad of impediments that traditional hospital			
25	communications posed that can "degrade patient and caregiver satisfaction," such as nurses' time			
26	away from bedside, the inability to reach the appropriate caregiver in a timely manner, noisy			
27	environments and the lack of closed loop communication. According to Vocera, these			
28				

	Case3:13-cv	-03567-EMC Document104 Filed09/19/14 Page129 of 141
1	impediments	caused inconvenience and frustration, medical errors and hospital inefficiencies,
2	which lead to	lost revenue opportunities.
3	375.	Vocera touted its products as providing the "solution" to these problems:
4		To address these deficiencies, hospitals are seeking more effective
5		alternatives for improving communication. We believe hospitals will increasingly turn to communication technologies to help improve patient safety and satisfaction, productivity and
6 7		caregiver satisfaction and retention. We believe our solutions are at the convergence of the healthcare IT market and the enterprise communications and collaboration market.(add cite)
8	376.	Vocera also laid out the pressures that hospitals might face because of healthcare
9	reform, but ec	qually touted the Company as the solution that hospitals needed to alleviate these
10	financial pres	sures:
11		Effective communication is extremely important among mobile and widely dispersed healthcare professionals in hospitals. As of
12		December 31, 2011, there were over 6,900 hospitals in the United States. We believe that a combination of policy changes through
13		healthcare reform, demographic trends and downward pressure on healthcare reimbursement is increasing financial pressure on
14		hospitals and other healthcare providers. Furthermore, the nursing shortage in the United States, with over 115,000 openings, can
15		detract from the patient experience and place further strain on hospital operations.
16		***
17		• Increase revenue and reduce expenses. Improved
18		communication facilitated by our solutions can enable hospitals to increase revenue and reduce expenses through more efficient use
19 20		of their resources, directly impacting profitability. With our solutions, hospitals can reduce nurse overtime expense and increases ich satisfaction, thereby improving purse recruiting and
20		increase job satisfaction, thereby improving nurse recruiting and retention. In addition, improvements in patient safety and reduction in errors can lead to reduced liability cost for hospitals.
21	377.	The Secondary Offering Materials further explained that because of the benefits
23		s" that Vocera provided to hospitals, Vocera's prospects for growth were
24	enormous:	
25		We estimate the worldwide hospital market opportunity for the
26		<i>full deployment of our Voice Communication solution to be over</i> \$6 billion on an aggregate basis.
27	378.	Vocera described its growth strategy to increase the amount of new healthcare
28	clients and co	ntinue to develop expansion into its existing customer base:
		CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 124 D. 3:13-CV-03567 EMC

	Case3:13-cv	v-03567-EMC	Document104	Filed09/19/14	Page130 of 141	
1 2 3 4 5 6 7 8 9 10 11		communicati of our strates • Expand our December 31 approximate expand our a hospitals of a • Further per Typically, ou Communicati gradually exp hospitals witt appreciate th strategy inclu	gy include: r business to new l, 2011, our solution ly 9% of U.S. hosp lirect sales force to all sizes. netrate our existin fr customers initian tion solution in a j pand to additionan hin a healthcare solution fu	e healthcare man U.S. healthcare of ons were deploye oitals. We plan to o win new custon ly deploy our Vo few departments, or ystem, as they co utions. A key pa rther adoption of lemonstrating th	rket. Key elements customers. As of d in o continue to ners among mer base. bice of a hospital and additional ome to fully rt of our sales f our Voice e value of our new	
12	379.	Vocera also p	provided informati	on showing their	continued growth o	over the past
13	year:					
14			Quarterly Res	Quarterly Results of Operations		
15	(in thousands) (unaudited)		September 2011	December 2011	March 2012	June 2012
			September	December	March	
16	(unaudited)		September	December	March	
	(unaudited) Revenue Product Service	l anuenu:-	September 2011 \$ 13,087 <u>7,314</u>	December 2011 \$ 13,674 <u>8,032</u>	March 2012 \$ 14,637 <u>8,482</u>	2012 \$ 16,155 <u>8,723</u>
16	(unaudited) Revenue Product Service	l revenue	September 2011 \$ 13,087	December 2011 \$ 13,674	March 2012 \$ 14,637	2012 \$ 16,155
16 17	(unaudited) Revenue Product Service		September 2011 \$ 13,087 7,314 \$ 20,401	December 2011 \$ 13,674 <u>8,032</u> \$ 21,706	March 2012 \$ 14,637 <u>8,482</u>	2012 \$ 16,155 <u>8,723</u> \$ 24,878
16 17 18	(unaudited) Revenue Product Service Tota 380.	The statemen	September 2011 \$ 13,087 7,314 \$ 20,401 atts in the Secondar	December 2011 \$ 13,674 <u>8.032</u> \$ 21,706 y Offering Mater	March 2012 \$ 14,637 <u>8,482</u> \$ 23,119	2012 \$ 16,155 <u>8,723</u> \$ 24,878 ne Company's
16 17 18 19	(unaudited) Revenue Product Service Tota 380. growth and gr	The statemen rowth potential	September 2011 \$ 13,087 7,314 \$ 20,401 atts in the Secondar I, and (2) concerning	December 2011 \$ 13,674 8.032 \$ 21,706 y Offering Mater ng the positive ef	March 2012 \$ 14,637 <u>8,482</u> \$ 23,119 ials (1) regarding th	2012 \$ 16,155 <u>8,723</u> \$ 24,878 ne Company's care reform
16 17 18 19 20	(unaudited) Revenue Product Service Tota 380. growth and gr initiative was	The statemen rowth potential having at the t	September 2011 \$ 13,087 7,314 \$ 20,401 atts in the Secondar I, and (2) concerning time of the Second	December 2011 \$ 13,674 8.032 \$ 21,706 y Offering Mater ng the positive ef ary Offering and	March 2012 \$ 14,637 <u>8,482</u> \$ 23,119 ials (1) regarding th fect that the healthc	2012 \$ 16,155 8.723 \$ 24,878 the Company's the reform have on
16 17 18 19 20 21	(unaudited) Revenue Product Service Tota 380. growth and gr initiative was Vocera's busi	The statement rowth potential having at the t iness, were ma	September 2011 \$ 13,087 7,314 \$ 20,401 ats in the Secondar ats in the Secondar ats in the Secondar the Second terially untrue and	December 2011 \$ 13,674 8.032 \$ 21,706 y Offering Mater ng the positive ef ary Offering and omitted to state t	March 2012 \$ 14,637 <u>8,482</u> \$ 23,119 ials (1) regarding the fect that the healthc would continue to h	2012 \$ 16,155 8,723 \$ 24,878 the Company's the company's the reform thave on the Secondary
 16 17 18 19 20 21 22 	(unaudited) Revenue Product Service Tota 380. growth and gr initiative was Vocera's busi Offering, heat	The statement rowth potential having at the t iness, were ma	September 2011 \$ 13,087 7,314 \$ 20,401 ats in the Secondar d, and (2) concerning time of the Second terially untrue and was already negat	December 2011 \$ 13,674 8.032 \$ 21,706 y Offering Mater ng the positive ef ary Offering and omitted to state t	March 2012 \$ 14,637 8,482 \$ 23,119 ials (1) regarding the fect that the healthce would continue to healthce that at the time of the	2012 \$ 16,155 8,723 \$ 24,878 the Company's the company's the reform thave on the Secondary
 16 17 18 19 20 21 22 23 	(unaudited) Revenue Product Service Tota 380. growth and gr initiative was Vocera's busi Offering, hea to do so. As a	The statement rowth potential having at the t iness, were main lthcare reform a result Vocera	September 2011 \$ 13,087 7,314 \$ 20,401 ats in the Secondar ats in the Secondar ats in the Secondar aterially untrue and was already negat	December 2011 \$ 13,674 8.032 \$ 21,706 y Offering Mater ng the positive ef ary Offering and omitted to state t ively impacting th	March 2012 \$ 14,637 8,482 \$ 23,119 ials (1) regarding the fect that the healthce would continue to healthce that at the time of the	2012 \$ 16,155 8.723 \$ 24,878 The Company's that the
 16 17 18 19 20 21 22 23 24 	(unaudited) Revenue Product Service Tota 380. growth and gr initiative was Vocera's busi Offering, hea to do so. As a	The statement rowth potential having at the t iness, were main lthcare reform a result Vocera	September 2011 \$ 13,087 7,314 \$ 20,401 ats in the Secondar ats in the Secondar ats in the Secondar aterially untrue and was already negat	December 2011 \$ 13,674 8.032 \$ 21,706 y Offering Mater ng the positive ef ary Offering and omitted to state t ively impacting th	March 2012 \$ 14,637 <u>8,482</u> \$ 23,119 ials (1) regarding the fect that the healthch would continue to he that at the time of the he Company and wo	2012 \$ 16,155 8.723 \$ 24,878 The Company's that the
 16 17 18 19 20 21 22 23 24 25 	(unaudited) Revenue Product Service Tota 380. growth and gr initiative was Vocera's busi Offering, hea to do so. As a Company nee	The statement rowth potential having at the t iness, were main lthcare reform a result Vocera	September 2011 \$ 13,087 7,314 \$ 20,401 ats in the Secondar ats in the Secondar ats in the Secondar aterially untrue and was already negat	December 2011 \$ 13,674 8.032 \$ 21,706 y Offering Mater ng the positive ef ary Offering and omitted to state t ively impacting th	March 2012 \$ 14,637 <u>8,482</u> \$ 23,119 ials (1) regarding the fect that the healthch would continue to he that at the time of the he Company and wo	2012 \$ 16,155 8.723 \$ 24,878 The Company's that the
 16 17 18 19 20 21 22 23 24 25 26 27 	(unaudited) Revenue Product Service Tota 380. growth and gr initiative was Vocera's busi Offering, hea to do so. As a Company nee	The statement rowth potential having at the t iness, were main lthcare reform a result Vocera	September 2011 \$ 13,087 7,314 \$ 20,401 ats in the Secondar ats in the Secondar ats in the Secondar aterially untrue and was already negat	December 2011 \$ 13,674 8.032 \$ 21,706 y Offering Mater ng the positive ef ary Offering and omitted to state t ively impacting th	March 2012 \$ 14,637 <u>8,482</u> \$ 23,119 ials (1) regarding the fect that the healthch would continue to he that at the time of the he Company and wo	2012 \$ 16,155 8.723 \$ 24,878 The Company's that the
 16 17 18 19 20 21 22 23 24 25 26 	(unaudited) Revenue Product Service Tota 380. growth and gr initiative was Vocera's busi Offering, hea to do so. As a Company nee company."	The statement rowth potential having at the t iness, were man lthcare reform a result Vocera eded to organic	September 2011 \$ 13,087 7.314 \$ 20,401 Ats in the Secondar I, and (2) concerning terially untrue and was already negat a was ally achieve in ord	December 2011 \$ 13,674 8.032 \$ 21,706 y Offering Mater ng the positive eff ary Offering and omitted to state to ively impacting the ler to sustain the interval of the second s	March 2012 \$ 14,637 <u>8,482</u> \$ 23,119 ials (1) regarding the fect that the healthch would continue to he that at the time of the he Company and wo	2012 \$ 16,155 8.723 \$ 24,878 The Company's that the

2	See
3	¶¶358-362.
4	381. The Offering Materials also failed to disclose material information that healthcare
5	reform was already a factor impacting the Company's bookings and revenue negatively. The
6	omitted information was required to be disclosed in the Form S-1 pursuant to Item 11(h) of the
7	instructions to Form S-1, which provides that companies disclose information called for under
8	Item 303 of Regulation S-K [17 C.F.R. §229.303]. Moreover, pursuant to SEC Regulation C,
9	registrants have an overarching duty to disclose material information necessary to ensure that
10	representations in a registration statement are not misleading. Specifically, Rule 408 states "In
11	addition to the information expressly required to be included in a registration statement, there
12	shall be added such further material information, if any, as may be necessary to make the
13	required statements, in light of the circumstances under which they are made, not misleading."
14	17 C.F.R. § 230.408(a).
15	THIRD CLAIM FOR RELIEF Violations Of Section 11 Of The Securities Act Against Vecase
16	Violations Of Section 11 Of The Securities Act Against Vocera, Zollers, Zerella, the Director Defendants, and the Underwriter Defendants
17	382. Plaintiff repeats and realleges each and every allegation above relating to the
18	Securities Act claims in ¶¶301 to 381 as if fully set forth herein, as well as in Section XII, ¶¶408
19	to 414, set forth below.
20	383. This Count does not sound in fraud. Any allegations of fraud or fraudulent
21	conduct and/or motive are specifically excluded. For purposes of asserting this and their other
22	claims under the Securities Act, Plaintiff does not allege that Defendants acted with intentional,
23	reckless or otherwise fraudulent intent.
24	384. This Count is asserted against Vocera, the Officer Defendants, the Director
25	Defendants, and the Underwriter Defendants for violations of Section 11 of the Securities Act,
26	15 U.S.C. § 77k, on behalf of all members of the Class who purchased or otherwise acquired the
27	stock sold pursuant or traceable to the Offerings.
28	
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 126

MASTER FILE NO. 3:13-CV-03567 EMC

385. Liability under this Count is predicated on these defendants' respective
 participation in each Offering.

3 386. The IPO Offering Materials and the Secondary Offering Materials contained
4 untrue statements and omissions of material fact.

5 387. In connection with offering and sale of the registered common stock to the public,
6 the defendants named in this Count, directly or indirectly, used the means and instrumentalities
7 of interstate commerce, the United States mails and a national securities exchange.

8 388. As the issuer of the registered securities, Vocera is strictly liable for the untrue
9 statements of material fact and material omissions described herein.

389. None of the other Defendants named in this Count made a reasonable
investigation or possessed reasonable grounds for the belief that the statements contained in the
IPO Offering Materials or the Secondary Offering Materials were accurate and complete in all
material respects. Had they exercised reasonable care, they would have known of the material
misstatements and omissions alleged herein.

15 390. Class members did not know, nor in the exercise of reasonable diligence could
16 have known, that the IPO Offering Materials or the Secondary Offering Materials contained
17 untrue statements of material fact and omitted to state material facts required to be stated or
18 necessary to make the statements particularized above not misleading when they purchased or
19 acquired the registered common stock.

391. As a direct and proximate result of the acts and omissions of the defendants
named in this Count in violation of the Securities Act, the Class suffered substantial damage in
connection with its purchase of Vocera common stock sold through the IPO and the Secondary
Offering.

392. By reason of the foregoing, the defendants named in this Count are liable forviolations of Section 11 of the Securities Act.

26

FOURTH CLAIM FOR RELIEF 1 For Violations Of Section 12(a)(2) Of The Securities Act **Against Vocera And The Underwriter Defendants** 2 Plaintiff repeats and realleges each and every allegation above relating to the 3 393. 4 Securities Act claims in ¶301 to 392 as if fully set forth herein, as well as in Section XII, ¶404 5 to 414, set forth below. 394. For the purposes of this Count, Plaintiff asserts only strict liability and negligence 6 7 claims, and expressly excludes from this count any allegations of fraud or reckless or intentional 8 misconduct, and expressly exclude from this Count any allegations of fraud or reckless or 9 intentional misconduct. 10 395. This Count is asserted against Vocera and the Underwriter Defendants for 11 violations of Section 12(a)(2) of the Securities Act, 15 U.S.C. § 77l(a)(2), on behalf of all 12 members of the Class who purchased or otherwise acquired Vocera common stock pursuant to 13 the IPO and/or the Secondary Offering. 14 396. Vocera and the Underwriter Defendants were sellers, offerors, and/or solicitors of 15 sales of the securities issued in the IPO and Secondary Offering pursuant to the offering 16 materials. These offering materials, including prospectuses, prospectus supplements and pricing 17 supplements incorporated therein, contained untrue statements of material fact and omitted other 18 facts necessary to make the statements not misleading, and failed to disclose material facts, as set 19 forth above. 20 397 None of the Underwriter Defendants made a reasonable investigation or possessed 21 reasonable grounds for the belief that the statements contained in the offering materials for the 22 IPO or the Secondary Offering were accurate and complete in all material respects. Had they 23 exercised reasonable care, these defendants would have known of the material misstatements and 24 omissions alleged herein. 25 398. By means of the offering materials for the IPO or the Secondary Offering, and by 26 using the means and instruments of transportation and communication in interstate commerce 27 and of the mails, the defendants named in this Count, through public offerings, solicited and sold

28 Vocera common stock to members of the Class.

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page134 of 141

1	399. Members of the Class purchased Vocera common stock by means of the
2	materially misstated offering materials for the IPO or the Secondary Offering. At the time they
3	purchased shares in the IPO or the Secondary Offering, no member of the Class knew, or by the
4	reasonable exercise of care could have known, of the material misstatements in and omissions
5	from the offering materials for the IPO or the Secondary Offering, which were materially
6	misstated, omitted to state facts necessary to make the statements made not misleading and
7	concealed or failed to adequately disclose material facts as alleged herein.
8	400. By reason of the foregoing, Vocera and the Underwriter Defendants are liable for
9	violations of Section 12(a)(2) of the Securities Act.
10	401. Accordingly, members of the Class who purchased or otherwise acquired Vocera
11	common stock pursuant to the IPO or the Secondary Offering have a right to rescind and recover
12	the consideration paid for their common stock. Members of the Class who have sold their
13	Vocera common stock issued in the IPO or the Secondary Offering are entitled to recissory
14	damages.
15 16	FIFTH CLAIM FOR RELIEF For Violations Of Section 15 Of The Securities Act Against the Officer Defendants and The Director Defendants
17	402. Plaintiff repeats and realleges each and every allegation above relating to the
18	Securities Act claims in ¶¶301 to 401 as if fully set forth herein, as well as in Section XII, ¶¶408
19	to 414 set forth below.
20	403. This Count is asserted against the Officer Defendants and the Director Defendants
21	for violations of Section 15 of the Securities Act, 15 U.S.C. § 770, on behalf of Plaintiff and the
22	other members of the Class who purchased or otherwise acquired Vocera common stock sold
23	pursuant to the Offerings.
24	404. For the purposes of this Count, Plaintiff asserts only strict liability and negligence
25	claims, and expressly excludes from this count any allegations of fraud or reckless or intentional
26	misconduct.
27	405. At times relevant hereto, the Officer Defendants and the Director Defendants
28	were controlling persons of Vocera within the meaning of Section 15 of the Securities Act. The
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 129 MASTER FILE NO. 3:13-CV-03567 EMC

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page135 of 141

Officer Defendants and each of the Director Defendants served as an executive officer and/or
 directors of Vocera prior to and at the time of the IPO and the Secondary Offering, as alleged
 herein (except for Wood who only served as a Director for the IPO).

4

406 The Officer Defendants and the Director Defendants at times relevant hereto 5 participated in the operation and management of Vocera, and conducted and participated, 6 directly and indirectly, in the conduct of Vocera business affairs. The Officer Defendants and 7 the Director Defendants, who signed the Offerings alleged herein, had a duty to disseminate 8 accurate and truthful information with respect to Vocera financial condition and operations. 9 Because of their positions of control and authority over Vocera, the Officer Defendants and the 10 Director Defendants were able to, and did, control the contents of the offering materials for the 11 IPO or the Secondary Offering, which contained materially untrue financial information.

407. By reason of the foregoing, the Officer Defendants and the Director Defendants
are liable under Section 15 of the Securities Act, to the same extent that Vocera is liable under
Sections 11, and 12(a)(2) of the Securities Act.

15

XII. CLASS ACTION ALLEGATIONS – APPLICABLE TO ALL CLAIMS

408. Plaintiffs brings this action on their own behalf and as a class action pursuant to
Rules 23(a) and (b)(3) of the Federal Rules of Civil Procedure on behalf of all persons and
entities who (1) purchased or otherwise acquired the securities of Vocera between March 28,
2012 and May 2, 2013, inclusive, and were damaged thereby, seeking to pursue remedies under
the Exchange Act, and/or (2) purchased or otherwise acquired the common stock of Vocera
pursuant or traceable to the IPO and/or the Secondary Offering, defined herein, and were
damaged thereby, seeking to pursue remedies under the Securities Act.

- 409. Excluded from the Class are the Defendants; members of the immediate families
 of the Individual Defendants; Vocera's subsidiaries and affiliates; any person who is or was an
 officer or director of Vocera or any of Vocera's subsidiaries or affiliates during the Class Period;
 any entity in which any Defendant has a controlling interest; and the legal representatives, heirs,
 successors and assigns of any such excluded person or entity.
- 28

1	410. The members of the Class are so numerous that joinder of all members is		
2	impracticable. During the Class Period, Vocera had between 22 million to 24 million shares of		
3	common stock outstanding and actively trading on the NYSE with the ticker symbol "VCRA."		
4	While the exact number of Class members is unknown to Plaintiffs at this time and can only be		
5	ascertained through appropriate discovery, Plaintiffs believe that the proposed Class numbers in		
6	the thousands and is geographically widely dispersed. Record owners and other members of the		
7	Class may be identified from records maintained by Vocera or its transfer agent and may be		
8	notified of the pendency of this action by mail, using a form of notice similar to that customarily		
9	used in securities class actions.		
10	411. Plaintiffs' claims are typical of the claims of the members of the Class. All		
11	members of the Class were similarly affected by Defendants' allegedly wrongful conduct in		
12	violation of the Exchange Act and Securities Act as complained of herein.		
13	412. Plaintiffs will fairly and adequately protect the interests of the members of the		
14	Class. Plaintiffs have retained counsel competent and experienced in class and securities		
15	litigation.		
16	413. Common questions of law and fact exist as to all members of the Class, and		
17	predominate over any questions solely affecting individual members of the Class. The questions		
18	of law and fact common to the Class include:		
19	(a) whether the federal securities laws were violated by Defendants' acts and		
20	omissions as alleged herein;		
21	(b) whether the statements made to the investing public during the Class		
22	Period contained material misrepresentations or omitted to state material information;		
23	(c) whether and to what extent the market price of Vocera's securities were		
24	artificially inflated during the Class Period because of the material misstatements alleged herein;		
25	(d) whether Defendants acted with the requisite level of scienter with respect		
26	to the Exchange Act claims;		
27	(e) whether the Individual Defendants, Officer Defendants, and Director		
28	Defendants were controlling persons of Vocera;		
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 131		
	MASTER FILE NO. 3:13-CV-03567 EMC		

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page137 of 141

1	(f) whether reliance may be presumed pursuant to the Affiliated Ute
2	presumption or fraud-on-the-market doctrine for the Exchange Act Claims; and
3	(g) whether the members of the Class have sustained damages as a result of
4	the conduct complained of herein and, if so, the proper measure of damages.
5	414. A class action is superior to all other available methods for the fair and efficient
6	adjudication of this controversy because, among other things, joinder of all members of the Class
7	is impracticable. Furthermore, because the damages suffered by individual Class members may
8	be relatively small, the expense and burden of individual litigation make it impossible for
9	members of the Class to individually redress the wrongs done to them. There will be no
10	difficulty in the management of this action as a class action.
11	XIII. PRAYER FOR RELIEF
12	WHEREFORE, Plaintiffs respectfully pray for judgment as follows:
13	A. Determining that this action is a proper class action maintained under Rules 23(a)
14	and (b)(3) of the Federal Rules of Civil Procedure, certifying Plaintiffs as class representatives,
15	and appointing Labaton Sucharow LLP as class counsel pursuant to Rule 23(g);
16	B. Declaring and determining that Defendants violated the Exchange Act and the
17	Securities Act by reason of the acts and omissions alleged herein;
18	C. Awarding Plaintiffs and the Class compensatory damages against all Defendants,
19	jointly and severally, in an amount to be proven at trial together with prejudgment interest
20	thereon;
21	D. Awarding rescission or a rescissory measure of damages for the Section $12(a)(2)$
22	claim;
23	E. Awarding Plaintiffs and the Class their reasonable costs and expenses incurred in
24	this action, including but not limited to attorney's fees and costs incurred by consulting and
25	testifying expert witnesses; and
26	F. Granting such other and further relief as the Court deems just and proper.
27	XIV. JURY DEMAND
28	Plaintiffs demand a trial by jury of all issues so triable.
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 132 MASTER FILE NO. 3:13-CV-03567 EMC

	Case3:13-cv-03567-EMC Document1	04 Filed09/19/14 Page138 of 141
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Case3:13-cv-03567-EMC Document1 DATED: September 19, 2014	04 Filed09/19/14 Page138 of 141 LABATON SUCHAROW LLP /s/Jonathan Gardner Jonathan Gardner Mark S. Goldman Carol C. Villegas 140 Broadway New York, NY 10005 Telephone: (212) 907-0700 Fax: (212) 818-0477 jgardner@labaton.com mgoldman@labaton.com cvillegas@labaton.com cvillegas@labaton.com Banta Counsel for Plaintiffs and the Class Shawn A. Williams ROBBINS GELLER RUDMAN & DOWD LLP One Montgomery Street, Suite 1800 San Francisco, CA 94104 Telephone: (415) 288-4545 Fax: (415) 288-4534 shawnw@rgrdlaw.com
17 18 19		Local Counsel
20		
21 22		
23		
24		
25 26		
26 27		
28		
	CONSOLIDATED CLASS ACTION COMPLAINT FOR VI MASTER FILE NO. 3:13-CV-03567 EMC	OLATIONS OF THE FEDERAL SECURITIES LAWS

1	CERTIFICATE OF SERVICE		
2	I hereby certify that on September 19, 2014, I authorized the electronic filing of the		
3	foregoing with the Clerk of the Court using the CM/ECF system which will send notification of		
4	such filing to the e-mail addresses denoted on the attached Electronic Mail Notice List, and I		
5	hereby certify that I have mailed the foregoing document or paper via the United States Postal		
6	Service to the non-CM/ECF participants indicated on the attached Service List.		
7	I further certify that I authorized an unredacted version of the Consolidated Complaint to		
8	be provided to the Court and to be served on Defendants.		
9	I certify under penalty of perjury under the laws of the United States of America that the		
10	foregoing is true and correct.		
11	Executed on September 19, 2014.		
12	<u>/s/ Jonathan Gardner</u>		
13	JONATHAN GARDNER		
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
	CERTIFICATE OF SERVICE 1 CASE NO. 3:13-CV-03567-EMC 1		

Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page140 of 141

1	Mailing Information for Case 3:13-cv-03567-EMC
2	Brado v. Vocera Communications Inc et al
3	Electronic Mail Notice List
4	The following are those who are currently on the list to receive e-mail notices for this
5	case.
6	Marie Caroline Bafus
7	mbafus@fenwick.com,vsheehan@fenwick.com,pnichols@fenwick.comJoel H. Bernstein
8	jbernstein@labaton.com,electroniccasefiling@labaton.com • Norman J. Blears
9	nblears@sidley.com,kmay@sidley.com,epickens@sidley.com
10	Jennifer Corinne Bretan jbretan@fenwick.com,vsheehan@fenwick.com,mbafus@fenwick.com,
11	kayoung@fenwick.com,pnichols@fenwick.com,Joseph Daniel Cohen
12	jcohen@scott-scott.com
13	Hal Davis Cunningham hcunningham@scott-scott.com,efile@scott-scott.com
14	Matthew James Dolan mdolan@sidley.com,adeparedes@sidley.com
15	Catherine Duden Kevane ckevane@fenwick.com,pnichols@fenwick.com
16	• Amber L. Eck
17	ambere@zhlaw.com,winkyc@zhlaw.com,RobynS@zhlaw.comJoseph A. Fonti
18	jfonti@labaton.com
19	• Jonathan Gardner jgardner@labaton.com,cvillegas@labaton.com,lmehringer@labaton.com,
20	fmalonzo@labaton.com Mark S. Goldman
21	mgoldman@labaton.com
22	 Joseph P. Guglielmo jguglielmo@scott-scott.com,edewan@scott-scott.com,
23	tcrockett@scott-scott.com,efile@scott-scott.comSusan Samuels Muck
24	smuck@fenwick.com,vsheehan@fenwick.com, rchang@fenwick.com,
25	 kayoung@fenwick.com,pnichols@fenwick.com Danielle Suzanne Myers
26	dmyers@rgrdlaw.com,e_file_sd@rgrdlaw.com,e_file_sf@rgrdlaw.com
20 27	e_file_sd@rgrdlaw.com
	David R. Scott drscott@scott-scott.com
28	Ronnie Solomon
	CERTIFICATE OF SERVICE 2

CASE NO. 3:13-CV-03567-EMC

	Case3:13-cv-03567-EMC Document104 Filed09/19/14 Page141 of 141
1 2 3 4 5 6 7 8 9	 rsolomon@fenwick.com,mguidoux@fenwick.com Michael Walter Stocker mstocker@labaton.com,drogers@labaton.com,lmehringer@labaton.com Simona Gurevich Strauss sstrauss@stblaw.com,twong@stblaw.com,niels.melius@stblaw.com, janie.franklin@stblaw.com,sblake@stblaw.com Carol C. Villegas cvillegas@labaton.com Shawn A. Williams shawnw@rgrdlaw.com,erinj@rgrdlaw.com,e_file_sd@rgrdlaw.com, e_file_sf@rgrdlaw.com Michael John von Loewenfeldt mvl@kerrwagstaffe.com,phan@kerrwagstaffe.com
10	Manual Notice List
11	The following is the list of attorneys who are not on the list to receive e-mail notices for
12	this case (who therefore require manual noticing). You may wish to use your mouse to select and
13	copy this list into your word processing program in order to create notices or labels for these
14	recipients.
15	• Stephen J. Teti Scott + Scott
16 17	156 South Main Street P.O. Box 192 Colchester, CT 06415
17	Coldiester, C1 00415
10	
20	
21	
22	
23	
24	
25	
26	
27	
28	
	CERTIFICATE OF SERVICE 3 CASE NO. 3:13-CV-03567-EMC